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ABSTRACT 
 
With bacterial antimicrobial resistance on the rise, alternative therapeutic agents are being 
sought. One such alternative is the use of anti-virulence strategies such as quorum-sensing 
inhibition (QSI), which has been proposed as a viable treatment option for pathogenic 
microorganisms such as multi-drug resistant Pseudomonas aeruginosa. Ninety-eight bacterial 
isolates from seven South African sponges harvested off the coast of KwaZulu-Natal 
underwent primary QSI screening using C. violaceum biosensor sandwich assays. Fifteen 
isolates presenting putative QSI activity were selected for further study, five of which were 
identified as Bacillus spp. while ten were identified as Actinomycete spp., following 16S rRNA 
PCR and sequencing. Crude extracts were obtained from these 30 isolates following shake-
flask fermentations with two production media, mannitol and medium 5294, and ethyl 
acetate extractions.  Extracts were then screened against QS-mediated P. aeruginosa 
virulence factor production, viz. pyocyanin, pyoverdine, elastase, protease, rhamnolipid, 
initial and mature biofilm production as well as swimming and swarming motilities. Extracts 
were additionally screened for putative anti-HIV reverse transcriptase (RT) activity due to the 
lack of current research examining the anti-HIV potential of sponge-associated bacteria. 
Actinomycete-derived mannitol extracts yielded the most significant inhibition for most of 
the P. aeruginosa virulence factors tested, while for the Bacillus spp. isolates medium 5294 
extracts resulted in more significant inhibitions, indicating that the selection of production 
media may need to be carefully considered. This was not the case for the anti-HIV RT activity, 
with mannitol and medium 5294 extracts yielding similar activity. Broad spectrum QSI activity 
was observed with a number of extracts, including those from Streptomyces spp. SP4-AB2 and 
SP3-AB22, and Bacillus weihenstephanensis SP5-AB7, each of which was able to significantly 
(p < 0.05) inhibit virulence factors mediated by each of the three P. aeruginosa quorum 
sensing systems, with inhibitions as high as 93% being observed. It was further observed that 
13 of the 30 extracts yielded RT-inhibition >90%; higher than that of the positive control 
nevirapine. Due to the high percentage of QSI and HIV-RT inhibition observed, sponge-
associated bacterial extracts should indeed be screened further for their QSI and anti-HIV 
potential, especially those belonging to the genus Bacillus and the family Actinomycetes. 
Sponge-associated bacteria, therefore, possess the QSI and anti-HIV RT potential necessary 
to serve as the solution to the current resistance crisis and should be further studied in this 
regard. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
Every year the world experiences huge economic losses, brought about by the fouling of 
important structures such as the membrane bioreactors of wastewater treatment plants 
(Fetzner, 2015). These losses are compounded through the infection of humans, plants, and 
animals by bacterial pathogens (Chankhamhaengdecha et al., 2013). Of increasing concern is 
the growing inability to combat these bacterial pathogens due to the toxicity of therapeutic 
agents (Moghadamtousi et al., 2015) and the rapid spread of multiple-, extensive- and even 
pan-drug resistance (Durai et al., 2013; Steckbeck et al., 2014; Moradali et al., 2017). These 
resistances are propagated by the very drugs and treatments which are being employed to 
fight them (Chankhamhaengdecha et al., 2013).  
A further key area of concern is the prevalence of nosocomial infections (Romero et 
al., 2012) caused by highly resistant “ESKAPE” (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter 
sp.) pathogens (Dorotkiewcz-Jach et al., 2015). This is especially true of multidrug-resistant P. 
aeruginosa (Soria-Mercado et al., 2012; Susilowati et al., 2015) which the International 
Nosocomial Infection Control Consortium declared to be a worldwide health issue (Moradali 
et al., 2017). The spread of drug resistance is not exclusive to bacteria but can also be seen in 
viruses such as the Human Immunodeficiency Virus (HIV) (Ellithey et al., 2014) which has also 
become a significant health concern over recent years (Mthethwa et al., 2014).  
In the face of this current antimicrobial resistance crisis, there is an obvious need for 
the rapid discovery and development of novel treatment options (Bramhachari et al., 2016). 
As multiple drug resistance has been officially recognized as a primary area of clinical concern 
and with the last truly new antimicrobial to enter the market being daptomycin in 2003 
(Steckbeck et al., 2014), clinicians and researchers world-wide have turned their attention to 
therapies which may serve as viable alternatives to the use of outdated antimicrobial 
compounds (Padmavathi et al., 2014).  
Nature has served as a source of medicinal products for thousands of years 
(Ramalingam and Amutha, 2013), often being used to treat bacterial and viral infections alike 
(Otang et al., 2014). Maintaining the trend, the majority of modern clinical drugs are either 
natural product-based or derivatives thereof (Saurav et al., 2016). The marine environment 
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serves as home to a huge array of diverse bacterial species (Egan et al., 2013). Additionally, 
due to the vast differences between the marine and terrestrial environments, it is surmised 
that compounds isolated from marine organisms should prove to be unique to those already 
isolated from terrestrial organisms (Cheung et al., 2014). Within the marine environment, 
sponges have also gained attention as an untapped resource (Bramhachari et al., 2016; Saurav 
et al., 2016) as they harbour dense microbial communities, including over 60 actinobacterial 
genera (Sun et al., 2015), and serve as a rich and prolific source of novel pharmacological 
products (Bramhachari et al., 2016; Saurav et al., 2016).  
The use of quorum sensing inhibition (QSI) to potentially control pathogenic bacterial 
infections is also receiving intense attention (Saurav et al., 2016). Quorum sensing in many 
cases is directly linked to pathogenesis through the induction of virulence factor production, 
such as the synchronized production of toxins and proteases (Saurav et al., 2016). Quorum 
sensing inhibition, therefore, focuses on targeting bacterial virulence rather than survival, and 
is thus less likely to spur evolutionary moves towards resistance by bacteria (Romero et al., 
2012; Padmavathi et al., 2014). Marine bacteria, such as sponge-associated Actinomycetes, 
have shown great promise in this area (Saurav et al., 2016).  
Viral infections, such as those caused by HIV or the herpes simplex virus (HSV) are a 
key research area as they have become a major health concern over the last decade 
(Moghadamtousi et al., 2015), leading to an increased risk of infection by opportunistic 
pathogens as well as an increased susceptibility to cancer (Ellithey et al., 2014). The ability of 
viruses to rapidly evolve and develop resistance has led to the search for new antiviral 
compounds gaining the highest priority in virological research (Cheung et al., 2014). Marine 
sponges and their associated bacteria are demonstrating strong promise in this area (Ellithey 
et al., 2014; Indraningrat et al., 2016). 
 
1.2 The sponge microbiome 
1.2.1 Phylum Porifera 
Sponges, belonging to the phylum Porifera, are some of the oldest multicellular animals 
known to man (Sun et al., 2015), dating as far back as the lower Cambrian era (Renard et al., 
2014). They can be found in a diverse range of environments: most marine habitats as well as 
certain freshwater bodies; tropical as well as polar climates (Renard et al., 2014). Although 
sponges, described first by Aristotle, have been used by mankind for bathing and cleaning for 
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over 4000 years (Renard et al., 2014), research into the use of the marine environment as a 
defence against microbial attack started with Bergman and Feeny a mere 65 years ago (Uzair 
et al., 2011; Jagadeesan and Balaiah, 2015). Since then the phylum Porifera has continuously 
topped the list of marine organisms of pharmacological interest (García-Vilas et al., 2016), 
proving to be a dominant group in the discovery of novel drugs as well as bioactive 
compounds (Bramhachari et al., 2016).  
Sponges have been considered a rich source of discovery for bioactive compounds due 
to their complex primary and secondary metabolites (Perdicaris et al., 2013). Over the last 30 
years, more than 15 000 structurally diverse bioactive compounds have been isolated from 
marine sponges alone, with more novel compounds being identified every year from sponges 
than any other taxon (Bramhachari et al., 2016). This includes the production of potent 
antioxidants as well as antifungal, antibacterial, antiviral, antitumour, immuno-suppressive 
(to treat allergies) and hypocholesterolemic compounds (Annapoorani et al., 2012; Perdicaris 
et al., 2013; Bramhachari et al., 2016).  For example, bioactive compounds from marine 
sponges Dendrilla nigra, Clathria gorgonoides and Axinella donnani have exhibited significant 
antimicrobial activity against various Gram-positive pathogenic bacteria (Bramhachari et al., 
2016). Additionally, alkaloids and their synthetic derivatives from Agelas sponges have been 
shown to inhibit biofilm formation as well as exhibit antifungal, antibacterial and 
antiprotozoal properties (Bramhachari et al., 2016). 
Due to their sessile nature, sponges are required to produce a wide range of defensive 
compounds to protect themselves from both predators and pathogens (Bramhachari et al., 
2016). It has been observed that the sponges displaying the greatest diversity and complexity 
in terms of the bioactive compounds they produce are those found in coral reefs or similar 
highly populated areas, as a result of the intense competition from other sponges and the 
survival pressure exerted by fish which feed on them (Perdicaris et al., 2013). Sponge-
produced secondary metabolites have also been shown to be enzyme inhibitors, to assist in 
the wound healing process, as well as to modulate the host immune system (Bramhachari et 
al., 2016). 
Sponges are set apart from other metazoans due to their anatomical simplicity 
(Renard et al., 2014; Santos-Gandelman et al., 2014); they do not possess digestive systems, 
and instead rely on a highly specialised aquiferous filtration system consisting of choanocytes 
to pump water unidirectionally through their bodies into a system of pores, canals and 
4 
 
choanocyte chambers (Renard et al., 2014). Since 2009, sponges have been placed into four 
classes, namely Calcarea, Demospongiae, Hexactinellida and Homoscleromorpha (Renard et 
al., 2014; Santos-Gandelman et al., 2014). These classes differ based on their tissular, skeletal 
(spicules) and developmental characteristics (Renard et al., 2014).  
Most sponges feed on an array of microorganisms, which they obtain through their 
filter-feeding method (Renard et al., 2014). The only selective preference given to what is 
consumed is based on size, determined by the size of the ostia through which the surrounding 
water is drawn in (Renard et al., 2014). The rapid rate at which sponges filter surrounding 
water (a volume equivalent to sponge-body volume is pumped every 7 seconds) has a 
substantial impact on both the ecology of their surrounding environment as well as on their 
own accrued microbial symbiont populations (Renard et al., 2014). While some symbionts 
may reside on the outer layers of the sponge (Selvin et al., 2010; Bramhachari et al., 2016), 
they are primarily found within the gel-like mesohyle of the sponge body (Selvin et al., 2010; 
Fuerst, 2014; Bramhachari et al., 2016), a fibril-rich and less organised cellular layer found 
between the pinacoderm (outer epithelial layer comprised of pinacocytes) and choanoderm 
layers (Fig. 1.1) (Renard et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Clathrina contorta (bottom left), exhibiting a pink pigmentation due to the 
presence of Cyanobacterial symbionts (Renard et al., 2014). (a) General macro-structure of 
the sponge organism as well as (b) the location of Cyanobacteria and other microorganisms 
within the mesohyle layer of the sponge body (Hentschel et al., 2012). 
 
The choanoderm consists of specialised flagellated cells, forming chambers which 
serve as the locations in which sponge feeding occurs (Santos-Gandelman et al., 2014). 
Through the harbouring of symbionts such as Cyanobacteria (often giving sponges a pink 
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pigmentation, Fig. 1.1), sponges may even play the role of primary oxygen producers, 
especially in environments where they form up to 80% of the benthic population (Renard et 
al., 2014). They are, therefore, considered to be important members of this benthic 
population, due to their potential to have a substantial impact on surrounding pelagic 
processes (Santos-Gandelman et al., 2014). 
Although it is difficult to estimate total sponge diversity (Renard et al., 2014), over 
8000 species of sponges have been identified to date and their associated bacterial species 
can be classified into over 32 different phyla (Fuerst, 2014; Bramhachari et al., 2016). Marine 
sponges and their associated microorganisms are some of the richest sources of 
pharmacologically active secondary metabolites (García-Vilas et al., 2016). These secondary 
metabolites are produced as a means of stability, adaptation, defence and to foster 
relationships with symbiotic microbial populations (Quintana et al., 2015). Marine sponges 
contribute nearly 30% of all marine compounds (Kurian and Elumalai, 2017), with potential 
applications as alternatives to currently available parasitic, bacterial, fungal and viral 
treatments (Kurian and Elumalai, 2017). Due to ecological concerns, however, such as the 
finite availability of sponges within the sea and the large amounts of sponge tissue required 
to produce these natural products, it has been suggested that focus should rather turn to the 
symbiotic bacteria associated with these sponges and their secondary metabolite production 
(Saurav et al., 2016).  
 
1.2.2 Sponge-associated bacteria 
While both marine sponges and their symbionts are considered to be relatively primitive 
organisms, their interactions are complex (Sun et al., 2015; Bramhachari et al., 2016). Sponges 
have even shown specificity in the kinds of bacteria they form symbiotic relationships with, 
even if those bacteria are not present in the sea water surrounding the sponge, and there is 
evidence for host-symbiont co-evolution (Bramhachari et al., 2016). Sponges offer a nutrient-
rich environment relative to the surrounding seawater and sediments, and a wide array of 
microbial symbionts can be found to inhabit these organisms (Abbamondi et al., 2014).  
The interactions between sponges and their dense microbial communities are some 
of the oldest and most complex on Earth (Fuerst, 2014; Sun et al., 2015), possibly dating as 
far back as the first appearance of the phylum 600 million years ago (Bramhachari et al., 
2016), with most sponges hosting a diverse and abundant range of bacterial communities 
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which contribute to sponge health, evolution and ecology (Selvin et al., 2010; Bramhachari et 
al., 2016). Symbionts can equate to as much as 40-60% of the sponges’ volume, and as a result 
of long-term evolutionary and ecological changes often consist of a diverse selection of 
bacteria, fungi, archaea and microalgae (Perdicaris et al., 2013; Santos-Gandelman et al., 
2014; Bramhachari et al., 2016). Modern sponges, often play host to almost all major 
evolutionary lineages of archaea as well as bacteria (Thacker and Freeman, 2012). Although 
sponges are inhabited by a range of microorganisms, bacteria have constantly emerged as 
the most dominant and diverse of all sponge symbionts (Bramhachari et al., 2016).  
Sponge-associated bacteria have been grouped into 32 different phyla, making them 
far more diverse in this regard than any other marine organism (Fuerst, 2014; Bramhachari et 
al., 2016). Of these phyla, bacteria belonging to Actinobacteria, Proteobacteria, Firmicutes, 
Cyanobacteria, Chloroflexi, Nitrospirae, Acidobacteria and Poribacteria (a potentially sponge-
specific phylum) are the most commonly isolated from marine sponges and dominate their 
symbiotic communities (Fuerst, 2014; Bramhachari et al., 2016; Saurav et al., 2016). However, 
new bacterial species are frequently being isolated from sponges, with Saurav et al. (2016) 
identifying one potentially novel bacterial taxon and as many as 17 novel bacterial strains (16S 
rRNA identities of <98% similarity to those in the BLAST database) (Saurav et al., 2016). Sun 
et al. (2015) have focussed on the characterisation as well as the distribution of South China 
Sea sponge-associated symbiotic bacteria. They observed that the sponge Plakortis simplex 
yielded the greatest number of actinomycete isolates, followed by Haliclona sp. The greatest 
diversity, however, was associated with Haliclona sp., from which six actinomycete genera 
were isolated (Sun et al., 2015). The region or type of habitat from which the sponges are 
obtained also affects the diversity of the associated symbionts, with Salinispora sp. being 
isolated most commonly from open sea sponges and Streptomyces sp. being obtained from 
distinct geographical locations such as harbours or other more enclosed areas (Sun et al., 
2015). Seven bacterial genera (i.e. Polymorphospora, Streptomonospora, Marihabitans, 
Catenuloplanes, Serinicoccus, Saccharopolyspora and Sphaerisporangium) not previously 
isolated from sponges of different regions were isolated from sponges of the South China Sea 
(Sun et al., 2015). In some cases, the symbionts are so pivotal to the survival of the sponge 
that they are vertically transmitted to the next generation (Fuerst, 2014).  
Ultimately the distribution and types of bacterial symbionts differs according to the 
species and location of the sponge being studied, the effect of the host-specific 
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microenvironment, previous host-symbiont co-evolution as a result of vertical transmissions 
and finally the time of year during which the sponges are studied, as each of these factors 
affects the microorganisms’ health and distribution and as a result the symbiotic population 
accrued (Thacker and Freeman, 2012; Quintana et al., 2015). As bacteria filtered by the 
sponge often serve as a source of supplemental nutrition (Thacker and Freeman, 2012), the 
mechanisms by which the symbionts escape phagocytosis by amoebocyte sponge cells whilst 
other bacteria do not, remain to be elucidated (Fuerst, 2014). It has been proposed that the 
host sponge provides ideal conditions such as the presence of specific lectins or glycans that 
upon arrival of the microorganisms, allows for the retention and colonization by some species 
or taxonomic groupings and not others (Selvin et al., 2010). These symbionts may then 
replicate and thrive off the nutrients provided by the sponge, acquired near the chaonocyte 
chambers (Selvin et al., 2010).  
This implies selectivity by the sponge, even though it was previously believed that 
there was a core bacterial population shared by all sponges (Thacker and Freeman, 2012). 
This “uniform community” hypothesis was disproved by Schmitt et al. (2011). Using 
techniques such as pyrosequencing, Schmitt et al. (2011) observed that the sponge symbiotic 
community consists of a constant population, but also consists of two other population 
groups or classifications. These three groups are the core bacterial community present in 
most sponges, the variable symbiotic community present in as little as 10% of sponges, and 
lastly the species-specific bacteria communities (Thacker and Freeman, 2012). It is this final, 
species-specific group, which was shown to be vertically transmitted (Thacker and Freeman, 
2012). This selectivity of symbionts by the sponge host was further reinforced as sponges also 
produce compounds to prevent biofilms consisting of undesirable microbial populations 
being formed (Quintana et al., 2015). Some sponge-associated bacteria, such as members 
belonging to the phyla Chloroflexi, Actinobacteria and Acidobacteria are amongst those which 
have been shown to be specific to a certain species within a sponge genus, such as those 
belonging to the sponge Xetospongia muta (Fuerst, 2014).  
The association between the sponge and its resident microbial population has been 
shown to be, in most cases, symbiotic (Thacker and Freeman, 2012; Bramhachari et al., 2016) 
with interactions between the host and bacteria occurring primarily via the production of 
cyclic dipeptides or N-acyl-homoserine lactones (AHLs) (Abbamondi et al., 2014). While the 
sponge provides the symbiotic bacteria with an environmental niche rich in nutrients and 
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shelter (Bramhachari et al., 2016), the microbes (in addition to acting as a source of nutrition 
for the sponge through photosynthesis) serve the purposes of waste processing via carbon 
and nitrogen fixation, the stabilization of the cellular matrix and provision of added rigidity to 
the sponge skeleton as well as providing protection against solar UV radiation (Selvin et al., 
2010; Thacker and Freeman, 2012; Bramhachari et al., 2016). Sponge-associated bacteria also 
protect the soft-bodied, vulnerable sponges from predation by producing secondary 
metabolites (Bramhachari et al., 2016) such as phospholipases (defence enzymes), altering 
host physiologies such that pathogens cannot become established, priming the sponge 
immune response such that there is a rapid response to pathogen infection, parasitizing the 
larger pathogen microbes and through producing bacteriocins toxic to competing strains 
(Selvin et al., 2010).  
In order to maintain their complex microbial communities, these bacteria are passed 
down to other sponges through both vertical and horizontal transmission (Bramhachari et al., 
2016). Sponges are, therefore, able to protect themselves from predation due to metabolites 
which are either produced by the sponges themselves or by their associated microorganisms 
(Sun et al., 2015) and are used primarily for defence against malignant microbial infections 
and cellular communication (García-Vilas et al., 2016). Arguably the most important role of 
the sponge-associated bacterial symbionts is, therefore, the production of unique and 
complex secondary metabolites by these microorganisms (Thacker and Freeman, 2012). 
 
1.2.3 Sponge-associated bacterial secondary metabolite production 
 Many of the biologically active secondary metabolites initially thought to be secreted by the 
sponge have since been shown to be produced instead by the sponge-associated symbiotic 
microorganisms, including bacteria, actinomycetes, blue-green algae and fungi (Durai et al., 
2013; Santos-Gandelman et al., 2014; Sun et al., 2015). This conclusion was drawn as 
phylogenetically-unrelated sponges often produced the same compounds, suggesting that 
these bioactive substances were being secreted by similar bacterial populations rather than 
the sponges themselves (Santos-Gandelman et al., 2014). The presence of many substances 
known to be produced only by bacterial cells, such as non-ribosomal peptides and 
polyketides, further validated this theory (Santos-Gandelman et al., 2014).  
Some of the microbial-produced products have been identified as enzymes, peptides, 
antibiotics, non-ribosomal peptides, alkaloids, quinolone derivatives, terpenoids and 
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quinones (Bramhachari et al., 2016). It is theorized that the high diversity and complexity of 
bacterial secondary metabolites may be due to the high level of complexity and stress found 
in the marine environment (Cheung et al., 2014). Due to microbial competition, secondary 
metabolites produced by such microorganisms exhibit a wide range of metabolic targets, 
affording them significant pharmacological potentials (Bastos et al., 2013). In general, 
mechanisms of bacterial competition are quite diverse, but include the activation of 
multidrug-efflux pumps (Egan et al., 2013) and production of antibiotics, siderophores, 
proteases, bacteriocins, lysosymes and organic acids which alter the pH of the growth 
environment (Soria-Mercado et al., 2012; Flemming et al., 2016).  
An example of these metabolites are the aromatic polyketides produced by sponge-
associated actinomycetes isolated from the South China Sea (Sun et al., 2015). These aromatic 
polyketides are produced by sponge-associated actinomycetes and cyanobacterial species 
through a type II polyketide pathway, and includes many important clinical drugs such as 
erythromycin, rapamycin, and tetracycline (Sun et al., 2015; Bramhachari et al., 2016). 
Aromatic polyketides, therefore, have highly valuable biological activities and remain 
successful candidates for novel drug discovery (Bramhachari et al., 2016).  
Also from the South China Sea, the sponge-associated bacterium (SPAB) Bacillus 
atrophaeus from sponge Dysidea avara was shown to produce two different antibiotics, 
Bacillamide C and Neobacillamide A (Bramhachari et al., 2016).  Many sponge-associated 
Bacillus species have shown antimicrobial potential, due to their proliferous production of 
metabolites such as cyclic lipopeptides, cyclic peptides and novel thiopeptides. Bacillus cereus 
QN03323, a SPAB from the marine sponge Halichondria japonica was shown to produce two 
novel antibiotics, YM-266183 and YM-266184 (Bramhachari et al., 2016).  
Bioactive compounds with a broad range of antimicrobial properties were also 
identified from various SPAB, including Pseudoalteromonas rubra, Pseudoalteromonas 
piscicida, Bacillus megaterium and Hymeniacidon perleve (Bramhachari et al., 2016). Iturins, 
fengycins and surfactins, compounds shown to have a bactericidal effect on resistant 
pathogens such as S. aureus and Staphylococcus epidermis, were all isolated from strains of 
Bacillus subtilis, associated with the Mediterranean sponge Aplysina aerophobe (Bramhachari 
et al., 2016). A sponge-associated actinomycete produced menzamine A, which exhibits 
antibacterial, anti-HIV, anti-malarial, anti-inflammatory as well as anti-tumour effects 
(Santos-Gandelman et al., 2014).  
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Alkaloids are also attracting much attention for further research, as due to their 
structural complexity and relatively low molecular masses they can be adapted and 
chemically optimized through the addition of functional groups and side chains (Bramhachari 
et al., 2016). Pseudoalteromonas-associated with various species of the sponge Aplysina was 
shown to produce brominated alkaloids with antimicrobial and cytotoxic effects, as well as 
the ability to repel predators (Bramhachari et al., 2016). Additionally, P. aeruginosa 
associated with the Antarctic sponge Isodictya setifera produced phenazine alkaloids, some 
of which exhibited antibacterial activity against Micrococcus luteus, S. aureus and B. cereus 
(Bramhachari et al., 2016).   
Another class of compounds, quinolones, produced by SPABs include 2-undecyl-4-
quinolone, isolated from Homophymia sp.-associated Pseudomonas and is active against HIV-
1 and Plasmodium falciparum (Bramhachari et al., 2016). Dipeptides are also commonly 
produced by SPABs, with Stelletta tenuis-associated Alcaligenes faecalis strain A72 producing 
L,L-diketopiperazine with antimicrobial activity, and Tedania ignis-associated Micrococcus 
species synthesizing three different diketopiperazines with antibiotic, antiviral and antitumor 
properties (Bramhachari et al., 2016). Further examples of potentially clinically relevant 
secondary metabolites produced by sponge-associated bacteria can be seen in Table 1.1.  
Used as a defensive response, these compounds generally affect competing cells 
through interfering with cell wall synthesis, nucleic acid synthesis, protein synthesis or 
disrupting cellular membranes (Cruz et al., 2014). Of the 237 bacteria isolated from the 
sponges Suberites carnosus and Leucosolenia sp., 50% of the isolates from S. carnosus showed 
antibacterial activity and 15% of the Leucosolenia sp. isolates showed antifungal properties 
(Perdicaris et al., 2013). These effects were more specifically attributed to Pseudovibrio and 
Spongobacter spp. and Bacillus, Pseudoalteromonas and Vibrio spp., respectively (Perdicaris 
et al., 2013). However, as bacteria are becoming increasingly resistant, either intrinsically or 
through the acquisition of resistance genes, new antimicrobial compounds are being sought 
(Cruz et al., 2014). In a move away from traditional antimicrobial agents, attention has 
recently turned to the targeting of quorum sensing (QS) molecules.  
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Table 1.1: Examples of sponge-associated bacterial compounds shown to exert biological 
activity (Fuerst, 2014; Santos-Gandelman et al., 2014; Sun et al., 2015; Bramhachari et al., 
2016) 
Bacterial source Associated sponge Compound produced Biological 
activity 
Micrococcus luteus 
R1588-10 
Xestospongia sp. 2,4,4’-trichloro-2’-hydroxy-diphenylether 
(triclosan) and Acyl-1-(acyl-6’ mannobiosyl)-3-
glycerol (lutoside) 
Antibacterial 
Streptomyces anulatus 
S71 
Unknown Landomycin Antibacterial 
Pseudomonas sp. 
1537-E7 
Homophymia sp. 2-nonyl-4-hydroxyquinoline n-oxide Antibacterial 
Bacillus atrophaeus Dysidea avara Bacillamide C and Neobacillamide A  
 
Antibacterial 
Bacillus cereus 
QN03323 
Halichondria 
japonica 
Antibiotics, YM-266183 and YM-266184 Antibacterial 
Bacillus subtilis Aplysina aerophobe Iturins, fengycins and surfactins Antibacterial 
P. aeruginosa Isodictya setifera Phenazine alkaloids Antibacterial 
Vibrio sp. M22-1 Hyatella sp. Andrimid Antibacterial 
Ruegeria sp. Suberites 
domuncula 
Cyclo-(glycyl-L-seryl-L-prolyl-L-glutamyl) Antibacterial 
Salinospora sp. Suberea clavata Rifamycin B and Rifamycin SV Antibacterial 
Pseudomonas sp. 
F92S91 
Not yet identified Pyrone-I Antibacterial; 
antifungal 
Alcaligenes faecalis 
A72 
Stelletta tenuis L,L-diketopiperazine Antimicrobial 
Nocardiopsis 
dassonvillei MAD08 
Dendrilla nigra Acetic acid, 2-(octyloxy)-oxalic acid, Allylnonyl 
ester, 2-Isopropyl-5-methyl-1-heptanol, 
Butylatedhydroxytoluene, 
Cyclohexanecarboxylic acid, Hexyl ester, Diethyl- 
phthalate, Pentadecanal- 1-tridecanol and 9-
Octadecenal 
Antimicrobial 
Ruegeria sp. Suberites 
domuncula 
Cyclic peptides Antimicrobial 
Pseudoalteromonas sp. Aplysina sp. Brominated alkaloids Antimicrobial 
Pseudomonas sp. Homophymia sp. 2-undecyl-4-quinolone Anti-HIV 
 
1.3 Quorum sensing inhibition (QSI) as an alternative to antimicrobial therapies 
1.3.1 Quorum sensing 
First identified in marine bacterium Vibrio harveyi (Bassler et al., 1997; Papenfort and Bassler, 
2016; Zhang and Li, 2016), QS is a vital physiological and biochemical process found 
ubiquitously in all bacterial cells (Banerjee and Ray, 2016; Zhang and Li, 2016). It is a density-
dependent, intercellular communication system used by various microorganisms to 
communicate, monitor the status of the bacterial population and coordinate group 
behaviours accordingly (Kim and Lee, 2016; Lee and Yoon, 2017). As quorum sensing is a 
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density-dependent bacterial communication system, where each bacterial cell in a population 
secretes its own QS signal, the total signal concentration therefore represents the size of the 
bacterial population (García-Contreras et al., 2016; Grandclément et al., 2016). When a 
threshold concentration of signal molecules, and therefore bacterial population density is 
reached, the genes of interest are expressed, and a cellular function is performed (Banerjee 
and Ray, 2016; Kim and Lee, 2016; Grandclément et al., 2016; Papenfort and Bassler, 2016; 
Castillo-Juárez et al., 2017). This threshold concentration varies according to population size 
and cellular factors such as anti-activator QsiA levels in P. aeruginosa, and therefore cannot 
be exactly quantified (Seet and Zhang, 2011).  
These signals, or autoinducers, are chemical signalling molecules which trigger their 
own biosynthesis through an autoinduction feedback loop (Chan et al., 2015; Fetzner, 2015) 
and are used for bacterial communication, in order to regulate social behaviours (Tang and 
Zhang, 2014). An example of this is the use of autoinducer LuxI, in conjunction with 
transcriptional regulator LuxR (Singh and Reddy, 2014), by Vibrio fischeri (Romero et al., 
2012). As can be seen in Fig. 1.2, LuxR is responsible for the activation of LuxI, and is only itself 
activated through cytoplasmic binding (Romero et al., 2012) with autoinducer 3-oxo-
hexanoyl-homoserine lactone (Singh and Reddy, 2014). Quorum sensing is crucial for 
pathogenesis and successful formation of bacterial communities (Rekha et al., 2016), 
regulating over 600 target genes in V. harveyi alone (Papenfort and Bassler, 2016).  
Quorum sensing is connected to the cellular global regulation network, with 
connections to sRNA synthesis, cyclic-di-GMP second messenger signalling pathways, flagella 
regulation, two-component systems, protein secretion systems as well as toxin-antitoxin 
systems (Chan et al., 2015).  Potentially hundreds of genes within bacterial cells, an equivalent 
of up to 7% of the genome (Castillo-Juárez et al., 2017), are regulated via QS. These include 
those responsible for producing public goods, bioluminescence, nutrient uptake, and 
competence (Banerjee and Ray, 2016; Papenfort and Bassler, 2016).  The purpose of QS 
systems within the bacterial cell can be broadly classified as being related to cell maintenance 
and reproduction (e.g., sporulation or exoenzyme production), cellular behaviour (e.g., 
biofilm formation), interactions with the host and other microorganisms (e.g., host 
colonization factor production) and horizontal gene transfer (Banerjee and Ray, 2016; 
Grandclément et al., 2016; Hassan et al., 2016; Kim and Lee, 2016; Papenfort and Bassler, 
2016).  
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Figure 1.2: Within the typical bacterial Gram-negative QS system – autoinducers are produced 
by signal synthases (I), diffuse into the extracellular environment and at high concentrations 
form a complex with the signal receptor (R) thereby activating expression of target genes as 
well as signal synthase genes (Lade et al., 2014). 
 
In more than 50 Gram-negative bacterial species, QS is mediated through the 
production of N-acyl L-homoserine lactones (AHLs) synthesized from S-adenosylmethionine 
(SAM) and fatty acid intermediates (Hassan et al., 2016; Papenfort and Bassler, 2016; Zhang 
and Li, 2016; Lee and Yoon, 2017). Acyl-homoserine lactones are formed using acyl carrier 
proteins which donate the acyl chain and S-adenosyl methionine for the formation of the 
homoserine lactone component (Safari et al., 2014). Produced by LuxI-type synthase genes 
(Banerjee and Ray, 2016; Hassan et al., 2016), theses AHL signals consist of a core N-acylated 
homoserine-lactone ring with an acyl side chain of between 4 and 18 carbons (Papenfort and 
Bassler, 2016) which can then be modified with simple acyl, 3-oxoacyl or 3-hydroxyacyl groups 
(Zhang and Li, 2016). These signals can further be divided into long chain (C10-AHL – C16-
AHL), medium (C6-AHL - C8-AHL) and short chain AHLS (C4-AHL) (Steindler and Venturi, 2006). 
N-acyl L-homoserine lactone signals are membrane-diffusible; accumulating such that they 
are directly proportional to cell density (Papenfort and Bassler, 2016; Welsh and Blackwell, 
2016). A LuxR-type receptor, found either within the cytoplasm or bound within the 
membrane, binds the signals and is activated once a threshold AHL concentration is reached, 
thereafter acting as a transcriptional regulator for the previously mentioned QS-mediated 
genes (Banerjee and Ray, 2016; Welsh and Blackwell, 2016) as well as for the further 
production of signalling molecules, creating a positive feed-back loop (Papenfort and Bassler, 
2016; Castillo-Juárez et al., 2017).   
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These QS signals are often induced in response to environmental stimuli, such that 
cellular energy in preserved and QS-mediated genes are not activated until the host 
environment is permissive to infection (Welsh and Blackwell, 2016). This ensures that through 
the production of costly virulence factors by a group of cells, rather than an individual, the 
host is overcome, and the pathogen can propagate, establishing infection (García-Contreras, 
2016; Castillo-Juárez et al., 2017).  
Quorum sensing also serves as communication between the symbiont and host 
(Quintana et al., 2015), as well as being key in the control of important bacterial traits (Saurav 
et al., 2016). These include violacein production by Chromobacterium violaceum (Padmavathi 
et al., 2014) and other traits often related to virulence (Chankhamhaengdecha et al., 2013) 
such as the exchange of genetic material (Romero et al., 2012), motility, antibiotic production, 
biofilm formation (Singh and Reddy, 2014; Chan et al., 2015; Fetzner, 2015), competence and 
extracellular enzyme production (Padmavathi et al., 2014). Alpha- and Gamma-
Proteobacteria associated with sponges Mycale laxissima and Ircinia strobilina additionally 
make use of QS molecules to outcompete other potential colonizing bacteria, and establish 
themselves within the sponge tissue (Selvin et al., 2010).  
Gram-positive bacteria do not make use of AHLs but instead employ modified cyclic or 
linear (Fetzner, 2015) oligopeptides (generally 5-20 amino acids in length) as their QS 
molecules (Romero et al., 2012; Chan et al., 2015; Papenfort and Bassler, 2016; Zhang and Li, 
2016; Lee and Yoon, 2017). Gram-positive Bacillus subtilis makes use of the ComP 
oligopeptide which is received by ComA and serves to regulate competence and sporulation 
(Romero et al., 2012). Oligopeptides are also used by Streptococcus pneumoniae for 
competence induction and S. aureus for virulence (Safari et al., 2014). Some Actinomycetes 
such as Streptomyces do not use peptides, however, they employ γ-butyrolactones as their 
QS molecule of choice (Fetzner, 2015), such as the IM-2 γ-butyrolactones used by 
Streptomyces lavendulae or A-factor by Streptomyces griseus (Safari et al., 2014). In Gram-
positive cells, the autoinducers are either received by membrane-bound receptors with signal 
transduction occurring through phosphorylation cascades (Romero et al., 2012) or the 
peptides are imported into the cell to directly interact with regulators which modulate gene 
expression (Fetzner, 2015; Papenfort and Bassler, 2016).  
Besides the signalling molecules mentioned above, over 500 species of Gram-positive 
and Gram-negative bacteria, including Vibrio harveyi and Streptococcus gordonii, may make 
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use of an additional signal produced as a by-product of the detoxification of SAM (Zhang and 
Li, 2016), termed the universal AI-2 QS system (Papenfort and Bassler, 2016; Zhang and Li, 
2016; Lee and Yoon, 2017). Additionally, used for inter-kingdom signalling, the AI-2 
autoinducer molecules regulates various virulence traits such as biofilm formation (Romero 
et al., 2012). Originally thought to be a borated tetrahydrofurone, the term AI-2 is now used 
to describe a wide variety of molecules, many of which are not borated (Grandclément et al., 
2016). These QS molecules are formed through the spontaneous cyclization of 4,5-dihydroxy-
2,3-pentanedione by the LuxS gene or its homolog in the respective system (Grandclément et 
al., 2016). In bacteria such as E. coli, the AI-2 signals are received by an Lsr system and enter 
the cell through transporters in the cell membrane (Fetzner, 2015). As AI-2s are employed by 
both Gram-positive and Gram-negative bacteria, they have been termed the “universal 
language for interspecies communication” (Romero et al., 2012). However, this may not be 
their only purpose, as the receptors for these molecules are not as widespread as the 
molecules themselves (Mai et al., 2015), leading to the thought that these signals may be a 
universal metabolic by-product rather than primarily a QS signal (Grandclément et al., 2016).  
Universal signals such as AI-2 can also be used in the formation of multispecies 
biofilms, such as those of Acinetobacter and Streptococcus species (Lee and Yoon, 2017). 
Lastly, not all Gram positive and Gram-negative bacteria use the traditional auto-inducing 
peptides and AHL QS systems. Some use alternative signals, such as Vibrio cholerae and 
Xanthomonas campestris which make use of S-3-hydroxytridecan-4-one and a diffusible 
extracellular factor, respectively (Zhang and Li, 2016). Pseudomonas aeruginosa also makes 
use of an alternative, Pseudomonas quinolone signal (PQS) (Hassan et al., 2016; Zhang and Li, 
2016). Finally, some Gram-negative QS signals may be amino acid-based, such as 
diketopiperazines, employed by Pseudomonas and other members of the phylum 
Proteobacteria (Grandclément et al., 2016). In general, autoinducer molecules are small, 
diffusible and organic (Romero et al., 2012).  
 
1.3.2 Mechanisms of quorum sensing inhibition to target virulence 
Due to the current antibiotic resistance crisis (Banerjee and Ray, 2016) and an inefficient 
discovery rate of novel, effective antimicrobial agents, alternative treatment options are 
being sought (Banerjee and Ray, 2016; Hassan et al., 2016). Quorum sensing molecules, which 
are not critical for bacterial survival (Tang and Zhang, 2014), may be targeted as a means of 
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reducing virulence without harming the health of the bacterial cell and therefore prevent the 
induction of resistance (Chankhamhaengdecha et al., 2013), or, in cases where growth is 
directly affected by QS, ensure that the resistance is not on the same level as that seen during 
antimicrobial therapies due to the significantly lower levels of AHLs produced (García-
Contreras et al., 2016). Research has focused on the development of small-molecule based 
quorum sensing inhibitory (QSI) and enzymatic quorum quenching (QQ) agents so as to 
disrupt the pathogenic virulence factors associated with the QS system (Banerjee and Ray, 
2016; Guendouze et al., 2017).  
Quorum sensing inhibition is a natural mechanism employed either by the QS 
organisms themselves to clear up or recycle their own signal molecules or by competing 
organisms in order to interfere with their communication networks (Grandclément et al., 
2016). Quorum sensing inhibitors such as tannins and flavonoids have been isolated from 
higher plants, or in some cases have been chemically synthesized such as phenothiazines or 
benzothiazole and its derivatives (Hassan et al., 2016). Dihydropyrrolones are also able to 
inhibit QS in various pathogenic organisms, preventing biofilm formation without affecting 
cell growth (Hassan et al., 2016). Microbial populations from soil have also been extensively 
studied, and QSI producers include Arthrobacter and Proteobacter species identified from 
Malaysian and Chinese soils, respectively (Hassan et al., 2016). Medicinal, edible and 
ornamental plants have thus far been the most widely studied organisms in the search for QSI 
compounds, with far less work having been done using marine sources (Quintana et al., 2015).  
Quorum sensing inhibition was first observed with the seaweed Delisea pulchra 
(Hassan et al., 2016). Delisea pulchra produces halogenated furanones resembling AHL 
molecules, which are capable of inhibiting bacterial QS through the inhibition of LuxR 
(Morrow et al., 2011; Hassan et al., 2016). The furanones can displace the AHLs from their 
receptors as well as reducing the half-life of the response regulator within the cell (Romero 
et al., 2012).  Additional examples of QSIs include furanones and their structural analogues, 
glycosylated flavonoids, bismuth porphyrin complexes and nanomaterials, to name but a few 
(Zhang and Li, 2016).  Quorum quenching enzymes have been given special attention as they 
may act catalytically without the need to enter the target cell (Guendouze et al., 2017). 
However, very few active QSI molecules have been fully characterised, and the biochemical 
nature of these compounds has proved to be highly diverse (Grandclément et al., 2016). 
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The AHL-based QS systems of Gram-negative bacteria have been the most widely 
considered as viable targets of QSI, due to their important role in the regulation of 
Proteobacterial virulence factor production (Rekha et al., 2016). In general, the aim of these 
agents is to reduce bacterial virulence in common pathogens such as P. aeruginosa without 
decreasing bacterial growth, thereby minimizing the selection for resistance (García-
Contreras, 2016; Granato et al., 2016; Hassan et al., 2016; Rekha et al., 2016). The host 
immune system should then theoretically stave off the weakened pathogens (García-
Contreras, 2016), or in the case of immune-compromised patients a dual-therapy approach 
pairing QSI agents and antibiotics may be used.  
Quorum sensing pathways in Gram-negative bacteria usually consist of three 
important steps: production of signals (autoinducer molecules), diffusion of signals and 
recognition of signals by receptor molecules which then activate the target genes (Tang and 
Zhang, 2014). Thus, any of these three steps, as well as the transcription of the QS genes 
(Quintana et al., 2015), may be targeted to inhibit the QS pathway, either through binding of 
receptors, interfering with the biosynthesis of AHLs or degradation of the QS molecules 
themselves to reduce their concentration (Romero et al., 2012; Tang and Zhang, 2014; 
Dorotkiewcz-Jach et al., 2015; Fetzner, 2015; García-Contreras, 2016; Zhang and Li, 2016).  
 
1.3.2.1 Inhibiting biosynthesis of AHLs 
It could be argued that to inhibit the biosynthesis of autoinducers would be the most efficient 
way to inhibit QS, as without AHLs the receptors cannot activate the transcription of virulence 
genes (Romero et al., 2012; Quintana et al., 2015). The enzymes which synthesize the 
signalling molecules AHL and PQS generally use SAM as the donor of the amino group, and 
various molecules as the donor of the acyl group in AHLs with anthranilic acid being used for 
PQS synthesis (Castillo-Juárez et al., 2017). Using an analogue of the substrate, such as methyl 
anthranilate in place of anthranilic acid, results in competition for binding of the synthase 
enzyme and in so doing inhibits the production of the QS signal (in this case PQS), thereby 
decreasing the production of virulence factors such as pyocyanin and elastase (Papenfort and 
Bassler, 2016; Castillo-Juárez et al., 2017). Similarly, tannic acid, salicylic acid and trans-
cinnamaldehyde may also be used to inhibit the synthases of AHL systems such as the LasI 
and RhlI synthases in P. aeruginosa (Papenfort and Bassler, 2016). The inhibition of LuxI and 
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its species-specific homologues may also be achieved through the use of S-adenosylcysteine, 
S-adenosylhomocysteine or sinefungin (Romero et al., 2012).  
 
1.3.2.2 Interfering with signal dissemination – Quorum quenching 
As QS is a density-dependent system, reducing the concentration of AHLs will reduce the 
efficacy of the system (Quintana et al., 2015). The first reports of quorum quenching (QQ) 
dealt with AHL degradation by soil bacteria belonging to the genera Bacillus and Variovorax 
(Grandclément et al., 2016). Many natural QQ enzymes have already been identified and may 
be classified based on their modes of action as lactonases, AHL-acylases or AHL-
oxidoreductases (Table 1.2) (Tang and Zhang, 2014; Banerjee and Ray, 2016).  
Lactonases (Fig. 1.3) belong to the esterase class of enzymes (Safari et al., 2014) 
because lactonases hydrolyse the ester bond, and therefore the lactone ring of the AHL 
molecules yielding N-acyl-homoserine AHL-lactonases (Tang and Zhang, 2014; Zhang and Li, 
2016). These can be classified into various groups, the most prominent of which are the 
metallo-ß-lactamase-like lactonases (Castillo-Juárez et al., 2017). The first identified lactonase 
was AiiA, identified from soil-associated Bacillus sp. which was shown to reduce virulence 
factor production in Erwinia carotovora (Castillo-Juárez et al., 2017). Lactonase AiiA as well as 
Agrobacterium tumefaciens AiiB (Table 1.2) belong to the metallo-β-lactamase superfamily, 
which prefer medium to long chain AHLs (Fetzner, 2015). Other lactonases may resemble 
phosphotriesterases or alternatively may belong to the paraoxonase family, although 
paraoxonases are usually only found in mammalian cells (Fetzner, 2015). Additional 
lactonases have been identified in Rhodococcus sp., Agrobacterium tumefaciens, and 
Acinetobacter sp. (Zhang and Li, 2016). Lactonases isolated from archaea such as SsoPox from 
Sulfolobus solfataricus have also been closely studied due to high lactonase activities as well 
as substantial stability due to their extremophilic origins (Guendouze et al., 2017).  The marine 
microorganism Pseudoalteromonas byunsanensis produces an inner membrane lactonase 
QsdH with a hydrolase domain as a periplasmic extension (Fetzner, 2015), while other 
lactonases include the AiiM from Microbacterium testaceum and AidH from Ochrobactrum 
sp. (Fetzner, 2015).  This lactolysis is only effective in alkaline pH however, and once in an 
acidic environment the process may be reversed (Grandclément et al., 2016; Castillo-Juárez 
et al., 2017). Additionally, it has been shown that AHLs with an acyl chain of 8 or more carbons 
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are less susceptible to degradation by this enzyme than those with shorter chains (Castillo-
Juárez et al., 2017). 
 
Table 1.2: Examples of QQ enzymes and their bacterial sources (Lade et al., 2014; Fetzner, 
2015; Banerjee and Ray, 2016; Grandclément et al., 2016; Zhang and Li, 2016; Guendouze et 
al., 2017) 
Enzyme class/name Source/producing strain AHLs degraded 
AHL-lactonases 
AiiA Bacillus sp. 240B1 C8-HSL 
AiiA B. cereus and B. mycoides C6-HSL, C8-HSL, C10-HSL 
AiiA B. thuringiensis Not specified 
AttM Agrobacterium tumefaciens c58 3-oxo-C8-HSL 
AiiB, BlcC A. tumefaciens 
C4-HSL, 3-oxo-C6-HSL, C6-HSL, 3-oxo-C8-HSL, C8-
HSL, C10-HSL 
AiiM 
Microbacterium 
testaceum StLB037 
3-oxo-C6-HSL, C6-HSL, 3-oxo-C8-HSL, C8-HSL, 
3-oxo-C10-HSL, C10-HSL 
PPH M. tuberculosis C4-HSL, 3-oxo-C8-HSL, C10-HSL 
QIcA Acidobacteria sp. 
3-oxo-C6-HSL, C6-HSL, C7-HSL, 3-oxo-C8-HSL, C8-
HSL, 3-oxo-C10-HSL, C10-HSL 
AhlD Arthrobacter sp. IBN110 
C4-HSL, 3-oxo-C6-HSL, C6-HSL, C8-HSL, 3-oxo-C10-
HSL, C10-HSL 
AidH Ochrobactrum sp. Not specified 
SsoPox Sulfolobus solfataricus Not specified 
QsdA Rhodococcus erythropolis Not specified 
QsdH Pseudoalteromonas byunsanensis Not specified 
AHL-acylases 
AiiD Ralstonia sp. XJ12B 3-oxo-C8-HSL, 3-oxo-C10-HSL, 3-oxo-C12-HSL 
VAI-C  Variovorax paradoxus Not specified 
Aac Ralstonia solanacearum Not specified 
AiiC Anabaena sp. PCC7120 C4-HSL, C14-HSL 
PvdQ Pseudomonas sp. strain PAI-A 
C10-HSL, 3-oxo-C10-HSL, C12-HSL, 3-oxo-C12-HSL, 
C14-HSL, C16-HSL 
HacA P. syringae strain B728a C8-HSL, C10-HSL, C12-HSL 
AhlM Streptomyces sp. strain M664 C8-HSL, C10-HSL, 3-oxo-C12-HSL 
Acylase Streptomyces sp. ≥C6-AHL 
QuiP P. aeruginosa C6-HSL, C8-HSL, C10-HSL, C12-HSL 
Oxidases 
CYP102A1 B. megaterium Not specified 
Oxidoreductases 
Not yet determined R. erythropolis W2 
Converts C8-HSL to C14-HSL to corresponding 3-
hydroxy derivatives 
Not yet determined Bacillus megaterium Not specified 
Not yet determined Burkholderia sp. Strain GG4 
Reduces; 3-oxo-AHL to corresponding 3-hydroxy 
derivatives. 
 
While lactonases such as AiiA (Table 1.2) hydrolyze the ester bond of the AHL 
molecules yielding N-acyl-homoserine, AHL acylases (sometimes referred to as amidases) 
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hydrolyse the amide bond to yield homoserine lactones and a fatty acid chain (Fig.  1.3) (Tang 
and Zhang, 2014; Grandclément et al., 2016; Zhang and Li, 2016; Castillo-Juárez et al., 2017). 
The fatty acids may then be used as an energy source whilst the homoserine lactones act as 
nitrogen sources (Fetzner, 2015). This hydrolysis is irreversible and renders the signalling 
molecule useless. The first QSI acylase to be discovered was VAI-C from Variovorax paradoxus 
(Castillo-Juárez et al., 2017). AHL acylases vary in their efficacy depending on the length of 
the AHL chain (Safari et al., 2014) and have been identified in cyanobacteria, P. aeruginosa, 
Ralstonia strains and Shewanella sp., as well as a host of other bacterial species (Fetzner, 
2015; Zhang and Li, 2016; Castillo-Juárez et al., 2017). Most acylases exhibit a preference for 
long chain AHLs although some bacteria such as Ralstonia sp. utilize acylases capable of 
degrading both long and short chain AHLs (Safari et al., 2014). Pseudomonas aeruginosa and 
Streptomyces sp. make use of acylases PvdQ and AhlM, respectively, which are active against 
AHL chains longer than and shorter than 8 carbons (Safari et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Catalytic sites of AHL-degrading enzymes (lactonase, acylase, and oxidoreductase) 
as well as their resulting products (Zhang and Li, 2016). 
 
The majority of AHL-acylases which have been characterized belong to the ntn-
hydrolase superfamily (Fetzner, 2015). While the N-acyl homoserine, formed by lactonases, 
can spontaneously recircularize to form AHLs under acidic pHs, the products of acylase activity 
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are stable (Fetzner, 2015). This combined with the metabolic advantages of fatty acids may 
lead to acylases gaining preferance to lactonases as QQ enzymes in the future (Fetzner, 2015).  
First observed in Rhodococcus erythropolis (Romero et al., 2012), oxidoreductases, the 
third class of QSI enzymes, have thus far been additionally identified as being produced by 
Bacillus megaterium (Zhang and Li, 2016).  These enzymes target either the acyl chain itself 
or the keto-group within 3-oxo-homoserine lactones (HSL) and have shown great success in 
inhibiting QS systems, especially when immobilized on solid materials (Zhang and Li, 2016). 
AHL oxidoreductases (Fig. 1.3) catalyze the modification of AHLs, such as the reduction of oxo-
substituted AHLs to their hydroxyl forms (Romero et al., 2012), rendering them 
unrecognizable by their receptors (Tang and Zhang, 2014). The oxidoreductase of R. 
erythropolis is used in conjunction with lactonases and acylases and catalyzes the reduction 
of 3-oxo-C(8-14)-HSL to their corresponding 3-hydroxy-HSLs, thereby rendering them 
unrecognizable to their receptor molecules (Fetzner, 2015). In some cases, the products may 
still act as auto-inducing molecules, but in a highly reduced state (Fetzner, 2015).  
No specific enzymes that degrade Gram-positive peptide QS signals have been 
described. The ability of reactive nitrogen and oxygen compounds, which are common by-
products of enzymes such as NADPH oxidase and NO synthase, to degrade the peptide signals 
of Staphylococcus aureus suggests that there is a possibility that in future their specific QQ 
enzymes may be characterized (Fetzner, 2015). The universal AI-2 molecules may also be 
quenched if the signals are phosphorylated to phospho-AI-2 by exogenously added kinase 
LsrK in conjunction with ATP, since their acquired negative charge prevents entrance to the 
cell and so are rendered redundant (Fetzner, 2015). The efficacy of this system has been 
shown in V. harveyi, Salmonella typhimurium and E. coli where the result was a reduction in 
QS response as well as a reduction in cross-talk between the species if performed in co-culture 
(Fetzner, 2015). Lastly, the Pseudomonas quinolone signal (PQS) and 4-hydroxy-2-
heptylquinoline (HHQ) signal molecules utilized by Pseudomonas and Burkholderia species, 
respectively, may also be quenched, although only one enzyme capable of this has thus far 
been identified (Fetzner, 2015). This enzyme, 1H-3-hydroxy-4-oxoquinaldine 2,4-dioxygenase 
(Hod), is produced by Arthrobacter sp. (Fetzner, 2015).   
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1.3.2.3 Blocking of receptors 
The blocking of receptors has become a popular route of QSI, with the majority of filed QSI-
related patents relating to this method (Romero et al., 2012; Quintana et al., 2015).  The 
efficiency of the binding of autoinducer molecules to their receptors depends strongly on the 
length of the acyl chain as well as the saturation state of the compounds (Dorotkiewcz-Jach 
et al., 2015). Quorum sensing receptors can be inhibited through their blocking with 
antagonistic molecules such as non-functioning, synthetic homoserine lactones 
(Kanagasabhapathy et al., 2009; Rekha et al., 2016; Castillo-Juárez et al., 2017). This requires 
the production of antagonistic molecules similar enough to AHLs to bind to their receptors, 
such as non-toxic phenthylamides, produced by the bacterium Halobacillus salinus (Romero 
et al., 2012).  
Further receptor inhibitors include brominated furanones like those produced by D. 
pulchra, as well as synthetic analogues thereof such as C-30 (Zhang and Li, 2016; Castillo-
Juárez et al., 2017). Treatment with these furanones renders biofilms more sensitive to 
antimicrobial treatment and immune effector cells like polymorphonuclear leukocytes 
(Castillo-Juárez et al., 2017). Additional examples include the production of piericidin A1 by 
the bacterium Kitasatospora (Romero et al., 2012) or monoalides from sponge Luffariella 
variabilis which contain lactone rings in their structures and thus resemble AHLs (Quintana et 
al., 2015).  
Receptors may also be inhibited through covalent bonding, e.g., the bonding of 
isothiocyanate to the cysteine 79 residue in the LasR binding pocket resulted in the 
inactivation of the receptor (Castillo-Juárez et al., 2017). The concentration of persister cells 
has additionally been decreased through the use of similar QSI agents (Castillo-Juárez et al., 
2017). Additionally, long chain AHLs (10 or more carbons in length) may be used to effectively 
inhibit short chain AHL receptors (Romero et al., 2012). However, AHLs can themselves act as 
virulence factors, causing an immune response, deeming this QSI mechanism inadvisable 
(Romero et al., 2012).  
As many virulence factors are controlled by QS circuits, they remain viable targets for 
QSI agents. These virulence factors which may be targeted via QSI are secreted products such 
as enzymes, toxins and siderophores as well as structural components such as pili and flagella 
(Granato et al., 2016). Biofilm formation may also be an important target of QSI, due to its 
important role in the onset of persistent and chronic infections such as cystic fibrosis (Rekha 
23 
 
et al., 2016). Biofilm formation has been successfully inhibited using lactonases, including a 
modified, thermostable lactonase from Geobacillus kaustophilus. This enzyme decreased P. 
aeruginosa biofilm thickness, surface areas and biomass of both new and mature biofilms 
(Castillo-Juárez et al., 2017). In addition to biofilm formation, various virulence factors of P. 
aeruginosa have been proposed as targets of QSI treatments. 
 
1.4 Quorum sensing inhibition and Pseudomonas aeruginosa 
1.4.1 Pseudomonas aeruginosa: An introduction 
Pseudomonas aeruginosa is an opportunistic pathogen (Moradali et al., 2017), with various 
Pseudomonas species being ubiquitous in the natural world; surviving in soil, water, and 
multiple hosts (Castillo-Juárez et al., 2017). Various species commonly cause infections in 
both animal and plant hosts (Lee and Yoon, 2017). Pseudomonas aeruginosa is the most well-
known of these (Lee and Yoon, 2017) and is a highly complex, highly resistant Gram-negative 
bacterium (García-Contreras, 2016) commonly associated with nosocomial infections of the 
skin, urinary tract (in the case of patients with catheters), respiratory tract (most notoriously 
those of cystic fibrosis patients), gut, traumatised corneas, vascular system and, although 
rare, the central nervous system (Kazmierczak et al., 2015; Granato et al., 2016; Hall et al., 
2016; Rekha et al., 2016; Welsh and Blackwell, 2016; Castillo-Juárez et al., 2017). Urinary tract 
infections by this pathogen tend to be chronic, due to the formation of biofilms on the 
catheters, which then adhere to the urothelium and secrete virulence factors (Hall et al., 
2016). This bacterium has also been shown to be responsible for a rare form of endocarditis 
in patients undergoing cardiac procedures or in intravenous drug users (Hall et al., 2016). 
 Although P. aeruginosa can cause minor infections such as otitis media in healthy 
individuals (Lee and Yoon, 2017), it is more commonly an opportunistic pathogen, infecting 
people who are immune-compromised (such as those suffering from cancer or infected with 
HIV) (Moradali et al., 2017), the elderly, burn patients, patients who are intubated for long 
periods or fitted with prosthetic devices, or those suffering from chronic conditions such as 
diabetes and associated diabetic foot ulcers (Guendouze et al., 2017), as well as cystic fibrosis 
(CF) of which it is the major cause of death (García-Contreras, 2016; Rekha et al., 2016; Lee 
and Yoon, 2017; Moradali et al., 2017). Besides the high mortality rate in CF patients, many 
other infections involving P. aeruginosa, such as meningitis, bacteremic pneumonia and the 
sepsis of burn wound infections often prove fatal (Lee and Yoon, 2017).  
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Pseudomonas cells possess a wide range of traits which make them highly competitive 
in colonizing their host environment and their virulence depends on cellular and secreted 
components, such as flagella, pili, toxins, siderophores and proteases (Grandclément et al., 
2016). The pathogenicity of P. aeruginosa can also be attributed to its large genome (∼5-7 
Mbp) in comparison to other prokaryotes (García-Contreras, 2016; Lee and Yoon, 2017; 
Moradali et al., 2017); intrinsic resistance to a wide range of antibiotics through biofilm 
formation, efflux pumps and the production of β-lactamases (Dorotkiewcz-Jach et al., 2015; 
Guendouze et al., 2017); the ability to easily develop resistance against novel compounds and 
stressors (Castillo-Juárez et al., 2017); its ability to form robust biofilms on a variety of 
surfaces and its production of a wide range of virulence factors (García-Contreras, 2016; 
Castillo-Juárez et al., 2017), including phenazines such as pyocyanin which are widely studied 
due to their role in P. aeruginosa infections (Hall et al., 2016). Pseudomonas aeruginosa is 
additionally able to degrade its own autoinducer molecules, thereby forming tetramic acid 
which is toxic to Gram-positive organisms (Singh and Reddy, 2014). 
Additionally, P. aeruginosa contains five of the six known secretion systems (all except 
type IV) present in Gram-negative bacteria, and several of these are present in multiple copies 
within its genome (García-Contreras, 2016). Due to a high number of regulatory genes 
(Moradali et al., 2017), this bacterium is also highly adaptable to varying nutrient conditions 
and environments and can sense and respond to local changes in nutrients such as iron, as 
well as sustain itself on varying carbon sources (Moradali et al., 2017) such as fatty acids in 
burn wounds and amino acids in cystic fibrosis laden airways (Welsh and Blackwell, 2016; Lee 
and Yoon, 2017). These features allow it to continuously change its virulence profile and adapt 
its mode of growth to either an acute or chronic infection, depending on the bacterium’s 
needs (Welsh and Blackwell, 2016).  
The virulence profile of P. aeruginosa is in itself a complicated system, regulated by 
numerous factors. These include cues from the host such as phosphate, iron, and calcium 
levels as well as the temperature within the host (Castillo-Juárez et al., 2017). The presence 
of metabolites such as hormones or adenosine also play a role, in addition to the presence of 
other symbiotic or competing bacteria (Castillo-Juárez et al., 2017). However, the main 
coordinator of P. aeruginosa virulence factors is the bacterium’s complicated QS network, 
which allows the bacteria to evaluate the size and status of their population, synchronize gene 
expression and adjust the production of virulence factors accordingly (Rekha et al., 2016; 
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Welsh and Blackwell, 2016; Castillo-Juárez et al., 2017; Guendouze et al., 2017). Virulence 
factors produced by P. aeruginosa and regulated by QS include biofilm production, type IV 
pili, elastases, pyoverdine (a siderophore), flagella, alkaline protease, phospholipase, 
lipopolysaccharide, exotoxin A, pyocyanin and many others (Guendouze et al., 2017; Lee and 
Yoon, 2017). Overall this pathogen can often be responsible for as much as 10% of nosocomial 
infections in a region, especially in countries with a warmer climate such as Africa and Asia 
and can have devastating social and economic implications (Guendouze et al., 2017). 
 
1.4.2 Quorum sensing systems of Pseudomonas aeruginosa 
Pseudomonas aeruginosa makes use of a complicated, hierarchical QS network of three 
distinctive QS systems (Dorotkiewcz-Jach et al., 2015; García-Contreras, 2016; Hassan et al., 
2016; Welsh and Blackwell, 2016; Castillo-Juárez et al., 2017; Lee and Yoon, 2017) to control 
the production of multiple virulence factors including biofilm production as well as the 
production of rhamnolipids, elastase A and B, hydrogen cyanide, exotoxins, lectins and 
proteases (García-Contreras, 2016; Hassan et al., 2016) (Fig. 1.4). These are the LasI/LasR 
system, the RhlI/RhlR system and the Pseudomonas quinolone signalling (PQS) system (Holm 
and Vikstrom, 2014). Affording the P. aeruginosa QS network its hierarchical structure, the 
HSL-LasR additionally activated a second LuxRI-type QS system, the RhlRI system which 
utilizes AHL N-butyryl-L-homoserine lactone (C4-HSL) (Hassan et al., 2016; Welsh and 
Blackwell, 2016; Castillo-Juárez et al., 2017). The production of this QS signal results in the 
activation of genes encoding virulence factors such as rhamnolipid and pyocyanin production 
(García-Contreras, 2016; Castillo-Juárez et al., 2017). This RhlR-AHL dimer once is additionally 
also responsible for induction of its own feed-forward loop (Papenfort and Bassler, 2016).  
Pseudomonas aeruginosa additionally makes use of a third QS system mentioned 
previously, the PQS system, which activates and regulates key components of the RhlRI 
system (Chan et al., 2015; Kim and Lee, 2016) and is itself activated by the LasRI system but 
antagonized by the RhlRI system (García-Contreras, 2016; Kim and Lee, 2016; Welsh and 
Blackwell, 2016; Castillo-Juárez et al., 2017). Unlike las, however, due to a feedback loop 
mechanism, the rhl system negatively controls the production of PQS, hence the referral to 
Pseudomonas QS systems as being hierarchical (Chan et al., 2015). This system is a quinolone-
based QS system (Kim and Lee, 2016), making use of quinolones 2-heptyl-4-quinolone (HHQ) 
and 2-heptyl-3-hydroxy-4-quinolone (PQS) (Hassan et al., 2016; Castillo-Juárez et al., 2017) 
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Both quinolones bind the transcriptional activator MvfR (also termed PqsR) and indirectly 
activate the genes involved in pyocyanin production and the release of eDNA during biofilm 
formation (Lee and Yoon, 2017) as well as the genes responsible for over 60 small secreted 
molecules (Castillo-Juárez et al., 2017; Lee and Yoon, 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: The hierarchical QS signalling system of P. aeruginosa and related virulence 
factors. The LasRI system mediates the IqsRI, RhlRI and PQS systems, making it the top of the 
hierarchy. When activated, this system is responsible for the production of elastases and 
proteases, among other virulence factors. The RhlRI system is activated by the PQS system in 
the absence of LasRI and is responsible for the production of virulence factors including 
rhamnolipids and pyocyanin. The PQS system is upregulated by the LasRI and IqsRI systems, 
but repressed by the RhlRI system. PQS plays a role in the production of pyocyanin and lectins 
(Lee and Zhang, 2015). 
 
A fourth QS system, termed the integrating quorum sensing (IQS) system, has recently 
been discovered (Papenfort and Bassler, 2016; Rekha et al., 2016; Lee and Yoon, 2017), and 
makes use of 2-(2-hydroxyphenyl)-thiazole-4-carbaldehyde (C10H7O2NS) as it’s signalling 
molecule (Lee and Yoon, 2017). The IQS system is activated by las whilst the cell is under 
phosphate stress, and may be responsible for the integration of environmental cues into the 
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broader QS network whilst acting as a secondary source of activation for C4-HSL and pqs-
mediated genes (Papenfort and Bassler, 2016; Lee and Yoon, 2017), thereby influencing 
pyocyanin, elastase and rhamnolipid production (Rekha et al., 2016). 
It should, however, be noted that this hierarchy is only true of ideal nutritional 
environments, and in cases of low iron or phosphate conditions the LasRI system may be 
bypassed through the induction of the RhlRI and PQS systems by cellular factors (Welsh and 
Blackwell, 2016; Guendouze et al., 2017). The QS networks may also be affected by the source 
and nature of available carbon sources (Welsh and Blackwell, 2016). It has been shown in 
some instances that although the LasRI system may be primarily controlled via population 
densities, the RhlRI system may respond primary to environmental cues (Welsh and Blackwell, 
2016). As PQS directly activates the rhl system, independent of the las system, ties between 
this system and biofilm dispersal have also been made (Kim and Lee, 2016).  
 
1.4.3 Pseudomonas aeruginosa biofilm production 
Biofilms were proposed to be ubiquitous by Costerton and colleagues in 1978, and have since 
been shown to be ubiquitous in the environment, industrial, engineering, and medical fields 
(Lee and Yoon, 2017). Many chronic medical conditions can also be attributed to biofilm 
formation, and biofilm formation on medical devices are untreatable and necessitate the 
removal of the device (Kim and Lee, 2016).  
Biofilms are classified as a sessile mode of growth, until the cells actively detach and 
once again become planktonic and disperse to infect new environments (Kim and Lee, 2016). 
A biofilm can be defined as a complex community of microorganisms attached to a surface 
and embedded in a self-produced extracellular matrix (ECM) comprised of extracellular 
polymeric substances (EPS) in the form of extracellular DNA, proteins, dead cells, RNA, lipids, 
polysaccharides (Kim and Lee, 2016; Zhang and Li, 2016; Lee and Yoon, 2017) and various 
other biomolecules which give the biofilm a strain-specific phenotype (Rasamiravaka et al., 
2015). Biofilms, with their diffusion-limiting ECM have been linked to 65-80% of all microbial 
infections (Rasamiravaka et al., 2015). The EPS is interspersed with interstitial voids and water 
channels, allowing for the transportation of water and the diffusion of oxygen into the biofilm 
and the creation of an oxygen and water gradients (Kim and Lee, 2016; Lee and Yoon, 2017). 
The ECM, therefore, keeps the cells attached to the surface (Kim and Lee, 2016) and affords 
the microorganisms protection from harsh environmental factors, including antimicrobial or 
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disinfection agents, resulting in biofilm-encased cells having a 1000-fold higher resistance to 
these substances than their planktonic counterparts (Lee and Yoon, 2017).  
Biofilm resistance is due to several biofilm-specific bacterial adaptations not available 
to planktonic cells. These include the ECM which retards the entrance of antimicrobial 
compounds into the biofilm, thereby acting as a physical barrier of protection, especially to 
those cells lower down in the matrix (Kim and Lee, 2016; Lee and Yoon, 2017). Within the 
biofilm also lies a subpopulation of cells termed persister cells which reproduce at a highly 
reduced rate, or in some cases altogether (Lee and Yoon, 2017). This reduction in respiration 
affords the cells protection against many classes of antibiotics (Lee and Yoon, 2017).  Biofilm-
embedded cells have additionally been shown to have increased efflux pump production, 
further adding to the resistance of these cells (Lee and Yoon, 2017).  
Being in a biofilm and therefore attached to a surface also ensures that external forces 
do not away sweep the encased cells such as those present in a stream or drain (Kim and Lee, 
2016). The development of biofilms can be broken down into several stages the process of 
which are elucidated in Fig. 1.5. These are initial attachment, irreversible attachment, 
maturation, and detachment (Kim and Lee, 2016; Zhang and Li, 2016). During initial 
attachment, planktonic cells adhere to a surface (Kim and Lee, 2016). Initial attachment 
involves many different components, such as hydrophobic interactions and Van der Waals 
forces, lipopolysaccharides, type IV pili and adhesins (Castillo-Juárez et al., 2017; Lee and 
Yoon, 2017). During irreversible attachment, microcolonies are formed through subsequent 
cell division (Kim and Lee, 2016). These microcolonies form a single layer on the surface, using 
both flagella and pili for attachment (Kim and Lee, 2016; Castillo-Juárez et al., 2017).  The 
attachment become irreversible once microcolonies have been formed and established, 
maturing through the production of EPS, and developing a highly ordered structure (Kim and 
Lee, 2016). The release of extracellular DNA in Pseudomonas biofilm formation is mediated 
by PQS and, in combination with type IV pili and flagella, facilitates the initial and irreversible 
attachment of the cells to a surface, as well as serving as a cell-to-cell interconnecting 
compound and nutrient source (Rasamiravaka et al., 2015). During this stage, the cells also 
undergo complex physiological changes, becoming increasingly resistant to antimicrobials 
and other stressors (Lee and Yoon, 2017).  
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Figure 1.5: Biofilm formation by Pseudomonas aeruginosa. In Stage I, cells reversibly attach 
to a surface. This attachment becomes irreversible in Stage II, shortly followed by the 
production of an extracellular matrix as well as microcolonies in Stage III. The biofilm can be 
seen to be maturing in Stage IV and lastly planktonic cells will disperse from the biofilm in 
Stage V to colonize new surfaces (Rasamiravaka et al., 2015). 
 
During the maturation stages, the self-produced EPS begins to form a mushroom 
shaped, highly porous structure. This structure is supplied with nutrients and oxygen through 
channels within the ECM, allowing for the growth of the cells within it (Kim and Lee, 2016). 
The fully developed biofilms can then be maintained if the environment remains suitable, 
after which cells will detach to become planktonic and colonize new niches (Kim and Lee, 
2016). Detachment can either occur through passive, shear related processed (termed 
sloughing for losses of large biofilm mass or erosion for small losses) or through an active 
process termed seeding (Kim and Lee, 2016; (Lee and Yoon, 2017). During seeding, the biofilm 
releases single planktonic cells or small microcolonies from the centre of the biofilm where 
the motile cells are located, thereby leaving cavities behind surrounding by the external, non-
motile cells (Lee and Yoon, 2017).  
Pseudomonas aeruginosa has been described as a model organism for biofilm study, 
as the protein expression of this organism differed as much as 35% when in a biofilm as 
compared to planktonic growing cells (Kim and Lee, 2016).  Cells of P. aeruginosa within a 
biofilm undergo spatial phenotypic differentiation, where the cells in the centre of the biofilm 
remain motile and those on the outskirts do not. The non-motile cells, therefore, form the 
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stalks of the biofilms during maturation, whilst the motile cells climb the stalks using type IV 
pili-mediated twitching motility, assisted by rhamnolipid production via the rhl QS system 
(Lee and Yoon, 2017), and aggregate at the top as the mushroom caps (Kim and Lee, 2016).  
These motile cells then swim away during active seeding dispersal if the surrounding 
environment is no longer suitable (Kim and Lee, 2016).  
Cells within the P. aeruginosa biofilm are afforded antimicrobial resistance as oxygen 
only penetrates 50–90 μm from the air interface, thereby reducing the metabolic activity of 
the cells (Kim and Lee, 2016). For the aerobic cells located in the upper layer of the biofilm, 
over 50% of the required oxygen is supplied through interstitial voids within the matrix (Kim 
and Lee, 2016). Because these microorganisms exhibit social or group behaviour (Kim and 
Lee, 2016), biofilm formation can, therefore, be associated AHL-mediated QS in many Gram-
negative organisms, including P. aeruginosa (Banerjee and Ray, 2016; Rekha et al., 2016; Lee 
and Yoon, 2017).  A variety of autoinducers, including AHLs with carbon chains of between 
four and 14 carbons in length and the AI-2 autoinducer, are present in sites contaminated by 
biofilms, further cementing the link between QS and biofilm formation (Zhang and Li, 2016). 
The las QS system regulates biofilm formation in P. aeruginosa through control of the pel 
operon, responsible for producing the glucose-rich ECM associated with these biofilms. This 
thick, protective EPS layer allows P. aeruginosa to outcompete other colonies by securing a 
nutrient supply (Zhang and Li, 2016).   
There are three major components of the EPS which have been identified in P. 
aeruginosa biofilms. These are Psl (polysaccharide synthase locus), Pel and alginate (Lee and 
Yoon, 2017). The Psl component initiates and maintains the biofilm by providing intercellular 
reactions and surface attachment, as well as interacting with eDNA to provide structural 
support (Lee and Yoon, 2017). Equally important is Pel, responsible for providing protection 
against aminoglycoside antibiotics and forming pellicles at the air liquid interface (Lee and 
Yoon, 2017). Alginate, however, is the most studied EPS component; retaining water and 
nutrients, providing immune evasion and antibiotic resistance, and differentiating non-
mucoid from the alginate rich mucoid biofilm phenotypes in the lungs of CF patients (Lee and 
Yoon, 2017). The release of eDNA is also mediated through QS-controlled quinolone 
production (Castillo-Juárez et al., 2017). The PQS system of P. aeruginosa mediates the 
release of quinolone 2-N-heptyl-4-hydroxyquinoline-N-oxide (HQNO), which then promoted 
the production of reactive oxygen species, damaging cell membranes and causing cell lysis, 
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allowing for the release of eDNA into the biofilm matrix (Castillo-Juárez et al., 2017). 
Pseudomonas aeruginosa is especially virulent when found in biofilms (Singh and Reddy, 
2014) and treatment of infections by this organism has been shown to be most effective if 
achieved prior to biofilm formation (Gellatly and Robert, 2013).  
 
1.4.4 Quorum sensing inhibition of Pseudomonas aeruginosa  
Pseudomonas aeruginosa has received much attention as a potential target of QSI, due to the 
severity of the infections caused by this pathogen (Rekha et al., 2016). With regulation of 
almost 20% of Pseudomonas proteome by QS (Gellatly and Robert, 2013), there are a range 
of virulence factors which may be combated using QSI.  These virulence factors include the 
production of proteases such as alkaline protease or protease IV, pyocyanin and pyoverdine 
as well as the use of swarming motility for stable biofilm formation (Otton et al., 2017). 
Indeed, many virulence factors produced by this organism have thus far been inhibited using 
QSIs, including biofilm formation and the production of rhamnolipids, siderophores and 
proteases (Guendouze et al., 2017). 
 
1.4.4.1 Targeting P. aeruginosa virulence factor production 
The phenazine pyocyanin is one of the most studied virulence factors produced by P. 
aeruginosa. It is secreted via a type II secretion system and is a nitrogen containing, tricyclic 
aromatic zwitterion (Hall et al., 2016; Moradali et al., 2017). Pyocyanin causes oxidative stress 
to the host, disrupting mitochondrial electron transport and host catalases as well as causing 
apoptosis in neutrophils (Gellatly and Robert, 2013). Due to its low molecular weight and 
zwitterionic properties pyocyanin can cross biological membranes, and through the 
production or reactive oxygen species has many effects on systems throughout the body, 
including cardiovascular, respiratory, urological and the central nervous system (Hall et al., 
2016). Once pyocyanin enters a body system, it attracts neutrophils and induces free radical 
and pro-inflammatory effects, damaging the mitochondria of cells, and leading to protein 
unfolding, ultimately causing cellular damage and apoptosis (Hall et al., 2016; Moradali et al., 
2017). Because of the induced oxidative stress, pyocyanin further causes damage to the host 
through the induction of oxidative-stress dependant MUC2 and MUC5AC, both encoding 
mucin secretion, thereby leading to increased mucous secretion in the infected respiratory 
tract and therefor further colonization by P. aeruginosa (Hall et al., 2016). This colonization is 
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further aided through the release of eDNA as a result of oxidative stress-induced cell death, 
as eDNA plays a vital role in biofilm formation (Hall et al., 2016). This has been most widely 
studied thus far in the airways of CF patients where the higher the concentration of 
pyocyanin, the greater the reduction of lung function of the patient (Hall et al., 2016). 
Pyocyanin has also been shown to promote biofilm formation (Chan etal., 2015). The 
production of pyocyanin is initiated through QS, and maintained through the QS-controlled 
expression of phzA-G operons (Hall et al., 2016).  Quorum sensing-mediated production of 
this green-blue pigment may also, therefore, be targeted using QSI. Pyocyanin is directly 
regulated by the Rhl and PQS QS systems, and indirectly by the Las QS system as las is 
responsible for inducing the production of rhl and PQS (Welsh and Blackwell, 2016).  It is, 
therefore, thought that inhibition of the las system should attenuate pyocyanin production 
through the suppression of rhl and PQS production (Welsh and Blackwell, 2016). 
Staphylococcus delphini and Candida albicans are both able to suppress the production of 
pyocyanin through the production of QS inhibitors yayurea A and B and PQS circuit-blocking 
farnesol, respectively (Tang and Zhang, 2014). Plant-derived compounds Taxifolin (Banerjee 
and Ray, 2016) and Cassia alata extracts (Rekha et al., 2017) have also been used successfully 
to inhibit the production of pyocyanin. Similarly, plant-associated Streptomyces coelicoflavus 
produced 1H-pyrrole-2-carboxylic acid capable of inhibiting P. aeruginosa PAO1 pyocyanin 
production without affecting cell growth (Hassan et al., 2016). Pyocyanin production may also 
be inhibited using synthetic compounds which are able to compete with N-(3-
oxododecanoyl)-L homoserine lactone (Dorotkiewcz-Jach et al., 2015), as well as engineered 
molecules and enzymes such as engineered lactonase SsoPox-W263I, which caused a near 
complete reduction in P. aeruginosa pyocyanin production (Guendouze et al., 2017).   
Elastase staphylolysin (LasA), a serine protease able to disrupt peptidoglycan 
stabilization in staphylococci, may be targeted as it is the most abundant of the Pseudomonas 
endopeptidases and increases the elastolytic activity of other elastases such as LasB during 
the infection process (Moradali et al., 2017). Protease LasB, another important elastase 
involved in Pseudomonas virulence, may also be targeted. LasB degrades host elastin and 
collagen, in conjunction with inactivating key components of the host defence system 
(Moradali et al., 2017). Plant-derived compound Taxifolin has been used successfully to inhibit 
the production of elastase in P. aeruginosa, however, flavonoid-based plant-compounds 
including naringenin and kaempferol have been described as the most potent plant-derived 
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QSIs (Banerjee and Ray, 2016). Although the active compound was unidentified, an extract 
from medicinal plant Cassia alata additionally resulted in P. aeruginosa elastase inhibition of 
greater than 90% at 0.2 mg/ml. Inhibition of elastase production was further achieved using 
marine-associated Streptomyces-derived compounds (Naik et al., 2013) as well as 
Streptomyces M664 which produced an acylase capable of 43% protease production (Chang 
et al., 2017). Plant-associated Streptomyces coelicoflavus produced 1H-pyrrole-2-carboxylic 
acid capable of inhibiting P. aeruginosa PAO1 elastase production without affecting cell 
growth (Hassan et al., 2016). Methyl anthranilate and halogenated anthranilate also resulted 
in elastase inhibition, while additionally inhibiting the PQS system (Dorotkiewcz-Jach et al., 
2015).  
Proteases are key in Pseudomonas host colonization and virulence, and so are often a 
key area of focus in anti-virulence studies (Guenzdouze et al., 2017). Quorum quenching 
enzymes have shown success in reducing P. aeruginosa protease production, such as 
engineered lactonase SsoPox-W263I which reduced P. aeruginosa PAO1 protease production 
by 90% and P. aeruginosa PA14 protease production by 57% at 0.5 mg/ml (Guenzdouze et al., 
2017) or Streptomyces M664-produced acylase which resulted in a 60% P. aeruginosa total 
protease inhibition (Chang et al., 2017). Small molecules, such as analogues of anthranilic 
acid, which compete with anthranilic acid for binding to the enzyme PqsA, have also been 
shown to inhibit protease production as a result of PQS inhibition (Castillo-Juárez et al., 2017). 
Medicinal plant extracts have also shown promise in reducing P. aeruginosa virulence, as 
plant extracts from C. alata resulted in a 90% protease reduction at 0.2 mg/ml (Rekha et al., 
2016).  
Pseudomonas aeruginosa additionally makes use of pyoverdine, a siderophore that 
acts both as a signalling molecule by obtaining iron for the bacterial cells and up-regulates the 
production of exotoxin A and endoprotease (Gellatly and Robert, 2013), although the exact 
importance of this compound in the severity of infections can vary significantly (Granato et 
al., 2016).  Unlike in plant hosts, within mammalian and invertebrate hosts pyoverdine-
deficient mutants of various P. aeruginosa strains showed reduced virulence (Granato et al., 
2016). However, this was to varying extents and proved to be more effective in mammalian 
hosts as compared to invertebrate hosts (Granato et al., 2016). The production of this 
siderophore may be extracellularly inhibited through the addition of elemental gallium, 
although further experimentation into the cytotoxic effects of the element needs to be 
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performed (García-Contreras et al., 2016). Additionally, because of the varying effects of 
pyoverdine inhibition on virulence, the targeting of pyoverdine would more likely attenuate 
rather than cure a P. aeruginosa infection, and as such should be applied in conjunction with 
another treatment option, such as further anti-virulence treatments targeting other virulence 
factors or in conjunction with antibiotics (Granato et al., 2016) such as the addition of 
Streptomyces-derived acylase AhlM (Romero et al., 2012), Ralstonia acylase AiiD 
(Dorotkiewcz-Jach et al., 2015) or AiiA from B. cereus which when added to P. aeruginosa 
reduced the production of virulence factors such as hydrogen cyanide as well as swarming 
motility of this organism (Dorotkiewcz-Jach et al., 2015; Fetzner, 2015).  
The production of rhamnolipids is instrumental in the formation of Pseudomonas 
biofilms (Moradali et al., 2017). Rhamnolipids are glycolipids produced by P. aeruginosa, the 
production of which is controlled by the RhlRI QS circuit (Kim and Lee, 2016). Rhamnolipids 
have been shown to be vital in mature biofilm inhibition, but a hindrance to initial biofilm 
production (Kim and Lee, 2016). In mature biofilm formation, rhamnolipids influence biofilm 
structure and maintain the interspersed channels around the microcolonies (Kim and Lee, 
2016). They have also been shown to promote detachment from the biofilm (Kim and Lee, 
2016). Pseudomonas aeruginosa produces two types of rhamnolipids, mono-rhamnolipids 
controlled by enzymes encoded by the RhlAB operon, and di-rhamnolipids produced by a 
rhamnosyl-transferase encoded by RhlC, using mono-rhamnolipids as substrates (Castillo-
Juárez et al., 2017). Rhamnolipid production is modulated primarily through the RhlRI QS 
system, however, it receives input from the remaining P. aeruginosa systems as well (Castillo-
Juárez et al., 2017). Additionally, rhamnolipids have been shown to lyse polymorphonuclear 
leucocytes as well as monocyte-derived macrophages in patients with cystic fibrosis, resulting 
in severe necrotic cell death (Moradali et al., 2017). As this can have serious health 
implications for the patient, and as biofilm formation is a key virulence trait of P. aeruginosa, 
it is pertinent that these be addressed in the treatment of infections by this opportunistic 
pathogen. With biofilm formation and rhamnolipid production being QS-mediated processes, 
QSI may serve as a viable means of achieving this (Rasamiravaka et al., 2015).  
The motility of P. aeruginosa cells plays an important role in both biofilm formation as 
well as dispersion. Motility allows cells to colonize a niche and begin biofilm formation, and 
because of spatial differentiation, it ensures that the motile and non-motile cells are localized 
appropriately for easy dispersal of the motile cells from the centre and mushroom cap of the 
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biofilm (Kim and Lee, 2016). Plant compounds, such as extracts from medicinal herb Cassia 
alata were shown to significantly decrease swarming motility in P. aeruginosa PAO1 (Rekha 
et al., 2016). Marine-associated Streptomyces-derived compounds were also shown to inhibit 
swarming motility as well as the establishment of a stable biofilm (Naik et al., 2013). Similarly, 
marine bacterial species Bacillus pumilus and Rhizobium sp. PAO1 could inhibit mature and 
initial biofilm formation, respectively, with Rhizobium inhibitions reaching 78% (Chang et al., 
2017).  
In addition to these, synthetic AHLs, where the homoserine lactone ring was replaced 
with a cyclohexanone ring, were shown to inhibit the LasR receptor, down-regulate LasI 
synthase (Rasamiravaka et al., 2015) as well as negatively regulate swarming motility and 
rhamnolipid production and in so doing reduced biofilm formation (Dorotkiewcz-Jach et al., 
2015). Enzymes have also been effective, with lactonase SsoPox-W263I reducing initial P. 
aeruginosa biofilm production by initial 90% in P. aeruginosa PAO1 and 60% in P. aeruginosa 
PA14 (Guendouze et al., 2017). Biofilm formation in P. aeruginosa PAO1 was also inhibited by 
extracts of C. alata, which resulted in significant biofilm inhibition at 0.4 mg/ml (Rekha et al., 
2016) as well as plant extracts of Callistemon viminalis, which reduced biofilm formation by 
89% at 1 mg/ml (Chang et al., 2017). Dual-therapy approaches may also be used in 
Pseudomonas biofilm treatments, where biofilms are initially treated with QSI substances and 
then by antimicrobial compounds to complete the treatment (Dorotkiewcz-Jach et al., 2015). 
The QSI compounds, such as Terminalia chebula fruit extracts, have been shown to increase 
the susceptibility of biofilms treated with antimicrobial compounds, such as tobramycin, as 
they down-regulate the expression of the lasR and rhlR genes (Dorotkiewcz-Jach et al., 2015). 
Similarly, when P. aeruginosa biofilms were treated with kanamycin in addition to a 5% QSI 
supernatant, almost complete killing of the biofilm cells was observed (Chang et al., 2017). 
From the marine world, D. pulchra halogenated furanones have inspired the creation of 
synthetic derivatives C-30 and C-56, which may affect biofilm production in P. aeruginosa, 
interfering with biofilm architecture and promoting detachment thereby significantly 
increasing survival in mice models (Castillo-Juárez et al., 2017). However, the use of furanones 
has been restricted to date due to its high toxicity (Castillo-Juárez et al., 2017). This could 
potentially be avoided through the combining of furanones with other QSI products or 
antibiotics, thereby reducing the quantity of furanone administered and decreasing the 
cellular toxicity observed (Castillo-Juárez et al., 2017). Enzymes have also proven successful, 
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with acylases from Agrobacterium tumefaciens and Pectobacterium atrosepticum having 
been successfully used to degrade AHLs produced by P. aeruginosa, and in so doing decrease 
virulence factor production (Guendouze et al., 2017). Lactonase MomL from marine 
bacterium Muricauda olearia had the same effect through the degradation of P. aeruginosa 
AHL signals (Guendouze et al., 2017).  
 
1.4.4.2 Targeting P. aeruginosa QS systems 
In addition to the virulence factors regulated by the QS sstems, the systems themselves may 
also be targeted. Inhibiting las and rhl related genes could reduce virulence factor secretion 
in P. aeruginosa (Banerjee and Ray, 2016), with Welsh and Blackwell (2016) showing marked 
activity using QSIs against both the LasR and RhlR receptors of wild-type P. aeruginosa, 
resulting in strong pyocyanin inhibition. In wastewater treatment environments, inhibition of 
the rhl system has resulted in P. aeruginosa exhibiting reduced phenol degradative and 
denitrification abilities (Zhang and Li, 2016).  The production of both elastase and protease 
production by P. aeruginosa is also controlled interactively by both the LasRI and RhlRI QS 
circuits. These enzymes have become important targets of novel compounds as they play 
important roles in the invasiveness of the pathogen (Rekha et al., 2016). Through the use of 
compounds such as lyngbic acid or lyngbyoic acid produced by the marine cyanobacterium 
Lyngbya majuscula, the LasR QS molecules of P. aeruginosa may be inhibited (Tang and Zhang, 
2014), with the theory being put forth that many molecules possessing aromatic ring head 
groups may exert a similar LasR inhibitory effect (Welsh and Blackwell, 2016). Inhibition of 
the LuxI homologue synthesis in P. aeruginosa, LasI, by analogues of S-adenosylmethionine 
significantly lowered the production of virulence factors (Romero et al., 2012). The AiiC 
acylase from Anabaena sp. is different to most acylases in that it displays a wide range of AHL 
activity, such as C4-HSL, and so can be used to target the RhlI system of P. aeruginosa (Fetzner, 
2015). Phytochemicals such as trans-cinnamaldehyde were also shown to inhibit the short 
chain AHL-synthase, RhlI (Chan et al., 2015). Compound iodo-phenoxyacetyl was shown to 
target RhlR, inhibiting pyocyanin and other virulence traits associated with the system (Welsh 
and Blackwell, 2016). A further example of such a QSI compound is meta-bromo-thiolactone 
which partially represses RhlR and LasR and blocks the formation of biofilms as well as the 
production of virulence factors (Papenfort and Bassler, 2016). Rhamnolipid and elastase B, 
however, were unaffected, potentially due the PQS system reactivating the Las- and Rhl-
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associated virulence factors. This was shown when a QSI agent inhibiting PQS was used, and 
no recovery of virulence factor production was observed (Welsh and Blackwell, 2016). It was 
found that PQS inhibition limited virulence factor production in a variety of environmental 
conditions (Welsh and Blackwell, 2016).  
In high phosphate conditions, PQS-regulated virulence was dependant on the las 
system. However, in low-phosphate conditions, PQS-regulated virulence proceeded 
independent of the las system (Welsh and Blackwell, 2016). Ureidothiophene-2-carboxylic 
acid was recently described as an inhibitor of the enzyme PqsD, necessary for the functioning 
of the PQS QS system (Zhang and Li, 2016), and in 2014 a MvfR inhibitor with a benzamide-
benzimidazole backbone was identified, capable of decreasing the concentration of PQS and 
the production of pyocyanin thereby increasing the survival of mice in lung infection and burn 
models (Castillo-Juárez et al., 2017). It has also been noted that blocking the PQS receptor 
interferes with the formation of persister cells (Papenfort and Bassler, 2016). The PQS system 
may also be targeted using Hod, a 2,4-dioxygenase produced by Arthrobacter 
nitroguajacolicus which is able to cleave the PQS molecule (Tang and Zhang, 2014), producing 
a N-octanoylanthranilic acid and carbon monoxide (Fetzner, 2015). The use of Hod led to a 
decrease in pyocyanin, rhamnolipid and lectin A production (Chan et al., 2015; Dorotkiewcz-
Jach et al., 2015). An unknown enzyme isolated from Achromobacter xylosoxidans was also 
able to inhibit the PQS system through the oxidation of the molecule, forming 2-heptyl-2-
hydroxy-1,2-dihydroquinoline-3,4-dione (HHQD) (Chan et al., 2015).  
Unfortunately, some QSI compounds can be agonists of one receptor while supressing 
another, therefore making it unfeasible to use only one type of QSI inhibitor at a time 
(Papenfort and Bassler, 2016). It has already been shown that combining a LasR or RhlR 
antagonist with a PQS antagonist could result in a broader spectrum activity, especially taking 
into regard the effects of environmental conditions on the signalling processes where one 
system may be favoured over another depending on the cellular conditions faced (Welsh and 
Blackwell, 2016). It is ideal then to use a QSI molecule, or cocktail thereof, capable of inhibiting 
both the rhl and PQS systems if effective inhibition is to be achieved (Welsh and Blackwell, 
2016). 
Although QSI research in pathogenic organisms such as P. aeruginosa is advancing 
rapidly, showing that QS mutants are less virulent than their parent strains, less work has 
been done to determine the effect of these molecules on cellular growth and global 
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metabolism (García-Contreras, 2016). Although very few transcriptomic-level changes in 
metabolic-related genes are usually observed when using QSIs, in some instances as much as 
one third of the produced metabolites may be altered (García-Contreras, 2016). Often, 
however, this results in an increase rather than a decrease in cell growth, as wild type strains 
devote many resources to the production of virulence factors such as pyocyanin while the QS-
inhibited strains are then freed up to use this energy for cellular growth and replication 
(García-Contreras, 2016). Further research is also needed on the effect of QSI on those 
virulence factors which are negatively regulated via QS in specific environmental conditions, 
such as the type III secretion system in P. aeruginosa which plays a pivotal role in burn, 
pneumonia, and bacteremia infections among others (García-Contreras, 2016).  
 
1.5 Sponges and sponge-associated bacteria as inhibitors of quorum sensing and biofilm 
production 
Quorum sensing inhibition has been theorized to be part of the original host or symbiotic 
bacteria’s strategy to deter bacterial settlers, such as sponges’ need to protect their water-
pumping mechanisms by inhibiting biofilm formation (Perdicaris et al., 2013). Sponges 
displaying promising QSI activities include Aphrocallistes bocagei, (Gellius) megastoma and 
Clathria atrasanguinea (Annapoorani et al., 2012) as well as Sarsia tubulosa which is known 
to produce long chain fatty acids, peptides, and steroidal compounds (Quintana et al., 2015). 
Additionally, of the 14 sponge species isolated from the Mediterranean and Red Seas and 
screened for QSI activities, 50% the isolates yielded positive, promising results (Saurav et al., 
2016). This could be as a result of many sponges producing diverse sesquiterpenoid QS 
inhibitors which, in addition to their QSI activity, also modulate biofilm formation in Gram-
negative bacteria (Grandclément et al., 2016). Finally, through the production of manoalide 
derivatives, marine sponge Luffariella variabilis exhibited strong QSI activity against various 
Gram-negative bacteria, including P. aeruginosa (Annapoorani et al., 2012). 
Anti-settlement strategies such as these are furthermore utilized by a wide variety of 
bacterial species, and is thought to be widespread across Actinobacteria, Flavobacteria, 
Alpha-proteobacteria, Beta-proteobacteria, Gamma-proteobacteria and Bacillus genera 
(Hollants et al., 2013; Grandclément et al., 2016). Special attention is being given to 
Actinomycetes as they are powerful producers of a wide range of secondary metabolites 
(Chankhamhaengdecha et al., 2013) such as azamerone and cytotoxic actinofuranones (Cho 
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and Kim, 2012) or novel polyketides produced by sponge-associated Saccharopolyspora 
species (Sun et al., 2015). Streptomyces have been well documented as producers of 
antibiotic agents, however, research into their production of QSIs has not been as expansive 
(Bramhachari et al., 2016; Hassan et al., 2016). Compounds produced by Streptomyces are 
generally safe for human consumption (Hassan et al., 2016), and QSI compounds such as the 
peptide proline-glycine and cinnamic acid have been derived from marine-associated 
Streptomyces (Hassan et al., 2016). Streptomyces sp. have also been shown to produce AHL-
acylases capable of degrading long chain AHLs (AHL chains consisting of more than 6 carbons) 
(Banerjee and Ray, 2016). 
It has already been demonstrated that Pseudoalteromonas, Micrococcus, Vibrio, 
Bacillus and Phaeobacter are efficient producers of QSI compounds (Hollants et al., 2013), 
with more than 3% of the Bacillus genome being dedicated to the production of secondary 
metabolites (Bastos et al., 2013). Marine-derived cyanobacteria, such as those associated 
with the sponge Clathrina contorta, have also been shown to produce many QSI molecules, 
with tumonoic acids derived from Blennothrix cantharidosmum inhibiting the 
bioluminescence of Vibrio harveyi without affecting bacterial growth (Tang and Zhang, 2014). 
Most importantly, while the growth of the microorganism was not inhibited, biofilm 
formation was inhibited through the interference in bacterial cell-to-cell signalling, thereby 
drastically reducing biofouling (Kanagasabhapathy et al., 2009; Quintana et al., 2015). Saurav 
et al. (2016) demonstrated that from 86 sponge-associated bacteria screened, 20% were 
capable of QSI when screened against C. violaceum and P. aeruginosa, most of which 
belonged to the Alphaproteobacteria with the most potent strains belonging to the genera 
Alteromonas, Nautella, Paracoccus, and Pseudovibrio. These isolates were capable of P. 
aeruginosa virulence factor inhibition, including a 50% and 70% reduction in biofilm and 
pyocyanin production, respectively (Saurav et al., 2016).  
Durai et al. (2013) showed that eight bacteria associated with sponge Haliclona sp. 
were able to, through QS inhibition, reduce the severity of the Vibrio alginolyticus infection 
in Caenorhabditis elegans with one isolate increasing survival rates by 60% 48 h post infection. 
Although these bacteria were not identified, and their Gram-designation is unknown, Gram-
positive marine bacteria such as Bacillus cereus, although not as abundant as Gram-negative 
bacteria (Martin et al., 2014), have also been shown to inhibit QS, often through the 
production of lactonases (Fetzner, 2015). Other QSI molecules produced by Gram-positive 
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bacteria are 3-methyl-N-(2-phenylethyl)-butyramide and N-(2-phenylethyl)-isobutyramide, 
produced by Halobacillus salinus and were effective against green fluorescent protein (GFP) 
production by QS biosensor E. coli JB525 as well as violacein production by C. violaceum (Tang 
and Zhang, 2014). However, much research is still needed, as research focussing on the QSI 
properties of SPAB is still in its infancy.  
 
1.6 Sponge-associated bacteria as inhibitors of HIV-1 
In many cases, the infection of patients with opportunistic pathogens such as P. aeruginosa 
is due to the patients suffering from a compromised immune system, often due to an HIV 
infection (Ellithey et al., 2014). This is especially true in developing or Third World nations 
such as South Africa (Otang et al., 2014). Viruses cause many severe diseases, and re-
emerging viral infections represent a major health risk to the global population (Bastos et al., 
2013). Viral infections often lead to additional health risks, such as the development of cancer 
in patients with lower CD4+ cell counts due to acquired immunodeficiency syndrome (AIDS) 
infections (Ellithey et al., 2014). Due to their high mutation rates, intracellular replication, and 
the limited antiviral compounds available, effective treatment for viruses such as HIV has yet 
to be achieved (Bastos et al., 2013). As such, alternative treatment options and novel antiviral 
compounds are constantly being sought (Mthethwa et al., 2014). 
 
1.6.1 Classes of antiviral compounds isolated from marine sources 
Due to the wide variety of secondary metabolites produced, natural marine sources are said 
to be a potentially inexhaustible source of promising novel antiviral agents (Bastos et al., 
2013). In 1963 there were only four papers published which focussed on marine natural 
products, however, between the years 1963 and 2013 24662 marine compounds were 
successfully isolated (Blunt et al., 2015), with the rate of discovery of compounds such as 
these from the marine world increasing by 10% annually (Jagadeesan and Balaiah, 2015).  
 
1.6.1.1 Sponge-derived antiviral compounds 
Possibly the most important antiviral sponge-derived drug to date is nucleoside Ara-A, or 
vidarabine, a synthetic analogue of an arabinose-containing spongouridine produced by the 
sponge Tethya crypta and isolated for the first time in 1950 (Santos-Gandelman et al., 2014; 
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Indraningrat et al., 2016). Vidarabine does not interact with RT or protease activity but instead 
targets DNA polymerase, thereby inhibiting the synthesis of viral DNA (Cheung et al., 2014).  
Many additional classes of antiviral drugs, often with activity potent enough to make 
it through to clinical trials, have since been isolated from marine sources such as sponges. The 
first sponge-derived nucleosides, spongouridine and spongothymidine, were isolated from 
Tethya crypta in 1950 by Bergmann et al. and were the first nucleosides to be licensed for the 
treatment of systematic herpes virus infections (Indraningrat et al., 2016). Nucleosides 
mycalamide A and B with activity against HSV and corona viruses were also isolated from 
marine sponges (Sagar et al., 2010). Mycalamide A and B from Mycale sponges were shown 
to inhibit viral protein synthesis with mycalamide B being more potent that mycalamide A 
(Sagar et al., 2010). Four analogues of mycalamide A displayed antiviral property against the 
influenza virus by binding the viral nucleoproteins and as such inhibiting viral replication 
(Sagar et al., 2010). 
In addition to nucleosides, sesquiterpene hydroquinones have also been isolated from 
marine sponges (Blunt et al., 2015; Moghadamtousi et al., 2015). The sesquiterpene 
hydroquinone avarol showed potent activity against the Gag protein of HIV as a result of 
increased intracellular levels of superoxide radicals and is one of the most promising sponge-
derived anti-HIV drugs (Sagar et al., 2010; Mehbub et al., 2014). Avarol was further shown to 
inhibit functionality of various viral proteases, 5’-lipoxygenase, cyclooxygenase as well as viral 
reverse transcriptase enzymes (Sagar et al., 2010). Several avarol derivates, such as avarone, 
have since been isolated from other sea sponges such as Dysidea cinerea (Sagar et al., 2010).  
Antiviral drug classes isolated from marine sponges further include cyclic 
depsipeptides such as anti-HIV papuamides A, B, C and D from sponges Theonella mirabilis 
and Theonella swinhoei from Papua New Guinea (Uzair et al., 2011; Mehbub et al., 2014) and 
microspinosamides isolated from Indonesian sponge Sidonops microspinosa (Sagar et al., 
2010). Membrane-targeting papuamides A and B serve as apt examples of the chemically 
complex, sponge-derived compounds showing high antiviral potential as they exhibit potent 
anti-HIV activities at concentrations in the nanogram-per-millilitre range (Uzair et al., 2011; 
Mehbub et al., 2014). Brominated alkaloids from sponge Lotrochota sp. as well as alkaloids 
such as 4-methylaaptamine (from Brazilian Aaptos sponges) and dragmacidin F (from Italian 
Halicortex sponges) have also been isolated and show antiviral activity against several viruses 
including influenza and HIV (Uzair et al., 2011; Quintana et al., 2015). This is also true of 
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calyceramides (from sponge Discodermia calyx) and phenolic macrolides such as hamigeran.  
B Neamphamide from marine sponge Neamphius huxleyi and petrosins from Petrosia similis 
were observed to inhibit HIV growth and crambescidin and norbatzelladine L from a 
Monanchora sponge inhibited the envelope fusion of HIV-1 with host cells by 97% (Uzair et 
al., 2011; Perdicaris et al., 2013).  
 
1.6.1.2 Sponge-associated bacteria-derived antiviral compounds 
In the past, the most pronounced bottleneck to commercial production of sponge-produced, 
antiviral compounds has always been the difficulties in meeting the demand for the supply of 
large quantities (Sagar et al., 2010). It is unfeasible to harvest these metabolites directly from 
sponges as the large amount of biomass needed in order to gain a significant quantity of 
metabolite is often unobtainable (Indraningrat et al., 2016). For example, approximately 40 
kg of sponge Discodermia dissoluta is needed to produce 1 g of discodermolide (Blunt et al., 
2015). Recent advances in high throughput microbial cultivation and fermentation, combined 
with the discovery that many sponge-derived compounds are actually/additionally produced 
by associated bacterial species, have meant that antiviral compounds derived from marine 
bacteria may prove to serve as promising and cost-effective alternatives to currently 
commercially available products (Jagadeesan and Balaiah, 2015).  
What little research has been done into such sponge-associated bacterial compounds 
continues (Jagadeesan and Balaiah, 2015; Indraningrat et al., 2016), with many showing 
promise but have yet to be identified and characterized. Bacillus sp. associated with sponges, 
such as B. cereus or B. intermedius, showed up to 90% antiviral activity against tobacco mosaic 
virus and rabies virus, respectively (Bastos et al., 2013). Unidentified compound B555 from 
Bacillus sp. associated with sponge Petromica cintrina inhibited bovine viral diarrhea virus, a 
substitute for HCV, by 98% (Bastos et al., 2013; Perdicaris et al., 2013). When tested against 
enveloped viruses, treatment with such marine bacterial extracts had a prophylactic effect, 
preventing viral entry into cells as well as resulting in a ≥ 80% viral inactivation (Tong et al., 
2012).  
Active quinolone 2-undecyl-4-quinolone was isolated from Pseudomonas sp. 
associated with marine sponge Homophymia and showed activity against both HIV-1 and 
malarial parasite Plasmodium falciparum (Bramhachari et al., 2016). Secosteroids are 
compounds which have previously only been isolated from soft corals, gorgonians and 
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sponges, and this particular prophylactic effect was attributed to the presence of secosteroid 
5α(H),17α(H),(20R)-β-Acetoxyergost-8(14)-ene within the bacterial extract (Tong et al., 
2012). Due to the complexity and size of molecules such as this, harvesting such potent 
compounds directly from large scale microbial fermentation reactors would in future prove 
more feasible than constructing suitable synthetic analogues (Tong et al., 2012), once again 
cementing the benefits of investigating sponge-associated bacteria for their antiviral 
properties. Antiviral compounds may target viruses through disruption of their replication 
cycle, the inhibition of viral adsorption or through the inactivation of the virus particle (Bastos 
et al., 2013). Amongst these, a popular choice is the testing of compounds’ ability to interfere 
with key viral replication enzymes, such as the reverse transcriptase enzyme. 
 
1.6.2 Targeting HIV-1 reverse transcriptase enzymes 
The HIV reverse transcriptase (RT) enzymes were established early on as potential targets for 
novel, HIV-targeting drugs (Fig. 1.6.) (Ahn et al., 2004; Ellithey et al., 2014). Reverse 
transcriptase has three identified, separate enzymatic functions. These are as a RNA-
dependent DNA polymerase, a ribonuclease and as a DNA-dependent DNA polymerase (Ahn 
et al., 2004). The combination of these three functions results in the RT converting the viral, 
single stranded RNA into proviral, double stranded DNA such that it may be integrated into 
the host genomic DNA (Ahn et al., 2004). These important functions make HIV RT key for HIV 
replication and as such can be said to be a potentially effective target for novel, marine 
derived drugs (Ahn et al., 2004). Non-marine derived drugs used currently to target the RT 
enzyme as a form of HIV treatment include zidovudine (AZT), abacavir (ABC) and nevirapine 
(Ahn et al., 2004).  However, a number of marine-derived inhibitors interacting with RT have 
already been identified, such as peyssonol and illimaquinone (Ahn et al., 2004) as well as 
clathsterol from sponge Clathria sp. (Uzair et al., 2011). Dehydrofurodendin, extracted from 
Madagascan sponge Lendenfeldia, was shown to inhibit both the DNA- and RNA-directed 
activities of the HIV-1 RT enzyme (Uzair et al., 2011).  
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Figure 1.6: HIV replication and infection cycle, showing potential drug targets. The first step 
in the HIV-1 replication cycle is attachment of the virus to the cell surface proteins CD4 and a 
co-receptor. Fusion of the viral and host cell membranes allows for entry of the viral capsid 
into the cell, and the viral RNA genome is reverse transcribed to double-stranded DNA, which 
is then integrated into the host genome. HIV RT is targeted by nucleoside analogue reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). 
After the viral DNA has been integrated, proviral transcription yields viral RNAs, which are 
translated into viral proteins that assemble with the unspliced viral RNA genome at the cell 
surface. The virions which bud from the cell are immature, and subsequently mature via 
proteolytic processing of viral polyproteins, which ultimately results in mature virions that are 
capable of infecting new cells. (Laskey and Siliciano, 2014). 
 
1.7 Rationale of study 
Due to the morbidity and mortality as well as economic losses experienced every year as a 
result of bacterial infections (Cho and Kim, 2012; Chankhamhaengdecha et al., 2013), 
alternative medical treatments are being sought (Bramhachari et al., 2016). The last novel 
antimicrobial agent was introduced to the market in 2003 (Steckbeck et al., 2014), and the 
rise in nosocomial infections due to resistant ESKAPE pathogens such as P. aeruginosa has 
caused a global crisis (Dorotkiewcz-Jach et al., 2015).  
 Quorum sensing inhibition has been proposed as a viable alternative to antimicrobial 
treatment as it does not hinder growth and therefore reduces bacterial virulence without 
inciting resistance (García-Contreras, 2016; Granato et al., 2016). Both enzymes and small 
molecules from various natural sources have shown promise as QS inhibitory agents 
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(Banerjee and Ray, 2016; Guendouze et al., 2017). The mining of natural resources from 
terrestrial environments for novel pharmaceutical products such as QSIs has dominated the 
research field for many years (Moghadamtousi et al., 2015), with the investigation of marine 
sources still being in its infancy (Abbamondi et al., 2014). What research has been done has 
focussed on marine macro-organisms, such as the seaweeds, corals and sponges themselves, 
with very little work being done on their associated microorganisms (Bramhachari et al., 2016; 
Saurav et al., 2016). This is especially true of South African-based studies, with this being (to 
the best of our knowledge) the first study focussing on sponge-associated bacteria isolated 
off the KwaZulu-Natal coast for the purpose of investigating their QSI potential. Sponges have, 
in the past, exhibited potent QSI potential, and recently it has been shown that often the 
metabolites responsible for this are produced primarily by the SPAB and not the sponge itself 
(Sun et al., 2015). Due to the bottleneck of research as a result of the limited sponge biomass 
available, the use of SPAB would provide a viable solution to this problem as they are easily 
culturable and propagated (Jagadeesan and Balaiah, 2015).   
Pseudomonas aeruginosa is an important candidate for QSI due to its prolific 
resistance mechanisms and prevalence in the nosocomial setting (Castillo-Juárez et al., 2017). 
Found ubiquitously in a variety of natural environments (Lee and Yoon, 2017) P. aeruginosa 
is the leading cause of death in patients suffering from CF (García-Contreras, 2016; Rekha et 
al., 2016; Moradali et al., 2017) as well as the causative agent in a number of other human 
infections (Lee and Yoon, 2017). Due to the complex nature of the P. aeruginosa hierarchical 
QS networks, and with almost 20% of its proteome being QS-regulated (Gellatly and Robert, 
2013), this organism was selected as a prime subject for the study, in order to determine the 
QS inhibitory potential of SPAB isolated off the KwaZulu-Natal coast. Extracts from these SPAB 
exhibiting positive QSI activity through the reduction of key P. aeruginosa virulence factors 
such as biofilm, protease, elastase, siderophore and phenazine production could then go on 
to serve as viable treatment alternatives and potential solutions to the current resistance 
crisis. Should these extracts also display potential anti-HIV activity, combination treatments 
may be explored in immuno-compromised patients, highlighting the need to further explore 
the potential antiviral activity of the SPAB extracts.  
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1.8 Hypotheses 
It was hypothesized that South African indigenous sponge-associated, QSI bacteria are able 
to inhibit the production of key quorum sensing-mediated virulence factors of Pseudomonas 
aeruginosa. It was further hypothesized that extracts from sponge-associated bacteria may 
exhibit putative anti-HIV potential through the inhibition of HIV-1 reverse transcriptase. 
 
1.9  Objectives  
The following objectives have been established: 
1.9.1 To identify sponge-associated bacteria exhibiting quorum sensing inhibitory 
and antimicrobial activity; 
1.9.2 To investigate the potential of seaweed-associated bacteria to inhibit quorum 
sensing-mediated virulence factor production by P. aeruginosa; and 
1.9.3 To investigate the putative anti-HIV potential of sponge-associated bacterial 
extracts.  
 
1.10 Aims  
The following aims were pursued: 
1.10.1 To analyse primary screening data and select 15 sponge-associated isolates 
with promising QSI activity;  
1.10.2 To perform ethyl-acetate extractions on selected bacterial isolates; 
1.10.3 To perform qualitative QSI screening on selected extracts using the agar well 
diffusion overlay assay;  
1.10.4 To screen for P. aeruginosa pyocyanin, pyoverdine, biofilm, LasB, protease, 
rhamnolipid and motility inhibition by sponge-associated bacteria extracts; 
and 
1.10.5 To determine the anti-HIV potential of selected sponge-associated extracts by 
examining their effect on HIV reverse transcriptase activity. 
 
1.11 Key questions to be answered 
A number of specific questions were relevant to this topic: 
1.11.1 Are sponge-associated bacterial isolates able to inhibit QS of other bacterial 
species? If so, to what degree? 
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1.11.2 Are these bacteria able to inhibit the production of QS-mediated virulence 
factors by P. aeruginosa? If so, to what extent? 
1.11.3 Do sponge-associated bacterial extracts possess putative anti-HIV potential? If 
so, is this an area of research worth pursuing? 
 
1.12 Thesis Layout and Chapter Design 
In order to allow for improved readability and result analyses, the research to follow has been 
divided into three experimental chapters, viz., Chapters two to four. These were then 
followed by Chapter 5 discussing the overall conclusions of this work. Although the 
experimental work was carried out simultaneously, it was determined that all observable QSI 
activity resulted from either sponge-associated Bacillus or Actinomycete species. It was, 
therefore, determined that the expansive experimental results should be separated 
accordingly. The putative anti-HIV testing was similarly allotted a separate short 
communication chapter. The supplementary material was also split for the same reason, so 
that graphs only pertaining to Bacillus-derived extracts would not interfere with the readers’ 
interpretation of Actinomycete-derived results. 
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CHAPTER TWO 
SPONGE-ASSOCIATED BACILLUS SPP. EXTRACTS AS QUORUM SENSING INHIBITORS OF 
PSEUDOMONAS AERUGINOSA 
 
Abstract 
With bacterial antimicrobial resistance on the rise, alternative therapeutic agents are being 
sought. Once such alternative is the use of anti-virulence strategies such as quorum-sensing 
inhibition (QSI). Ninety-eight bacterial isolates from seven South African sponges harvested 
off the coast of KwaZulu-Natal underwent primary QSI screening using C. violaceum biosensor 
sandwich assays. Fifteen isolates presenting putative QSI activity were selected for further 
study, five of which were identified as Bacillus spp. following 16S rRNA PCR and sequencing. 
Using two separate production media, mannitol and medium 5294, ten Bacillus spp. extracts 
were obtained from the five isolates, which were then screened against QS-mediated 
Pseudomonas aeruginosa virulence factor production. Medium 5294 yielded the most 
significant inhibition of P. aeruginosa rhamnolipid, pyoverdine, protease, motility, initial and 
mature biofilm production, while mannitol yielded the most significant inhibition of 
pyocyanin and protease. Medium 5294 proved to be superior, demonstrating broad spectrum 
inhibition. Extracts produced from Bacillus cereus group isolate SP5-AB7 yielded some of the 
highest inhibitions for pyocyanin, pyoverdine, elastase, initial biofilm, mature biofilm, and 
rhamnolipid production. This suggests broad spectrum QSI activity and this isolate should be 
studied further. Two other B. cereus group isolates (SP1-AB4 and SP2-AB7) demonstrated 
similar broad-spectrum activity. Overall, the Bacillus spp. extracts significantly decreased (p < 
0.05) all virulence factors tested, with inhibitions as high as 93% being observed. Sponge-
associated bacteria, therefore, possess the QSI potential necessary to serve as the solution to 
the current antimicrobial crisis and should be further studied in this regard. 
2.1 Introduction 
While in the past antimicrobial agents may have been a vital component of modern medicine, 
this is no longer the case (Grandclément et al., 2016). The World Health Organization 
published a report in 2014 entitled “Antimicrobial resistance: Global report on surveillance”, 
highlighting the urgency of antimicrobial resistance, and the threat it poses on health care 
worldwide (Grandclément et al., 2016).  Antimicrobial resistance often occurs due to the use 
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of antimicrobial agents as growth enhancers in agriculture (Ramalingam and Amutha, 2013), 
non-compliance by patients failing to complete a course of antimicrobial agents (Cruz et al., 
2014) or the presence of sub-lethal doses of antimicrobial agents in food and water supplies 
(Dorotkiewcz-Jach et al., 2015). As antimicrobial resistance contributes to as many as 700 000 
deaths per year, a figure which could jump to 10 million by 2050 (Indranigrat et al., 2016), 
alternative treatments are urgently needed.  
 Quorum sensing inhibition (QSI) has gained popularity as such an alternative 
therapeutic option (García-Contreras, 2016), with the Gram-negative acyl homoserine 
lactone QSI being the most widely studied (Rekha et al., 2016). Many bacteria employ quorum 
sensing (QS) to communicate and regulate virulence and other community behaviours such 
as biofilm formation (Müller et al., 2015; Banerjee and Ray, 2016; Zhang and Li, 2016). 
Quorum sensing inhibition could, therefore, be used to inhibit these virulence traits to treat 
infections by important pathogens such as Pseudomonas aeruginosa (García-Contreras, 2016; 
Hassan et al., 2016), one of the primary organisms recovered from hospital sewage and 
associated with a large number of hospital infections (Otton et al., 2017).   
 Marine microorganisms have gained interest, as they are gaining impetus as a 
promising source of biologically active compounds (Abbamondi et al., 2014). Relatively little 
research has, however, been undertaken on these marine natural products, as they are 
difficult to cultivate under standard conditions (Abbamondi et al., 2014). It has been 
estimated that only 0.01 - 0.1% of marine microbial species are known to scientists, 
highlighting how much work still needs to be done (Moghadamtousi et al., 2015). Marine 
species have developed QSI enzymes and mechanisms as a result of competition for limited 
habitats and nutrients (Grandclément et al., 2016). Marine sponges and their associated 
microorganisms are considered the topmost producers of natural products within their 
environment (Kurian and Elumalai, 2017).  
 The diversity of sponge and sponge-associated bacterial-derived natural products is 
vast, and includes fatty acids, terpenes, nucleosides and halogenated amino acids (Kurian and 
Elumalai, 2017). Bacillus subtilis strains, associated with sponge Aplysina aerophoba, produce 
a multitude of antimicrobial compounds effective against multi-drug resistant Staphylococcus 
aureus (Bramhachari et al., 2016) while Bacillus spp. from the sponge Tedania anhelans 
possess potent antioxidant potential (Kurian and Elumalai, 2017). From the South China Sea, 
the sponge-associated Bacillus atrophaeus from Dysidea avara was shown to produce two 
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different antibiotics, Bacillamide C and Neobacillamide A and Bacillus cereus QN03323, a 
sponge-associated bacterium from the marine sponge Halichondria japonica, was shown to 
produce two novel antibiotics, YM-266183 and YM-266184 (Bramhachari et al., 2016). 
Furthermore, coral-associated Bacillus horikoshii and marine sediment-associated Bacillus 
pumilus S8-07 have also shown QSI potential (Musthafa et al., 2011). Evidently, with more 
than 3% of the Bacillus genome being dedicated to the production of secondary metabolites 
(Bastos et al., 2013), these organisms are one of the top candidates for antimicrobial 
production. Isolates of the genus Bacillus can be broken up into a number of groups based on 
highly similar 16S and 23S rRNA sequences, including the Bacillus subtilis and the more 
common Bacillus cereus groups (Patiño-Navarrete and Sanchis, 2017).  This latter group 
consists of 8 species, namely Bacillus toyonensis, Bacillus weihenstephanensis, Bacillus 
mycoides, Bacillus cytotoxicus, Bacillus pseudomycoides, Bacillus thuringiensis and Bacillus 
cereus (Ceuppens et al., 2013; Patiño-Navarrete and Sanchis, 2017). 
Bacillus spp. isolates also possess great potential as quorum sensing inhibitors. 
Halobacillus salinus, from the same family, produces two powerful QSI compounds, N-(2-
phenylethyl)-isobutyramide and 3-methyl-N-(2-phenylethyl)-butyramide, capable of 
inhibiting violacein production in Chromobacterium violaceum CV026 (Tang and Zhang, 2014; 
Saurav et al., 2016). Similarly, B. cereus D28 produced cyclo-L-proline-L-tyrosine, capable of 
inhibiting QS in C. violaceum ATCC 12472 (Tang and Zhang, 2014; Saurav et al., 2016). Bacillus 
species are also known producers of AHL-degrading lactonase enzymes, which hydrolyze the 
AHL lactone ring (Zhang and Li, 2016; Guendouze et al., 2017). Lactonases can be divided into 
two clusters, with all lactonases belonging to the more extensive AiiA cluster being exclusively 
produced by these Gram-positive bacilli (Castillo-Juarez et al., 2017). Producers of these 
lactonases include B. thuringiensis, B. anthracis, and B. cereus (Banerjee and Ray, 2016; 
Castillo-Juarez et al., 2017). As a result, Bacillus species have shown strong QSI potential, such 
as the inhibition of biofilm formation in E. coli (Durai et al., 2013).  
Even more important is the ability of Bacillus species to inhibit QS in P. aeruginosa. 
Bacillus spp. SS4 inhibited QS in P. aeruginosa PAO1, with B. pumilus inhibiting biofilm 
formation by the same organism (Kumar et al., 2013; Chang et al., 2017). Furthermore, when 
the aiiA gene from B. cereus A24 was expressed in P. aeruginosa, a reduction in both C4-
homoserine lactone (HSL) and 3-oxo-C12-HSL was observed, resulting in reduced virulence 
factor production (Fetzner, 2015).  
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Overall, this indicates that sponge-associated bacteria, especially those belonging to 
the genus Bacillus, have the potential to lessen the virulence of P. aeruginosa through QSI 
strategies (Chang et al., 2017). This chapter serves then as an investigation into the QSI 
potential of extracts from five sponge-associated Bacillus species against P. aeruginosa, using 
C. violaceum as a primary screening organism. 
 
2.2 Methods and Materials 
2.2.1 Primary QSI screening and maintenance of cultures  
Ninety-eight bacterial cultures, previously isolated from seven South African marine sponges, 
were selected for study. A primary QSI screening using the sandwich assay (Chu et al., 2011) 
was carried out to detect presumptive QSI activity. Biosensors C. violaceum CV026 and VIR07 
were used to assess QSI activity of the test organisms. Corresponding AHL over-producers 
used for the assay were C. violaceum ATCC 31532 and ATCC 12472, respectively (McClean et 
al., 1997).    
Biosensor C. violaceum CV026 was streaked in a line on Luria-Bertani (LB) agar plates 
while the over-producer C. violaceum strain CV31532 was then streaked in parallel, 15 mm 
apart. Test isolates were inoculated between the biosensor and the AHL donor strain, in 
parallel, at 7.5 mm (Chu et al., 2011). This allowed for detection of QSI of short chain AHLs (4 
– 8 carbons in length). Positive QSI activity was indicated by the inhibition of purple pigment 
production by C. violaceum CV026 after plates had been incubated at 30 °C for 24 - 48 h (Chu 
et al., 2011). An identical assay was carried out with C. violaceum VIR07 and over-producer C. 
violaceum strain ATCC 12472 to test for the quenching of long chain AHLs (Morohoshi et al., 
2008). Bacillus cereus ATCC 14579 was used as a QSI-positive control (Chu et al., 2011). From 
selected isolates, colonies appearing to have unique morphological characteristics were then 
sub-cultured onto ISP2 agar plates using the four-way streak method and incubated at 30 °C 
for 2 – 14 days to ensure pure cultures.  
 
2.2.2 Preparation of ethyl acetate culture extracts 
Fifteen selected QS inhibitory isolates were cultured in 5 ml of ISP2 broth for 2 d at 30 °C with 
shaking at 200 rpm. Thereafter, cultures were inoculated into 250 ml of Mannitol and Medium 
5924 broth in 1 l glass flasks and incubated with shaking at 200 rpm at 30 °C for 7 d. Samples 
were then centrifuged at 7000 rpm for 15 min in order to pellet cells, and supernatants 
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collected. An equal volume (1:1) of ethyl acetate was added to each supernatant and then 
agitated at 30 °C for 1 h. The organic ethyl acetate layer was collected, and the remaining 
aqueous layer subjected to a second extraction of 1:1 volume ethyl acetate, with agitation at 
30 °C overnight. The ethyl acetate layer was again collected, and the combined organic layers 
completely evaporated in a rotary evaporator (ILMVAC RObath) at 40 °C. The dry extract was 
then resuspended in  ̴4 ml methanol and added to a pre-weighed vial, after which the 
methanol was allowed to evaporate. Extracts were then resuspended to a final stock 
concentration of 50 mg/ml using 10% dimethyl sulfoxide (DMSO) (Baltes et al., 1998). 
 
2.2.3 Qualitative QSI screening  
The QSI potential of the selected extracts was explored through the use of the semi-
quantitative overlay assay. Molten LB soft agar (0.15% w/v, pH 7.5) was prepared and 5 ml 
inoculated with 100 μl of an overnight, wild-type, pigmented biosensor C. violaceum ATCC 
12472 culture (McClean et al., 1997). The agar-culture solution was then immediately poured 
over LB agar plates. Once the solution had solidified, wells (4 mm in diameter) were punched 
into the plate using a steel cork borer. Two wells were used for each extract, one containing 
10 µl (0.5 mg) and the other 20 µl (1 mg) of the 50 mg/ml extract. Extracts yielding unclear 
results were tested further at 2 mg. Following the same procedure, 0.01 mg and 0.02 mg of 
(Z-)-4-bromo-5-(bromoethylene)-2(5H)-furanone were used as the positive control and 10 µl 
and 20 µl of 10% DMSO as the negative control. Plates were then incubated in an upright 
position at 30 °C overnight (McClean et al., 1997). The inhibition of pigment production, 
visible as opaque white zones around the wells, was indicative of QSI whereas clear zones 
around the wells indicated cell death.  
 
2.2.4 Molecular identification of isolates 
2.2.4.1 Genomic DNA isolation 
Genomic DNA isolation was carried out using the GeneJet Genomic DNA purification kit 
(Thermo Scientific) for non-sporulating isolates and the ZR Fungal/Bacterial DNA MiniPrep 
DNA isolation kit (Zymo Research) for sporulating isolates, according to manufacturers’ 
instructions. Following overnight incubation on ISP2 plates, agar plates were flooded with 1 
ml sterile distilled water and bacterial cells were scraped off using a glass Pasteur pipette into 
1.5 ml microfuge tubes. Thereafter the contents in microfuge tubes were centrifuged for 10 
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min at 5000 × g and supernatants discarded. Cells were then resuspended accordingly and 
treated according to kit instructions. Finally, the DNA was eluted in 100 μl of DNA elution 
buffer and stored at -20 °C until required. 
 
2.2.4.2 16S rRNA gene amplification and sequencing 
The 16S rRNA gene amplification was performed for all 15 selected isolates using various 
primer sets (Table 2.1). The PCR reaction mixture used was the same for all primer sets, and 
consisted of 2 μl of template DNA, 0.1 μl of each primer set, and 15 μl DreamTaq Green PCR 
Master Mix (2x) (Thermo Scientific) which consisted of DNA Polymerase, 2X DreamTaq buffer, 
0.4 mM each of dATP, dCTP, dGTP and dTTP, and 4 mM MgCl2 dH2O, to a total volume of 30 
μl. 
 
Table 2.1: Sequences of 16S rRNA gene primers used in the identification of sponge-
associated bacterial isolates  
Primer set and sequence Band size (kb) Reference 
F243: 5’-GGATGAGCCCGCGGCCTA-3’ 1.2  Heuer et al. (1997) 
A3R: 5’-CCAGCCCCACCTTCGAC-3’ 1.2  Monciardini et al. (2002) 
F1: 5’-AGTTGATCCTGGCTCAG-3’ 
R5: 5’-TACCTTGTTACGACTTCACCCA-3’ 
1.5  Vaneechoutte et al. (2000) 
F1: 5’-AGAGTTTGATCITGGCTCAG-3’  
R5: 5’-ACGGITACCTTGTTACGACTT-3’ 
1.5  Coram and Rawlings (2002) 
 
Amplification was then performed in a MJ MINITM Personal Thermal cycler (Bio-Rad) 
using the following conditions: DNA denaturation at 94 °C for 1 min, followed by 35 cycles of 
denaturation at 94 °C for 30 s, primer annealing at 52 °C for 1 min and extension at 72 °C for 
1 min. Amplified products were then subjected to electrophoresis in 1% agarose gel at 80V 
for 2 h. PCR products were visualized, following exposure to 0.1 mg/ml ethidium bromide, 
using UV trans-illumination (Syngene, UK).  Successfully amplified DNA was sequenced using 
the ABI PRISM 377 automated DNA sequencer at the Central Analytical Facility at Stellenbosch 
University. These sequences were then subjected to identification using the NCBI-BLAST 
nucleotide database.  
 
2.2.5 Antimicrobial testing of bacterial extracts using agar-well diffusion method  
An inoculum, equivalent to a 0.5 McFarland standard, of P. aeruginosa ATTC 27853 was used 
to prepare bacterial lawns. Agar wells (8 mm diameter) were prepared with the help of a 
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sterilized stainless-steel cork-borer. Wells were loaded with 5 and 10 mg of the ten Bacillus 
spp. extracts (mannitol and medium 5294) and plates were incubated at 37 °C for 24 h, after 
which they were examined for the presence of zones of inhibition (El-Naggar and 
Abdelwahed, 2014). 
 
2.2.6 Screening of extracts against P. aeruginosa virulence factor production 
Pseudomonas broth (PB 3 ml) was inoculated with 100 µl of an overnight P. aeruginosa ATCC 
27853 culture, standardized to an OD600 nm of 1. Pseudomonas aeruginosa ATCC 27853 was 
then exposed to varying concentrations of the ethyl acetate extracts (0 – 1000 μg/ml) at 37 
°C overnight with agitation. Broth containing P. aeruginosa ATCC 27853 but no extract was 
used as a negative control while cinnamaldehyde, at concentrations corresponding to those 
of the bacterial extracts tested, was used as a positive control.  Growth readings were taken 
at 600 nm using a microtitre plate reader (Promega Glomax Multi+ Detection System), where 
inhibition in conjunction with a growth inhibition ≥40% were regarded as due to bacterial 
killing and not QSI. All assays were carried out in triplicate. The effect of identical volumes of 
10% DMSO without extract was assessed for all assays in order to confirm that the solvent 
had no effect on virulence factor production (pyocyanin, pyoverdine, elastase, protease, 
rhamnolipid, motility and biofilm formation).  
 
2.2.6.1 Inhibition of pyocyanin production  
Inhibition of pyocyanin was tested according to Ra’oof and Latif (2010), with slight 
modifications. Treated and untreated cells were centrifuged at 2500 rpm for 10 min, and 
supernatants extracted. Chloroform (1.5 ml) was then added to 3 ml of the supernatant and 
vortexed for 30 s. The mixture was then centrifuged at 2000 rpm for 15 min to allow for the 
cell debris and aqueous phase to separate. A 1 ml volume of the organic, chloroform layer 
was carefully transferred to a fresh tube, with care having been taken to transfer none of the 
aqueous phase. The separated chloroform layer was mixed with 1 ml of 0.2 M HCl and 
vortexed for 30 s. It was expected that the chloroform fraction, if blue, should have turned 
clear and then pink due to the addition of HCl. This mixture was then centrifuged at 7 800 
rpm for 10 min, and the upper HCl layer removed and used to measure pyocyanin 
concentration. This was done using a microtitre plate reader (Promega Glomax Multi+ 
Detection System) at 560 nm, using 0.2 M HCl as a blank. OD560 nm was multiplied by 17.072 in 
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order to obtain the pyocyanin concentration in μg/ml (Ra’oof and Latif, 2010). This value was 
further multiplied by a factor of 1.5, in order to account for the remaining organic 
chloroform/pyocyanin layer that remained unused. Concentrations of pyocyanin from the 
treated and untreated samples were then compared.  
 
2.2.6.2 Inhibition of pyoverdine production  
Pyoverdine was measured using a protocol described previously by Huerta et al. 
(2008).  Briefly, 0.04 ml of the aqueous phase from the pyocyanin assay was mixed with 1.96 
ml of 0.05 M Tris hydrochloride buffer (pH 7.4).  Fluorescence was determined by excitation 
at 365 nm and emission at 460 nm (Promega Glomax Multi+ Detection System), with values 
being given in relative fluorescence units (RFU).  These readings were then divided by the 
respective OD600 nm readings in order to account for the effect of growth on pyoverdine 
production. The percent pyoverdine inhibition was determined as follows: 
Pyoverdine inhibition =  
(Untreated RFU ÷  OD600 nm) − (Treated RFU ÷  OD600 nm) 
Untreated RFU ÷  OD600 nm 
 
 
2.2.6.3 Inhibition of LasB production  
Elastase activity of extracts was determined by the Elastin Congo-red (ECR) assay as described 
by George et al. (2005) with minor modifications. Samples were centrifuged at 12 000 rpm 
for 15 min. One ml of 0.5% elastin-Congo red (Sigma) in Tris-HCl (pH 7.4) was added to 200 μl 
of the cell-free supernatant and incubated at 37 °C for 24 h with agitation.  Samples were then 
vortexed and centrifuged at 1 200 rpm for 15 min to remove insoluble ECR.  The absorbance 
of the supernatants from both controls and treatments were then determined at 494 
nm, using a Shimadzu 1800 UV spectrophotometer, as a measure of elastase B activity.  The 
percentage change in absorbance was then calculated from the absorbance values.   
 
2.2.6.4 Qualitative inhibition of casein hydrolysis  
 The effect of extracts on casein proteolytic activity was assessed using an agar well diffusion 
assay (Flemming et al., 2007) with modifications. A sample volume of 600 μl was centrifuged 
three times at 12 000 rpm for 15 min to remove cells and 100 μl of the supernatant inoculated 
into 9 mm wells within TYES agar (4 g tryptone, 0.4 g yeast extract, 0.2 g CaCl2, 0.5 g MgSO4, 
10 g agar) plates enriched with 1% skim milk. This was performed in duplicate, and incubated 
for 24 h at 37 °C.  Appearance of zones of clearance around the wells was taken as a positive 
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result, whilst no zone formation after the 24 h period was classified as negative for proteolytic 
ability.  Zone diameters were measured and the percentage inhibition of caseinolytic activity 
determined as follows:  
Percentage inhibition
=  (
Zone diameter (untreated) − zone diameter (treated)
zone diameter (untreated)
) × 100 
(Zacaria et al., 2010).  
 
2.2.6.5 Quantitative inhibition of casein hydrolysis  
Casein hydrolysis was quantified using the azocasein assay (Guendouze et al., 2017), with 
modifications. Cell-free culture supernatants were prepared by centrifuging samples at 
12 000 rpm for 5 min. Protease activity was then determined using azocasein (Sigma, 
Germany) as a substrate (Guendouze et al., 2017). The reaction was performed in PBS solution 
(pH 7.0) with 50 µl of azocasein (30 mg/ml, dissolved in water) and 25 µl of culture 
supernatant to a final volume of 750 µl. Reaction tubes were incubated at 37 °C for 1 h and 
subsequently stopped by adding 125 µl of 20% (w/v) trichloroacetic acid. Reaction mixtures 
were centrifuged at 12 000 rpm for 5 min, after which absorbance was measured at 450 nm 
using a microtitre plate reader (Promega Glomax Multi+ Detection System) (Guendouze et al., 
2017). A blank control was prepared using only azocasein and PBS buffer, which was 
incubated at the same conditions as the sample tubes (Nicodème et al., 2005).  Proteolytic 
activity was defined as the difference between the absorbance at 450 nm of the treatments 
and the blank. The proteolytic activity of the treated and untreated samples was then 
compared (Nicodème et al., 2005).  
 
2.2.6.6 Qualitative inhibition of rhamnolipid production  
Rhamnolipid production by P. aeruginosa was detected using M9-glutamate minimal medium 
(of 12.8 g Na2HPO4-7H2O, 3 g KH2PO4, 0.5 g NaCl, 1.0 g NH4Cl, 2 ml of 1M MgSO4, 20 g of 
glucose, 100 µl of 1M CaCl2, 15 g of agar, 0.2 g cetyltrimethylammonium bromide and 5 mg 
methylene blue in 1 l of dH2O) agar plates. M9-glutamate minimal medium agar plates were 
inoculated with 200 µl of an overnight PB culture of P. aeruginosa (Senturk et al., 2012). After 
an overnight incubation at 37 °C, the diameter of the clear zone around the bacterial colony 
was measured as evidence of rhamnolipid production using a UV-transilluminator (Senturk et 
al., 2012).  
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2.2.6.7 Quantitative inhibition of rhamnolipid production  
 Rhamnolipid inhibition was quantified following the protocol of Koch et al. (1991) with 
modifications. Aliquots of the final culture supernatant (1 ml) were transferred to 1-dram 
glass vials and extracted twice with 1 ml of diethyl ether. The pooled organic fractions were 
evaporated to dryness, and the resulting residue reconstituted in 200 µl of de-ionized water. 
In a 2 ml plastic centrifuge tube, 75 µl of this extract was diluted into 675 µl of a solution of 
0.19% (w/v) orcinol in 50% (v/v) concentrated H2SO4. Tubes were vortexed thoroughly to mix 
and incubated in an 80 °C heating block for 30 min. After briefly cooling to room temperature, 
200 µl of the resulting yellow to yellow-orange solutions were transferred to a clear 96-well 
microtiter plate, and the absorbance at 421 nm measured (Multiskan Ascent plate reader, 
AEC Amersham). Media background absorbance (measured from a ‘‘no bacteria’’ control) was 
subtracted, the resulting growth values normalized by dividing by the final OD600 nm. For this 
assay (Z-)-4-bromo-5-(bromoethylene)-2(5H)-furanone, and not cinnamaldehyde, was used 
as a positive control at concentrations corresponding to 10% of the bacterial extracts tested.   
 
2.2.6.8 Inhibition of swimming and swarming motilities 
The effect of extracts on swimming motility was conducted with swimming agar medium (10 
g tryptone, 5 g NaCl and 0.3% bacteriological agar) (Rashid et al., 2000).  Swim plates were 
prepared 24 h in advance and allowed to dry overnight within a laminar flow.  Five microlitres 
of the treated bacterial suspension was point-inoculated at the centre of the medium and 
plates incubated at 30 °C for 72 h. Swim diameters were read every 24 h in order to determine 
the effect of the extracts on swimming motility over time.  
Swarming motility was assessed with LB agar overlaid with 5 ml swarming soft 
agar (1% peptone, 0.5% NaCl, 0.5% agar) supplemented with 0.5% D-glucose (Packiavathy et 
al., 2012).  Five microlitres of treated P. aeruginosa bacterial suspension, was point-
inoculated at the centre of the swarm medium.  Plates were then incubated for 24 h at 37 °C 
followed by incubation at 30 °C and monitoring every 24 h over a 3 d period. The alteration 
in swimming and swarming migration was assessed by measuring the swim and swarm zones 
of the treated and untreated bacterial cells. 
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2.2.6.9 Inhibition of biofilm production 
Extracts were tested against indicator organism P. aeruginosa ATTC 27853 for their effect on 
initial attachment and mature biofilm formation. Sixteen hour-old cultures were used to 
prepare cell suspensions which were standardized to an OD600 nm of 1. For the initial 
attachment studies, extracts were added at 0.5, 1, 5 and 10 mg/ml to 90 µl TSB and 10 µl of 
standardized cell suspension and incubated for 24 h at 37 °C with agitation (Basson et al., 
2008).  For pre-formed biofilm detachment assays, 24 h biofilms were established following 
addition of 90 µl TSB and 10 µl of standardized cell suspension to microtiter plate wells, which 
were incubated at 37 °C for 24 h. Microtitre plates were washed three times with sterile 
deionised water and allowed to air-dry. Following air-drying, 90 µl TSB as well as extracts at 
the relevant, respective concentrations were added to wells and microtitre plates incubated 
for 24 h with agitation at 37 °C. The negative control contained only broth, while positive 
controls contained cell suspensions with no extracts added.  
 After incubation, planktonic cells were removed by turning the plate over and shaking 
out the liquid. Thereafter, the plate was washed three times with 250 µl sterile dH20. Cells 
were fixed with 200 µl of methanol for 15 min and left to air dry. Staining was done by adding 
150 µl of 2% Huckers crystal violet for 5 min. Wells were gently rinsed under running water 
and allowed to air dry. Crystal violet was resolubilized with 150 µl of 33% (v/v) glacial acetic 
acid and the OD595 nm values determined using Promega at OD600 nm (Basson et al., 2008).  A 
measure of efficacy, termed percentage reduction, was calculated from the blank, control, 
and treated absorbance values (Pitt et al., 2003):  
Percentage reduction =  (
(C − B) − (T − B)
C − B
) × 100 
where B denotes the average absorbance per well for blank wells (no biofilm, no treatment), 
C denotes the average absorbance per well for control wells (biofilm, no treatment), and T 
denotes the average absorbance per well for treated wells (biofilm and treatment). Wells 
containing TSB broth and P. aeruginosa ATCC 27853 but no extract was used as a growth 
control while cinnamaldehyde, at 0.5, 1, 5 and 10 mg/ml, was used as a positive control. The 
solvent, 10% DMSO, was used at identical volumes in order to confirm that it had no effect 
on bacterial motility. 
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2.2.7 Statistical analyses 
Data was obtained after assays had been performed in either duplicate or triplicate, in order 
to ensure the validity of the results.  One-way ANOVA analyses were performed for each assay 
to determine the significance of inhibitions exacted by the Bacillus spp. extracts, as well as 
the mannitol and medium 5294 extracts separately. Following this, a number of two-tailed t-
tests were performed for each assay, examining the effects of the mannitol and medium 5294 
extracts at each concentration tested, both together and separately, in order to determine 
the significance of any inhibitions observed. The null hypothesis put forth was that there was 
no difference between the mean untreated inhibition and the mean inhibition observed at 
each concentration. For all tests a p-value of <0.05 was taken to be significant, such that the 
null hypothesis may be rejected. All statistical analyses were performed using Microsoft Excel 
following the installation of Real Statistics Add-In software.  
 
2.3 Results 
2.3.1 Sponge-associated bacterial inhibition of AHL reception in bio-sensing 
mutant strains of C. violaceum Vir07 and 026  
Following the biosensor sandwich assay screening of 98 sponge-associated bacteria, results 
were compared to that of the positive control B. cereus ATCC 14579 and given a QSI rating of 
between 0 and 4, whereby isolates which were rated 4 showed QSI activity equal or greater 
than that of the control (Fig. 2.1). Of the screened isolates, 88% (86/98) were able to quench 
short chain signal transduction with a rating of 3 or 4, while only 17% (17/98) were able to 
achieve the same results for long chain degradation. Based on QSI screening, 15 isolates 
(Table 2.2) were selected for shake flask fermentations using mannitol medium and medium 
5294, followed by ethyl acetate extractions. 
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Figure 2.1: Sandwich assay screening of quorum sensing inhibitory potential of 98 sponge-
associated bacteria. Controls included (A) A growth control (no test organism streaked 
between biosensors) and (B) QSI positive control, B. cereus ATCC 14579. All isolates were 
screened for QSI activity using C. violaceum biosensors CV026 and VIR07 and respective over-
producer strains ATCC 31532 and ATCC 12472. Inhibition of pigment production or QSI activity 
was rated 0-4, whereby 4 was a near total loss of pigment as compared to the control. (C) SP-
AB2 and (E) SP2-AB3 were rated 4 for both long chain (top) and short chain (bottom) AHL 
inhibition. (D) SP2-W3 was rated 3 for both while (F) SP2-AB6 was rated as 3 for long chain 
and 4 for short chain QSI. 
 
Table 2.2: Sandwich assay results for 15 selected sponge-associated bacterial isolates, using 
bacterial biosensor Chromobacterium violaceum strains CV026 and VIR07 
Isolate Code CV026 * 
(short chain AHLs) 
VIR07 * 
(long chain AHLs) 
SP-AB2 4 4 
SP1-AB4 4 3 
SP1-V4 4 3 
SP2-AB1 3 0 
SP2-AB2 1 4 
SP2-AB3 4 4 
SP2-AB6 4 3 
SP2-AB7 3 4 
SP2-W3 3 3 
SP2-W6 2 4 
SP3-AB22 2 4 
SP4-AB2 3 4 
SP4-AB6 2 4 
SP5-AB7 3 4 
SP6-AB5 3 3 
* Results depicted using a 0-4 number system, where 0 depicts no 
discernible quenching activity and 4 depicts a result where complete 
quenching of the violacein pigment was observed.  
 
2.3.2 Sponge-associated bacterial extracts continue to display QSI activity against 
C. violaceum ATCC 12472 
Following ethyl acetate extraction, all 30 extracts (15 mannitol and 15 medium 5294) were 
subjected to further long chain QSI screening using C. violaceum ATCC 12472 in the agar 
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overlay-well diffusion assay (Fig. 2.2). Of the 30 extracts, 13% (4/30) exhibited QSI activity 
(Table 2.3).  
 
 
 
 
 
 
Figure 2.2: Four extracts exhibited long chain quorum sensing inhibition when tested against 
C. violaceum ATCC 12472 violacein production. SP-AB2 (Mann) (A) and SP2-AB3 (5294) (B) 
exhibited QSI at 2 mg while SP4-AB2 (Mann) (C) and SP2-W6 (Mann) (D) showed QSI at both 
0.5 and 1 mg. Cytotoxic Cytotoxic (Z-)-4-bromo-5-(bromoethylene)-2(5H)-furanone (0.01 and 
0.02 mg) was used as a positive control (E). 
 
Table 2.3: Agar overlay assay results for 30 selected sponge associated bacterial extracts, 
using bacterial biosensor Chromobacterium violaceum ATCC 12472 
Organism 
Code 
Zone of violacein inhibition 
Mannitol (mm)* 
Zone of violacein inhibition 
5294 (mm)* 
 0.5 mg 1 mg 2 mg$ 0.5 mg 1 mg 2 mg$ 
SP-AB2 0 8  14 0 0 0 
SP1-AB4 0 0 nt# 0 0 nt# 
SP1-V4 0 0 nt# 0 0 nt# 
SP2-AB1 0 0 nt# 0 0 nt# 
SP2-AB2 0 0 nt# 0 0 nt# 
SP2-AB3 0 0 nt# 0 8  10  
SP2-AB6 0 0 nt# 0 0 nt# 
SP2-AB7 0 0 nt# 0 0 nt# 
SP2-W3 0 0 nt# 0 0 nt# 
SP2-W6 7  9  nt# 0 0 nt# 
SP3-AB22 0 0 nt# 0 0 nt# 
SP4-AB2 10  16  nt# 0 0 nt# 
SP4-AB6 0 0 nt# 0 0 nt# 
SP5-AB7 0 0 nt# 0 0 nt# 
SP6-AB5 0 0 nt# 0 0 nt# 
* Values indicate the diameter of quenching, including the 6 mm wells.  
$ Concentration of 2 mg/ml only tested for those extracts which displayed putative activity at 1 mg/ml. 
# nt – Not tested at this concentration. 
 
Of these, SP-AB2 (Mann) extract exhibited an inhibition halo of 8 mm at 1 mg, and 14 
mm at 2 mg. Extract SP2-AB3 (5294) exhibited 10 mm of violacein inhibition only after 
exposure to 2 mg of extract. Extract SP2-W6 (Mann) caused a 7 mm reduction at 0.5 mg and 
a 9 mm reduction at 1 mg, while SP4-AB2 (Mann) caused a 10 mm reduction at 0.5 mg and a 
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16 mm reduction at 1 mg. No zones of cell death were observed around any of the wells (Fig. 
2.2). 
 
2.3.3 16S rRNA identification of selected isolates 
Following 16S rRNA amplification and DNA sequencing, 5/15 (33%) of the selected sponge-
associated bacterial isolates were identified as belonging to the genus Bacillus (Supp. Fig. 
S2.1.1). Four of the five isolates were further identified as belonging to the B. cereus sub-
group (Table 2.4). 
 
Table 2.4: Identification of sponge-associated Bacillus species using NCBI-BLAST database  
Isolate code Identification Percentage identity* Sub-group 
SP-AB2 Bacillus thuringiensis 99% B. cereus 
SP1-AB4 Bacillus thuringiensis 100% B. cereus 
SP2-AB7 Bacillus toyonensis 99% B. cereus 
SP2-W6 Bacillus pumilus 99% B. pumilus 
SP5-AB7 Bacillus weihenstephanensis 99% B. cereus 
* Percentage identity match to the corresponding isolate using the NCBI-BLAST database. 
 
2.3.4 Antimicrobial testing of sponge-associated Bacillus spp. extracts against 
Pseudomonas aeruginosa ATCC 27853 
To ensure that any QSI and/or anti-virulence activity observed would not be as a result of cell 
death, antimicrobial agar well diffusion testing was performed with all ten Bacillus spp. 
extracts at 5 and 10 mg. No cell death was observed for any of the extracts tested.  
 
2.3.5 Bacillus spp. extracts and P. aeruginosa pyocyanin production 
Pyocyanin production is thought to be primarily controlled by the PQS QS system of P. 
aeruginosa, with some influence from the rhl QS system. All ten sponge-associated Bacillus 
spp.  extracts were able to inhibit pyocyanin production to some extent, with inhibition 
ranging from -0.73% to 39.36%, with cell death not exceeding 40% (Supp. Fig. S2.2.1-2.2.6). 
Of these, 80% (8/10) of extracts were able to inhibit pyocyanin production by >30% (Table 
2.5). While none of the Bacillus spp. extracts achieved an inhibition of ≥50%, they resulted in 
a significant overall decrease in pyocyanin production (p < 0.01). Each treatment 
concentration additionally resulted in a significant decrease (p < 0.01), with the average 
pyocyanin inhibition at 1000 µg/ml proving to be the most significant.  
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Exposure to medium 5294 extracts resulted in an overall significant decrease in 
pyocyanin production (p < 0.01) as well as significant decreases at all concentrations, 
particularly with 750 and 1000 µg/ml (Table 2.5). A concentration-dependent pyocyanin 
inhibition could be observed for a number of individual extracts, such as SP-AB2 (Mann and 
5294) (Supp. Fig. S2.2.2 A and B). For medium 5294, 1000 µg/ml proved to be the most 
significant concentration, with a mean pyocyanin production of 27.10%.  
 
Table 2.5: Effect of sponge-associated Bacillus spp. extracts on pyocyanin production by P. 
aeruginosa ATCC 27853. Percentage pyocyanin inhibition of both mannitol and medium 5294 
extracts were assessed at 250-1000 µg/ml 
 Percentage pyocyanin inhibition 
 250 µg/ml** 500 µg/ml** 750 µg/ml** 1000 µg/ml** 
Extract Code Mann* 5294* Mann** 5294* Mann* 5294** Mann** 5294** 
B. cereus group SP-AB2 17.80 17.99 23.02 26.58 29.57 28.24 32.63 36.21 
B. cereus group SP1-AB4 25.66 30.09 32.72 29.05 24.75 30.60 37.57 32.37 
B. cereus group SP2-AB7 23.10 19.83 28.31 17.58 25.09 16.81 31.54 19.70 
B. pumilus group SP2-W6 -0.73# 3.37 16.67 3.59 15.93 5.85 8.06 36.76 
B. cereus group SP5-AB7 30.46 18.44 35.33 21.40 39.36 23.69 32.69 30.97 
Cinnamaldehyde 9.79  12.89  37.34$  79.53$  
10% DMSO 17.43  -6.13#  10.79  0.59  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
# Negative values indicate an increase in pyocyanin production. 
$Pyocyanin inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
Mannitol, while yielding significant inhibitions overall (p < 0.01), gave slightly different 
results (Table 2.5). Although 1000 µg/ml remained the most significant treatment 
concentration, with a mean inhibition of 31.95%, a 500 µg/ml exposure proved to be more 
significant than 750 µg/ml, even though the resulting mean inhibitions were relatively similar 
(24.2% and 25.9%, respectively). This speaks to the variance of these concentrations, with 500 
µg/ml achieving more consistent inhibition of pyocyanin production. However, as mannitol 
yielded higher mean pyocyanin inhibitions, and extracts from both media yielded inhibition 
of equal significance, it may be said that mannitol may prove the preferable production 
medium for effective pyocyanin inhibition.   
Examining the Bacillus spp. extracts at an isolate level, Bacillus weihenstephanensis 
SP5-AB7 (Mann) yielded the highest inhibition in pyocyanin production, with a decrease of 
39.36% at 750 µg/ml (Supp. Fig. S2.2.6A). This extract consistently yielded the highest 
inhibition of both media at each concentration except 1000 µg/ml, where the resulting 
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pyocyanin inhibition decreased to 32.69%. However, as a lower treatment concentration is 
desirable, this extract can be said to be worthy of further examination in this regard.  
Cinnamaldehyde was used as positive control (250-1000 µg/ml). However, unlike the 
extracts, cinnamaldehyde was cytotoxic, resulting in a maximum pyocyanin inhibition of 
12.89% at 500 µg/ml (Supp. Fig. S2.2.1A).  
 
2.3.6 Bacillus spp. extracts and P. aeruginosa pyoverdine production 
Production of the siderophore pyoverdine is thought to be controlled in a similar manner to 
that of pyocyanin, with influence from both the PQS and rhl QS systems. Following treatment 
with the sponge-associated Bacillus spp. extracts, inhibition of between 2.51% and 38.43% 
was observed, with all extracts inhibiting pyoverdine to some extent and 50% (5/10) inhibiting 
pyoverdine production by >30% (Table 2.6). The failure of these extracts to exert inhibition of 
≥50% on pyocyanin or pyoverdine production may be indicative of a lack of PQS-QSI ability.  
 
Table 2.6: Effect of sponge-associated Bacillus spp. extracts on pyocyanin production by P. 
aeruginosa ATCC 27853. Percentage pyocyanin inhibition of both mannitol and medium 5294 
extracts were assessed at 250-1000 µg/ml 
 Percentage pyoverdine inhibition 
 250 µg/ml** 500 µg/ml** 750 µg/ml** 1000 µg/ml** 
Extract Code Mann* 5294* Mann 5294* Mann 5294* Mann* 5294** 
B. cereus group SP-AB2 12.05 9.47 26.19 14.61 23.13 18.52 38.43 26.89 
B. cereus group SP1-AB4 30.15 31.33 31.43 28.26 31.32 29.80 29.37 23.96 
B. cereus group SP2-AB7 10.55 23.82 6.39 19.02 21.45 18.87 18.02 30.92 
B. pumilus group SP2-W6 7.15 2.51 4.64 4.77 9.80 5.63 27.91 7.55 
B. cereus group SP5-AB7 8.72 31.56 2.69 34.86 3.90 33.40 8.17 29.33 
Cinnamaldehyde -41.39  -57.07  -205.22$  -932.37$  
10% DMSO 13.33  15.30  12.65  18.09  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Pyoverdine inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
Bacillus spp. extracts were able to exert an overall significant inhibitory effect on 
pyoverdine production (p < 0.01), as well as with each treatment concentration (Table 2.6). 
Overall, 1000 µg/ml yielded the highest mean pyoverdine inhibition (24.05%, p < 0.01), while 
no significant cell death was observed for any of the extracts at the concentrations tested 
(Supp S2.2).  
Medium 5294 yielded significant inhibition at each concentration tested (p < 0.05), 
with the most significant inhibition occurring at 1000 µg/ml (p < 0.01) (Table 2.6). Like medium 
5294, treatment of the P. aeruginosa cells with mannitol extracts resulted in a significant 
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overall decrease in pyoverdine production (p < 0.05). However, mannitol only yielded 
significant mean pyoverdine inhibition at 250 and 1000 µg/ml of 13.72% and 23.13%, 
respectively. However, as the significance and overall mean inhibitions were higher for 
medium 5294, it can be suggested that this medium be employed if effective inhibition of P. 
aeruginosa pyoverdine production is to be achieved.  
At the individual isolate level, the sponge-associated Bacillus spp. extract with the 
highest pyoverdine inhibition was SP-AB2 (Mann), achieving a pyoverdine inhibition of 
38.43% at 1000 µg/ml (Supp. Fig. S2.2.2A). The effect of 10% DMSO on pyoverdine inhibition 
overall proved to be insignificant (p > 0.05), ruling out the possibility that the efficacy of the 
bacterial extracts may be attributed to the 10% DMSO used as the solvent. Pyoverdine 
inhibition using the positive control cinnamaldehyde resulted in increased pyoverdine 
production, possibly as a result of cell death at 750 and 1000 µg/ml, since growth was factored 
into the pyoverdine inhibition calculation (Supp. Fig. S2.2.1A). 
 
2.3.7 Bacillus spp. extracts and P. aeruginosa elastase production 
Production of elastase LasB is mediated by the long chain las QS system of P. aeruginosa.  
Following treatment of P. aeruginosa with sponge-associated Bacillus spp. extracts, an 
elastase inhibition range of -8.20% to 71.32% was observed (Table 2.7), with 60% (6/10) of 
extracts resulting in LasB inhibition of ≥30% (Supp. S2.3). Mean elastase inhibition as a result 
of treatment with Bacillus spp. extracts proved to be significant (p < 0.01), with this 
significance being carried through to each of the three individual concentrations tested (Table 
2.7). The average inhibition observed at 250 µg/ml was 11.14% (p < 0.05), at 500 µg/ml 
24.37% (p < 0.01) and 33.51% at 1000 µg/ml. This same concentration-dependent effect can 
be seen with individual extracts such as SP1-AB4 (Mann) and with both SP2-AB7 extracts 
(Supp. Fig. S2.3.3A and S2.3.4). 
 Inhibition by mannitol-based extracts proved to be more significant than that of 5294-
based extracts. While medium 5294 resulted in an overall mean decrease in LasB production 
(p < 0.05), it was only when used at 1000 µg/ml that the medium 5294 extracts proved to 
result in significant mean LasB inhibition (26.04%; p < 0.05) (Table 2.7). Mannitol, by contrast, 
exerted an overall significant average LasB inhibition (p < 0.01) as well as significant inhibition 
at each tested treatment concentration. The ideal conditions for maximal LasB inhibition can, 
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therefore, be said to be through the use of the mannitol production medium at 1000 µg/ml 
of extract. 
 
Table 2.7: Effect of sponge-associated Bacillus spp. extracts on elastase production by P. 
aeruginosa ATCC 27853. Percentage pyocyanin inhibition of both mannitol and medium 5294 
extracts were assessed at 250-1000 µg/ml 
 Percentage elastase inhibition 
 250 µg/ml* 500 µg/ml** 1000 µg/ml** 
Extract Code Mann** 5294 Mann* 5294 Mann* 5294* 
B. cereus group SP-AB2 17.85 -4.17# 26.04 -0.93# 25.66 2.35 
B. cereus group SP1-AB4 16.63 -3.5# 20.74 25.16 50.32 11.39 
B. cereus group SP2-AB7 30.92 21.63 38.75 40.17 51.76 46.01 
B. pumilus group SP2-W6 14.95 -8.20# 43.08 -1.26# 5.09 34.41 
B. cereus group SP5-AB7 15.18 12.43 19.40 35.46 71.32 43.86 
Cinnamaldehyde 38.30  42.67  67.45$  
10% DMSO 7.51  7.28  12.81  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
# Negative values indicate an increase in elastase production. 
$Elastase inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
  
Examining the results in terms of the individual sponge-associated Bacillus spp. 
extracts, it was previously noted that 60% of the extracts reduced LasB production by ≥30%. 
However, in comparison to cinnamaldehyde, where inhibition of 42.67% was observed before 
the compound became cytotoxic (Supp. Fig. S2.3.1A), only extracts capable of >50% 
inhibitions were considered to be meaningful. Three of the mannitol-derived Bacillus spp. 
extracts were capable of this at 1000 µg/ml, highlighting the preference for mannitol as the 
ideal production medium for elastase reduction.  The strongest inhibitor of LasB production 
was Bacillus spp. SP5-AB7 (Mann), achieving an elastase inhibition of 71.32% at 1000 µg/ml 
without affecting cell growth (Supp. Fig. S2.3.6A). The other isolates capable of a >50% 
elastase inhibition were B. toyonensis strain SP2-AB7 (Mann) and B. thuringiensis SP1-AB4 
(Mann), which resulted in 51.76% and 50.32% elastase inhibition, respectively.  
 
2.3.8 Bacillus spp. extracts and P. aeruginosa protease production 
Another virulence factor primarily controlled by the long chain las QS system is the 
production of proteases. In order to determine if exposure to the extracts reduced the ability 
of P. aeruginosa to produce proteases, two separate assays were performed: the qualitative 
casein agar well diffusion assay and the quantitative azocasein spectrophotometric assay. The 
first assay allowed visual determination of protease production through a reduction in zones 
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of casein hydrolysis as compared to the untreated control. Cinnamaldehyde was used as the 
positive control, with clear inhibition being visible (Fig. 2.3), however, the reduction in casein 
hydrolysis at 1 mg/ml was a result of cell death. No visible decrease in protease production 
was observed with 10% DMSO (Table 2.8). The testing of the sponge-associated Bacillus spp. 
extracts yielded nine definitive reductions in casein hydrolysis (Table 2.8), including SP5-AB7 
(Mann) (Fig. 2.3), equalling a total of 90% of potentially active extracts (Table 2.8).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Inhibition of protease production was determined through the comparison of skim 
milk agar hydrolysis zones of untreated versus treated sample. (A) Positive control 
cinnamaldehyde. (B) Sponge-associated Bacillus spp. extract SP5-AB7 (Mann) demonstrated 
decreased zones of hydrolysis at both 250 µg/ml and 1000 µg/ml.  
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Table 2.8: Qualitative protease inhibition following treatment with sponge-associated Bacillus spp. extracts. Zones of hydrolysis on casein agar 
plates following 24 h incubation at 37 °C are given with the calculated percentage inhibition for each extract treatment indicated 
 Untreated 250 µg/ml 500 µg/ml 1000 µg/ml 
Extract code 
Zone of hydrolysis 
(mm) ± SD* 
Zone of hydrolysis 
(mm) ± SD* 
Protease 
inhibition (%)** 
Zone of hydrolysis 
(mm) ± SD* 
Protease 
inhibition (%)** 
Zone of hydrolysis 
(mm) ± SD* 
Protease 
inhibition (%)** 
Cinnamaldehyde$ 25.14 ± 0.71 20.50 ± 0.71 18.46 18.00 ± 0.00 28.40 11.50 ± 0.71 54.26 
10% DMSO 25.14 ± 0.71 23.50 ± 0.71 6.52 23.00 ± 1.41 8.51 23.50 ± 0.71 6.52 
SP-AB2 (Mannitol) 25.14 ± 0.71 22.25 ± 1.06 11.50 23.50 ± 1.32 6.52 22.50 ± 1.29 10.50 
SP-AB2 (5294) 25.14 ± 0.71 20.00 ± 0.00 20.45 20.75 ± 0.35 17.46 19.75 ± 0.35 21.44 
SP1-AB4 (Mannitol) 25.14 ± 0.71 19.50 ± 0.71 22.43 19.00 ± 0.00 24.42 17.50 ± 0.71 30.39 
SP1-AB4 (5294) 25.14 ± 0.71 21.00 ± 2.00 16.47 21.88 ± 1.93 12.99 21.58 ± 1.59 14.15 
SP2-AB7 (Mannitol) 25.14 ± 0.71 20.13 ± 0.18 19.95 21.75 ± 0.35 13.48 20.50 ± 0.50 18.46 
SP2-AB7 (5294) 25.14 ± 0.71 21.38 ± 0.18 14.98 21.88 ± 0.53 12.99 20.63 ± 0.18 17.96 
SP2-W6 (Mannitol) 25.14 ± 0.71 21.00 ± 1.41 16.47 18.00 ± 0.71 28.40 19.00 ± 0.00 24.42 
SP2-W6 (5294) 25.14 ± 0.71 19.50 ± 0.00 22.43 18.50 ± 0.71 26.41 19.38 ± 0.53 22.93 
SP5-AB7 (Mannitol) 25.14 ± 0.71 17.38 ± 0.53 30.89 18.75 ± 0.35 25.42 19.75 ± 0.35 21.44 
SP5-AB7 (5294) 25.14 ± 0.71 19.13 ± 0.18 23.93 19.13 ± 0.18 23.93 18.63 ± 0.53 25.91 
**Protease activity is expressed based on the diameter of the hydrolysis zone. QS inhibitory compounds should reduce protease activity of P. aeruginosa ATCC 27853, and 
thus, in their presence, the hydrolysis zone should be of smaller dimensions than in the untreated control (<20.71 mm).   
* Average of casein hydrolysis zones ± standard deviation. 
$ Protease inhibition for cinnamaldehyde at 1000 µg/ml is as a result of P. aeruginosa cell death. All other extracts tested had a growth inhibitory effect of <40%.  
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Using the quantitative azocasein assay, only eight of the extracts were confirmed to 
possess the ability to quench protease production by >20%. Four of the eight positive extracts 
(50%) yielded inhibitions ≥50% (Table 2.9). No resultant cell death (>40%) was observed 
following treatment with any of the sponge-associated Bacillus spp. extracts (Supp. S2.4). The 
Bacillus spp. extracts did, however, cause a significant average decrease in protease 
production (p < 0.01), and this same level of significance was seen at each individual 
treatment concentration (Table 2.9).  
 
Table 2.9: Effect of sponge-associated Bacillus spp. extracts on protease production by P. 
aeruginosa ATCC 27853. Both mannitol and medium 5294 extracts were tested at 250-1000 
µg/ml and the percentage protease inhibition calculated  
 Percentage protease inhibition 
 250 µg/ml** 500 µg/ml** 750 µg/ml** 1000 µg/ml** 
Extract Code Mann 5294* Mann 5294* Mann* 5294** Mann* 5294** 
B. cereus group SP-AB2 13.85 38.55 4.96 34.47 7.08 40.72 9.19 53.51 
B. cereus group SP1-AB4 38.89 12.47 43.69 16.35 50.07 16.01 41.02 15.66 
B. cereus group SP2-AB7 -1.88# 23.06 31.67 39.75 30.08 42.11 42.36 59.93 
B. pumilus group SP2-W6 8.33 49.73 7.59 50.69 16.56 59.17 28.47 63.81 
B. cereus group SP5-AB7 35.05 9.30 31.28 15.06 34.36 43.22 38.77 46.90 
Cinnamaldehyde 22.38  95.23  109.72$  111.91$  
10% DMSO 3.80  6.33  10.13  12.66  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
# Negative values indicate an increase in protease production. 
$Protease inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
It was observed that medium 5294 yielded significant inhibition at each treatment 
concentration, in a concentration-dependent manner, while the mannitol extracts yielded 
significant mean inhibition only at 750 and 1000 µg/ml. Medium 5294, at a concentration of 
1000 µg/ml, was the most ideal treatment for effective protease inhibition. Examining 
individual extracts’ protease inhibitory potentials, extract SP2-W6 (5294) yielded the best 
inhibition profile in a concentration-dependent manner (Supp. Fig. S2.4.5B), achieving a 
minimum inhibition of 49.73% at 250 µg/ml and a maximum inhibition of 63.81% at 1000 
µg/ml. Extracts SP-AB2 (5294), SP1-AB4 (Mann), SP2-AB7 (5294) and SP5-AB7 (Mann) 
additionally yielded promising protease inhibitory activities of >50%. No growth inhibition 
was observed as a result of any of the extracts, and 10% DMSO without bacterial extract was 
found to increase protease production of P. aeruginosa (Supp. Fig. S2.4.1B). Cinnamaldehyde 
resulted in a significant (p < 0.05) decrease in protease production (Supp. Fig. S2.4.1A).  
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2.3.9 Bacillus spp. extracts and P. aeruginosa rhamnolipid production 
The qualitative rhamnolipid test was the CTAB agar test, where the cationic CTAB binds to the 
anionic rhamnolipids, forming blue halos. Any inhibition of these zones can then be visually 
observed (Fig. 2.4), however, zones of growth are subtracted as varying diameters of growth 
may skew the results. The positive control cinnamaldehyde caused rhamnolipid inhibition at 
all concentrations tested, although at 1000 µg/ml this was as a result of cell death. The 10% 
DMSO solvent, however, had no noticeable effect on P. aeruginosa rhamnolipid production 
(Table 2.10). It was observed that 90% (9/10) of the extracts produced some degree of 
rhamnolipid inhibition (Table 2.10). 
 
 
 
 
 
 
Figure 2.4: Rhamnolipid production using the qualitative CTAB agar assay. Extract SP-AB2 
yielded a positive result in the qualitative CTAB agar rhamnolipid inhibition assay. Blue halos 
observed under UV light (A and B) were indicative of rhamnolipid production. Inhibition of 
these zones, more easily observable under greyscale (C and D) were taken as a positive for 
potential rhamnolipid inhibitions. The four cultured spots from left to right represent P. 
aeruginosa after treatment with 0, 250, 500 and 1000 µg/ml of extract.  
 
Following quantitative analysis of the rhamnolipid inhibitory effects of the Bacillus 
spp. extracts, 78% (7/9) were confirmed to have an anti-rhamnolipid activity of >20%. One 
extract not identified in the plate assay gave positive inhibition, therefore, 80% (8/10) of the 
extracts yielded positive rhamnolipid inhibitory activities of >20%, six of which were >50% 
(Table 2.10). Following statistical analysis of the quantitative rhamnolipid inhibition data, the 
mean rhamnolipid inhibition resulting from treatment with the Bacillus spp. extracts was 
significant (p < 0.05). When examining the individual treatment concentrations, significant 
mean inhibitions were only achieved at ≥500 µg/ml (Table 2.11). Mannitol-derived extracts 
did not yield a significant mean inhibition, while medium 5294 extracts yielded significant 
inhibition at both 500 µg/ml (p < 0.01) and 750 µg/ml (p < 0.05) (Table 2.11), of 39.36% and 
48.83%, respectively. 
A B C D 
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Table 2.10: Qualitative rhamnolipid inhibition following treatment with sponge-associated Bacillus spp. extracts. Zones of rhamnolipid 
production on CTAB agar plates following 24 h incubation at 37 °C are given with percentage inhibition for each extract treatment indicated 
 0 250 µg/ml 500 µg/ml 1000 µg/ml 
Extract code 
Rhamnolipid production 
(mm)** ± SD* 
Rhamnolipid production 
(mm)** ± SD* 
Rhamnolipid 
inhibition (%) 
Rhamnolipid production 
(mm)** ± SD* 
Rhamnolipid 
inhibition (%) 
Rhamnolipid production 
(mm)** ± SD* 
Rhamnolipid 
inhibition (%) 
Cinnamaldehyde$ 20.71 ± 0.35 19.25 ± 0.35 7,05 13.50 ± 0.71 34,81 9.50 ± 0.71 54,13 
10% DMSO 20.71 ± 0.35 20.75 ± 0.35 -0,19# 20.75 ± 0.35 -0,19# 21.00 ± 0.00 -1,40# 
SP-AB2 (Mannitol) 20.71 ± 0.35 11.50 ± 4.24 44,47 10.00 ± 1.41 51,71 9.38 ± 1.24 54,73 
SP-AB2 (5294) 20.71 ± 0.35 10.13 ± 2.65 51,11 10.25 ± 5.30 50,51 12.50 ± 2.12 39,64 
SP1-AB4 (Mannitol) 20.71 ± 0.35 16.13 ± 0.88 22,14 16.50 ± 0.71 20,33 17.25 ± 0.35 16,71 
SP1-AB4 (5294) 20.71 ± 0.35 12.88 ± 4.77 37,83 13.13 ± 3.71 36,62 12.00 ± 3.54 42,06 
SP2-AB7 (Mannitol) 20.71 ± 0.35 12.00 ± 5.66 42,06 12.38 ± 4.42 40,25 11.00 ± 4.95 46,89 
SP2-AB7 (5294) 20.71 ± 0.35 12.00 ± 4.95 42,06 12.50 ± 4.24 39,64 12.50 ± 4.95 39,64 
SP2-W6 (Mannitol) 20.71 ± 0.35 18.50 ± 2.12 10,67 19.75 ± 0.35 4,64 18.75 ± 1.77 9,46 
SP2-W6 (5294) 20.71 ± 0.35 15.50 ± 5.66 25,16 18.00 ± 3.54 13,09 18.50 ± 1.41 10,67 
SP5-AB7 (Mannitol) 20.71 ± 0.35 10.75 ± 2.47 48,09 6.50 ± 1.41 68,61 6.75 ± 2.47 67,41 
SP5-AB7 (5294) 20.71 ± 0.35 12.00 ± 2.83 42,06 10.00 ± 1.41 51,71 12.00 ± 1.41 42,06 
** Rhamnolipid production is expressed based on the diameter of the rhamnolipid hydrolysis zone – bacterial growth diameter. QS inhibitory compounds should reduce 
rhamnolipid production of P. aeruginosa ATCC 27853, and thus, in their presence, the hydrolysis zone should be of smaller dimensions than in the untreated control (<20.71 
mm). 
* All readings of rhamnolipid production are given ± standard deviation. 
$ Rhamnolipid inhibition for cinnamaldehyde at 1000 µg/ml is as a result of P. aeruginosa cell death. All other extracts tested had a growth inhibitory effect of <40% at all 
concentrations tested.  
# Negative values are indicative of an increase in rhamnolipid production at this concentration. 
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Table 2.11: Effect of sponge-associated Bacillus spp. extracts on rhamnolipid production by 
P. aeruginosa ATCC 27853. Both mannitol and medium 5294 extracts were tested at 250-1000 
µg/ml and the percentage rhamnolipid inhibition at each concentration was calculated  
 Percentage rhamnolipid inhibition 
 250 µg/ml 500 µg/ml* 750 µg/ml** 1000 µg/ml** 
Extract Code Mann 5294 Mann 5294** Mann 5294* Mann 5294 
B. cereus group SP-AB2 5.54 11.92 14.18 44.65 21.08 74.22 21.30 14.69 
B. cereus group SP1-AB4 12.22 45.17 17.41 50.30 17.44 54.68 9.02 56.81 
B. cereus group SP2-AB7 86.03 47.53 79.47 50.95 80.71 51.27 85.73 51.49 
B. pumilus group SP2-W6 -40.52# -14.99# -34.96# 14.17 3.14 4.23 21.80 -24.67# 
B. cereus group SP5-AB7 89.31 36.25 93.88 36.72 93.07 59.74 88.44 79.96 
Furanone 26.96  23.90  24.37  28.90  
10% DMSO 26.90  28.39  25.75  20.88  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Rhamnolipid inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
# Negative values indicate an increase in rhamnolipid production.  
 
Individually, the strongest inhibitors of rhamnolipid production were SP5-AB7 (Mann) 
(Supp. Fig 2.5.6A) and SP2-AB7 (Mann) (Supp. Fig 2.5.4A), without exerting cytotoxic effects. 
SP5-AB7 (Mann) resulted in a minimum rhamnolipid inhibition of 88.44% at 1000 µg/ml and 
a maximum inhibition of 93.88% at 500 µg/ml. Similarly, SP2-AB7 (Mann) yielded a minimum 
inhibition of 79.47% at 500 µg/ml and a maximum inhibition of 86.03% at 250 µg/ml. While 
medium 5294 yielded significant overall inhibitions, individually the strongest inhibitors were 
both mannitol-derived.  
Furanone was used as a positive control for this assay at concentrations of 2.5, 5, 7.5 
and 10 µg/ml, and was found to have an insignificant effect on rhamnolipid production, 
achieving a maximum inhibition of 29.3% at 5 µg/ml (p > 0.05). The 10% DMSO solvent 
without bacterial extract was found to have a similarly insignificant effect on P. aeruginosa 
rhamnolipid production, thereby ruling out any added effect of the solvent on the inhibitions 
observed above. Neither affected cell growth (Supp. Fig. S2.5.1).  
 
2.3.10 Bacillus spp. extracts and P. aeruginosa swimming motility 
The effects of each sponge-associated Bacillus spp. extract at varying concentrations was 
monitored for swimming motility for 3 d. However, to monitor only sustained inhibition of P. 
aeruginosa motility, only inhibitory effects which were maintained for the full 72 h were taken 
as positive results, such as those of SP1-AB4 (5294) and SP2-AB7 (5294) (Fig. 2.5).  
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Figure 2.5: Effect of sponge-associated bacterial extracts on P. aeruginosa ATCC 27853 
swimming motility. Positive extracts for motility inhibition were those with a sustained 
reduction in swim zones after 72 h. (A) Clear reduction in swimming motility was observed 
after treatment of the cells with sponge-associated Bacillus spp. extract SP1-AB4 (5294). (B) 
Positive motility inhibition as a result of treatment with Bacillus spp. extract SP2-AB7 (5294). 
In each instance cells were treated with 0, 250, 500 and 1000 µg/ml of bacterial extract (from 
left to right).  
 
Statistically, the sponge-associated Bacillus spp. extracts caused a significant (p < 0.01) 
mean reduction in P. aeruginosa swimming motility for 72 h. This same level of significance 
was maintained at each individual treatment concentration, and only altered upon the 
examination of the extracts according to production media (Table 2.12). Even so, the results 
maintained significance, both for the mannitol (p < 0.01) and medium 5294 (p < 0.01) extracts. 
The mannitol extracts yielded average swim inhibition of 26.61%, 26.52% and 23.53% at 250, 
500 and 1000 µg/ml, respectively. Medium 5294 resulted in moderately higher and more 
significant inhibition of 33.73%, 26.14% and 33.24% at 250, 500 and 1000 µg/ml, respectively. 
Therefore, the mean greatest motility inhibition was achieved at 250 µg/ml while utilizing 
medium 5294 Bacillus spp. extracts. Overall, 80% (8/10) of the extracts resulted in a >30% 
inhibition in swim motility, while only one of these was capable of >50% inhibition. 
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Table 2.12: Effect of sponge-associated Bacillus spp. extracts on P. aeruginosa ATCC 27853 
swimming motility. Both mannitol and medium 5294 extracts were tested at 250-1000 µg/ml 
and the percentage swimming inhibition at each concentration was calculated  
 Percentage swimming inhibition 
 250 µg/ml** 500 µg/ml** 1000 µg/ml** 
Extract Code Mann* 5294** Mann** 5294** Mann** 5294** 
B. cereus group SP-AB2 20.52 34.71 15.67 32.06 6.72 37.35 
B. cereus group SP1-AB4 19.40 19.40 20.15 20.15 37.35 18.28 
B. cereus group SP2-AB7 36.47 40.29 28.82 27.65 18.28 37.94 
B. pumilus group SP2-W6 17.16 36.47 39.55 28.82 37.94 28.24 
B. cereus group SP5-AB7 32.94 55.88 27.94 43.53 28.24 50.59 
Cinnamaldehyde 50.40  55.09  44.37$  
10% DMSO 17.90  18.90  20.91  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Swimming inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
The strongest inhibitor of swimming motility at 72 h was extract SP5-AB7 (5294), 
which resulted in a maximum swimming inhibition of 55.88% at only 250 µg/ml. Also 
achieving a maximum swim inhibition of 40.29% at 250 µg/ml was extract SP2-AB7 (5294), 
further stressing the ideal nature of these treatment conditions. No growth inhibition was 
observed with any of the extracts, and 10% DMSO without bacterial extract was found to 
result in an insignificant (p > 0.05) inhibition of P. aeruginosa swimming motility (Supp. Table 
S2.6.2). Cinnamaldehyde resulted in a >50% decrease in swimming motility but was found to 
be insignificant due to high variances as well as cytotoxicity at 1000 µg/ml (Supp. Table 
S2.6.2).  
 
2.3.11 Bacillus spp. extracts and P. aeruginosa swarming motility 
The effects of each sponge-associated Bacillus spp. extract at varying concentrations was 
monitored for P. aeruginosa swarming motility over 3 d. However, while swarm readings for 
the sponge-associated bacterial extracts were taken every 24 h for 72 h, the results at 72 h 
indicated a sustained inhibitory effect on cells (Fig. 2.6). The sponge-associated Bacillus spp. 
extracts sustained a significant (p < 0.01) mean reduction in P. aeruginosa swarming motility 
at 72 h, as well as at 250 µg/ml (p < 0.05) and 500 and 1000 µg/ml (p< 0.01) (Table 2.13). 
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Figure 2.6: Effect of sponge-associated bacterial extracts on P. aeruginosa ATCC 27853 
swarming motility. Positive extracts for motility inhibition were those with a sustained 
reduction in swarm zones after 72 h. (A) Clear reduction in swimming motility was observed 
after treatment of the cells with sponge-associated Bacillus spp. extract SP-AB2 (5294). (B) 
Positive motility inhibition as a result of treatment with Bacillus spp. extract SP1-AB4 (5294). 
In each instance cells were treated with 0, 250, 500 and 1000 µg/ml of bacterial extract (from 
left to right). 
 
Neither production media resulted in a significant mean swarm inhibition at 250 
µg/ml, while at 500 µg/ml only the medium 5294 extracts resulted in significant inhibition (p 
< 0.05) (Table 2.13). However, at 1000 µg/ml both mannitol and medium 5294 extracts 
yielded significant swarming inhibition (p < 0.05), suggesting this as the ideal treatment 
concentration for swarming inhibition. Mannitol extracts yielded a significant average swim 
inhibition of 13.67% at 1000 µg/ml, while medium 5294 resulted in significant mean 
inhibitions of 38.10% and 38.60% at 500 µg/ml and 1000 µg/ml, respectively. As the average 
swarm inhibition exerted by the medium 5294 extracts were both greater and more 
significant, medium 5294 can be proposed as the preferred medium for swarming inhibition. 
As this was true for swimming inhibition as well, medium 5294 may be the ideal production 
medium for producing sponge-associated bacterial extracts capable of P. aeruginosa motility 
inhibition.  
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Table 2.13: Effect of sponge-associated Bacillus spp. extracts on P. aeruginosa ATCC 27853 
swarming motility. Both mannitol and medium 5294 extracts were tested at 250-1000 µg/ml 
and the percentage swarming inhibition at each concentration was calculated  
 Percentage swarming inhibition 
 250 µg/ml* 500 µg/ml** 1000 µg/ml** 
Extract Code Mann 5294 Mann 5294* Mann* 5294* 
B. cereus group SP-AB2 18.99 30.38 7.59 46.2 13.29 42.41 
B. cereus group SP1-AB4 27.85 56.96 31.65 55.7 5.7 51.9 
B. cereus group SP2-AB7 10.76 36.71 59.49 55.7 8.86 29.11 
B. pumilus group SP2-W6 18.99 -18.35# -1.27# 12.66 11.39 45.57 
B. cereus group SP5-AB7 -17.72# 24.68 5.06 20.25 29.11 24.05 
Cinnamaldehyde 43.04  12.66  -8.23#$  
10% DMSO -58.23#  -83.54#  -49.37#  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Swarming inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
# Negative values indicate an increase in swarming motility. 
 
Overall, 60% (6/10) of extracts reduced swarming motility by >30%, with three of 
these exceeding 50% inhibition. The strongest inhibitor of swarming motility at 72 h was 
extract SP1-AB4 (5294), which resulted in a maximum swarming inhibition of 56.96% at 250 
µg/ml. Extract SP-AB2 (5294) also exhibited promising swarming inhibitory effects, resulting 
in a maximum swarm inhibition of 46.2% at 500 µg/ml. Furthermore, SP2-AB7 (5294) resulted 
in 55.7% swarming inhibition, also at 500 µg/ml, suggesting this as a potentially ideal 
treatment concentration for swarming inhibition. No growth inhibition was observed as a 
result of any of the extracts, and 10% DMSO without bacterial extract was found to result in 
an insignificant (p > 0.05) inhibition of P. aeruginosa swarming motility (Supp. Table S2.6.1). 
Cinnamaldehyde resulted in a >50% decrease in swarming motility, but was found to be 
insignificant due to high variances as well as cytotoxicity effect of the compound at 1000 
µg/ml.  
 
2.3.12 Bacillus spp. extracts and P. aeruginosa initial biofilm formation 
The effect of the ten sponge-associated Bacillus spp. extracts on P. aeruginosa initial biofilm 
formation was tested at 0, 0.5, 1, 5 and 10 mg/ml. Initial biofilm inhibition ranged from -
17.92% to 73.58%. Overall 50% (5/10) of the Bacillus spp. extracts resulted in an ≥40% 
reduction in initial biofilm formation, with three of these further resulting in a >65% inhibition 
without causing cell death. While some extracts achieved a >80% initial biofilm reduction, this 
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was due to the cytotoxic effects of the extracts at those concentrations (Table 2.14; Supp. 
S2.7).  
 
Table 2.14: Effect of sponge-associated Bacillus spp. extracts on initial biofilm formation by 
P. aeruginosa ATCC 27853. Both mannitol and medium 5294 extracts were tested at 0.5, 1, 5 
and 10 mg/ml and the percentage initial biofilm inhibition at each concentration was 
calculated 
 Percentage initial biofilm inhibition 
 0.5 mg/ml 1 mg/ml* 5 mg/ml** 10 mg/ml** 
Extract Code Mann 5294* Mann 5294** Mann 5294 Mann 5294 
B. cereus group SP-AB2 -17.73# 3.50 -17.92# 13.82 78.77$ 20.80 88.77$ 40.96 
B. cereus group SP1-AB4 2.84 6.97 31.13 16.54 58.89 69.39 73.58 81.41$ 
B. cereus group SP2-AB7 1.27 4.99 2.94 4.03 2.93 2.78 8.32 4.35 
B. pumilus group SP2-W6 -2.97# 11.09 -3.16# 19.39 -3.22# 41.11 -2.36# 41.84 
B. cereus group SP5-AB7 21.26 19.54 31.43 17.59 66.51 14.47 71.70$ 1.13 
Cinnamaldehyde -22.50#  -21.12#  70.25$  70.19$  
10% DMSO -23.36#  -21.12#  -18.47#  -18.52#  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Swarming inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
# Negative values indicate an increase in swarming motility. 
 
 Statistically the sponge-associated Bacillus spp. extracts were found result in a 
significant overall decrease in P. aeruginosa initial biofilm formation (p < 0.01). However, 
upon further examination it was observed that as an individual treatment concentration 0.5 
mg/ml proved to be insignificant, while 1 mg/ml (p < 0.05) and both 5 mg/ml and 10 mg/ml 
(p < 0.01) resulted in significant average initial biofilm inhibition. Furthermore, when 
examining each concentration for the individual production media (mannitol and medium 
5294), only medium 5294 yielded significant mean initial biofilm inhibition, which occurred at 
0.5 and 1 mg/ml (Table 2.14). This lack of significance could, however, be attributed to the 
large variances seen between the different bacterial extracts of each production media at 
each treatment concentration.  
The three best inhibitors each resulted in a >60% reduction in initial biofilm formation. 
These were SP1-AB4 (Mann) which resulted in a 73.58% decrease at 10 mg/ml, SP1-AB4 
(5294) with a 69.39% inhibition at 5 mg/ml and SP5-AB7 (Mann) with an inhibition of 66.51% 
at 5 mg/ml (Table 2.14). However, only SP5-AB7 (Mann) exerted a significant effect (p < 0.05) 
on initial biofilm production. No growth inhibition was observed as a result of any of the 
extracts unless indicated (Table 2.14), and 10% DMSO without bacterial extract actually 
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resulted in an increase in initial biofilm formation (Supp. Fig. S2.7.1 and S2.7.2). 
Cinnamaldehyde resulted in an insignificant average effect on initial biofilm production due 
to the cell death observed at both 5 and 10 mg/ml.  
 
2.3.13 Bacillus spp. extracts and P. aeruginosa mature biofilm formation 
The ten sponge-associated Bacillus spp. extracts were further screened at 0, 0.5, 1, 5 and 10 
mg/ml for their effect on P. aeruginosa mature biofilm formation. Mature biofilm inhibitions 
ranged from 7.49% to 86.28% with no killing being observed for any of the extracts (Supp. Fig. 
S2.7.3A and S2.7.4A). Overall only one of the Bacillus spp. extracts resulted in an ≥40% 
reduction in initial biofilm formation, reaching a maximum inhibition of 86.28% (Table 2.15).  
 
Table 2.15: Effect of sponge-associated Bacillus spp. extracts on mature biofilm formation by 
P. aeruginosa ATCC 27853. Both mannitol and medium 5294 extracts were tested at 0.5, 1, 5 
and 10 mg/ml and the percentage mature biofilm inhibition at each concentration was 
calculated 
 Percentage mature biofilm inhibition 
 0.5 mg/ml** 1 mg/ml** 5 mg/ml** 10 mg/ml* 
Extract Code Mann 5294** Mann* 5294** Mann 5294** Mann 5294** 
B. cereus group SP-AB2 35.96 11.78 40.43 12.11 40.67 12.29 86.28 12.33 
B. cereus group SP1-AB4 12.04 11.69 12.25 14.53 12.34 15.34 13.26 17.82 
B. cereus group SP2-AB7 7.49 11.18 10.87 11.21 11.14 12.48 13.81 12.55 
B. pumilus group SP2-W6 10.06 12.56 9.75 13.63 7.53 14.24 7.97 14.74 
B. cereus group SP5-AB7 8.57 11.26 9.86 11.71 10.20 12.20 15.71 12.54 
Cinnamaldehyde 38.85  38.55  45.39  46.43$  
10% DMSO 14.63  15.48  18.16  21.03  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Swarming inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
Statistically, the sponge-associated Bacillus spp. extracts resulted in a significant 
overall decrease in P. aeruginosa mature biofilm formation (p < 0.01), as well as for each of 
the individual treatment concentrations. Mannitol was found to yield overall average 
inhibition only at 1 mg/ml, while media 5294 yielded significant mean initial biofilm inhibition 
at all four treatment concentrations tested (p < 0.01) (Table 2.15). The lack of significance for 
the mannitol could, however, be attributed to the large variances seen between the different 
bacterial extracts of each production media at each treatment concentration. In terms of the 
5294 extracts, an average inhibition of 11.69% was achieved at 0.5 mg/ml, 12.64% at 1 mg/ml, 
13.31% at 5 mg/ml and 14% at 10 mg/ml. Due to the low inhibition range observed, a lower 
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treatment concentration (such as 1 mg/ml) may be suggested without losing treatment 
efficacy. In terms of the individual extracts, Bacillus spp. extract SP-AB2 (Mann) was the only 
extract to yield a >20% mature biofilm inhibition, reaching a maximum inhibition of 86.28% 
at 10 mg/ml. This extract was further found to exert a statistically significant (p < 0.05) 
inhibitory effect on P. aeruginosa mature biofilm formation. No growth inhibition was 
observed as a result of any of the extracts, and 10% DMSO without bacterial extract was found 
to result in a significant mean decrease of 12% (p < 0.05) in mature biofilm formation (Supp. 
Fig. S2.7.3 and S2.7.4). As a result, those extracts yielding a lower (<12%) mature biofilm 
inhibition should be further tested to ensure that the inhibition observed was not as result of 
the solvent used. Cinnamaldehyde resulted in a significant average decrease of 29.7% on 
mature biofilm production (p < 0.05), however, the cell death observed at 10 mg/ml as a result 
of this extract should be taken into account.  
 
2.3.14 Sponge-associated Bacillus spp. extracts as inhibitors of specific P. 
aeruginosa QS systems 
The P. aeruginosa QS network can be broken down into three distinct QS systems (excluding 
the newly integrated IQS network). These three systems are the long chain las QS system, the 
short chain rhl QS system and the quinolone-based PQS system (Holm and Vikstrom, 2014; 
Boopathi et al., 2017). As such, the virulence factors tested were themselves broken up into 
these three systems.  Virulence factors primary under control of the las system are the 
production of elastase LasB and protease, while those under the control of the rhl system are 
rhamnolipid production and, due to the influence of rhamnolipids on this process, mature 
biofilm formation (Lee and Zhang, 2015). Pyocyanin and pyoverdine production receive their 
influence primarily through the PQS system (Welsh and Blackwell, 2016), although not 
exclusively, while the exact QS control mechanism in regard to swimming and swarming 
motility as well as initial biofilm formation remains to be fully elucidated and may consist of 
mixed influences. Due to the partially segregated nature of virulence factor production by P. 
aeruginosa in terms of its QS network, the top three inhibitors of each of these assays were 
examined in order to see if a trend was revealed in regard to any specific sponge-associated 
Bacillus spp. extract or isolate.  
 In terms of the short chain rhl-AHL QS system, maximal inhibitions of over 75% were 
observed for rhamnolipid production while an inhibition of 86.28% was observed for mature 
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biofilm formation (Fig. 2.7). One bacterial isolate which stood out was B. weihenstephanensis 
SP5-AB7, which filled three of the top six spots as inhibitors of these two virulence factors. 
This extract clearly displays then a proficiency for short chain QS inhibition.  
 
 
 
 
 
 
 
 
 
Figure 2.7: Three of the best inhibitors of rhamnolipid and mature biofilm production which 
are primarily mediated through the short chain rhl system in P. aeruginosa. Extract SP5-AB7 
(Mann) was identified as the lead inhibitor of rhamnolipid production (93.88%) as well as the 
third highest inhibitor of mature biofilm formation (15.71%). The medium 5294 extract of this 
isolate additionally resulted in a 79.96% rhamnolipid inhibition. Bacillus toyonensis extract 
SP2-AB7 (Mann) resulted in an 86.03% rhamnolipid inhibition while SP-AB2 (Mann) was the 
key inhibitor of mature biofilm formation (86.28%).  
 
Similar to the observed inhibition in rhl-mediated virulence factor production, extract 
SP5-AB7 (Mann) proved once again to be a major inhibitor, this time of elastase production 
(71.32%) (Fig. 2.8). Also making a reappearance was B. toyonensis strain SP2-AB7 (Mann), 
which in addition to its rhamnolipid-inhibitory potential seen above, inhibited elastase 
production by 51.76% while the medium 5294 extract of the same isolate resulted in a 59.93% 
decrease in protease production. Similarly, SP1-AB4 (5294) was one of the top inhibitors of 
mature biofilm formation, and the mannitol extract of the same organism inhibited both 
elastase and protease production by 50%, suggesting a broad spectrum QSI ability of this 
organism in addition to SP5-AB7 and SP2-AB7.  
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Figure 2.8: Three of the best inhibitors of elastase and protease production, which are 
primarily mediated through the long chain las system in P. aeruginosa. Extract SP5-AB7 
(Mann) was identified as the lead inhibitor of elastase production (71.32%). This was followed 
by Bacillus toyonensis strain SP2-AB7 (Mann) and SP1-AB4 (Mann) with elastase inhibition of 
51.76% and 50.32%, respectively. Medium 5294 extract of the B. toyonensis strain further 
inhibited protease production by 59.93% while SP1-AB4 (Mann) was additionally able to 
inhibit protease production by 50.07%, in conjunction with its elastase-inhibitory activity. The 
key inhibitor of protease production proved to be SP2-W6 with an inhibition of 63.81%. 
 
  For the quinolone-based PQS system in P. aeruginosa, similar trends in inhibition 
were observed. Extract SP5-AB7 (Mann) was the top inhibitor of both elastase and 
rhamnolipid production, and similarly it was the top inhibitor of pyocyanin production 
(39.36%). The medium 5294 extract was a top inhibitor of mature biofilm formation, as well 
as one of the top inhibitors of pyoverdine production (33.4%) (Fig. 2.9). Pyocyanin inhibition 
by SP5-AB7 (Mann) was followed by that of SP2-W6 (5294), which resulted in a decrease of 
36.76% in conjunction with its previously observed protease-inhibitory capabilities. In 
conjunction to its pyoverdine-inhibitory activity (31.43%), SP1-AB4 (Mann) was a major 
inhibitor of protease and elastase production. Extract SP-AB2 (5294) inhibited pyocyanin 
production by 36.21% and SP-AB2 (Mann) inhibited pyoverdine production by 38.43%, the 
highest observed pyoverdine inhibition. This extract was not a top inhibitor of any of the 
previously discussed virulence factors, suggesting its QSI potential may be specific to the PQS 
system. 
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Figure 2.9: Three of the best inhibitors of pyocyanin and pyoverdine production, which are 
primarily mediated through the quinolone-based PQS system in P. aeruginosa. Extract SP5-
AB7 (Mann) was identified as the lead inhibitor of pyocyanin production (39.36%) while the 
medium 5294 extract of the same was identified as one of the lead inhibitors of pyoverdine 
production (33.4%). Extract SP-AB2 (5294) resulted in a 36.21% decrease in pyocyanin 
production while the mannitol of extract of this organism resulted in the highest inhibition of 
pyoverdine production (38.43%). Extract SP2-W6 (5294) resulted in a pyocyanin inhibition of 
36.76% while SP1-AB4 (Mann) resulted in a 31.43% reduction in pyoverdine production.  
 
 While the QS systems primarily mediating many of the P. aeruginosa virulence factors 
are well understood, in some instances there are too many systems with influence over the 
production of a virulence factor for the correlations to be so clear. Swimming and swarming 
motility as well as initial biofilm production are examples of such virulence factors (Fig. 2.10), 
although the PQS system has been putatively suggested to play a role in initial biofilm 
formation (Boopathi et al., 2017).  Although unelucidated, these systems are themselves 
clearly linked, as similar extracts form the top inhibitors of each virulence factor. Extract SP1-
AB4 (5294) swarming and initial biofilm formation by 56.96% and 69.39%, respectively. The 
mannitol extract of the same organism was the best inhibitor of initial biofilm formation, 
resulting in a reduction of 73.58%. Extract SP2-AB7 (5294) inhibited swimming and swarming 
(40.29% and 55.7%) while the mannitol extract of this organism was the major inhibitor of 
swarming motility, resulting in an inhibition of 59.49%. Both these organisms were proficient 
inhibitors of the rhl and las-mediated virulence factors, while SP1-AB4 additionally inhibited 
pyoverdine production, suggesting a broad spectrum QSI activity for these extracts. Extract 
SP5-AB7 (Mann) inhibited initial biofilm formation by 66.51%, in addition to being the top 
inhibitor of pyocyanin, LasB and rhamnolipid production. The medium 5294 extract of the 
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same organism resulted in the strongest inhibition in swimming motility (55.88%). This isolate 
clearly then possesses the ability to inhibit a broad range of QS systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: The mediation of swimming and swarming motility as well as initial biofilm 
formation are closely intertwined, however the exact QS influence of these three virulence 
factors is not yet completely understood. They are either not known or highly variable. Here 
we see the best three inhibitors each of swimming, swarming and initial biofilm production. 
Bacillus toyonensis extract SP2-AB7 (5294) resulted in >40% inhibition in both swimming and 
swarming motility, while the mannitol extract of this organism resulted in the highest 
swarming inhibition (59.49%). Extract SP1-AB4 (5294) resulted in a 56.96% reduction in 
swarming motility as well as a 69.39% reduction in initial biofilm formation.  The mannitol 
extract of the same organism (SP1-AB4) resulted in the highest inhibition in initial biofilm 
formation, 73.58%. Extract SP2-W6 (Mann) resulted in a 39.55% reduction in swimming 
motility and SP5-AB7 (Mann) a 66.51% reduction in initial biofilm formation while SP5-AB7 
(5294) resulted in a 55.88% reduction in swimming motility.  
 
2.4 Discussion  
In recent years, the marine environment has gained attention as a potential source of novel 
pharmaceutical and biotechnological products (Gutiérrez-Barranquero et al., 2018). In order 
to determine the potential QSI activities of sponge-associated bacteria isolated from sponges 
off the coast of Durban, KwaZulu-Natal, seven sponge samples were harvested and a total of 
98 bacterial isolates purified and used for this screening study. These were then tested for 
putative QSI abilities using the C. violaceum sandwich assay. Chromobacterium violaceum is a 
common soil-associated Gram-negative bacterium which produces a QS-mediated purple 
pigment, violacein (Mani et al., 2012). Mutants thereof are commonly used to pre-screen 
bacterial isolates for the inhibition of AHL production through a reduction in violacein 
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production (Naik et al., 2013; Tang and Zhang, 2014; Hassan et al., 2016). Upon using the 
sandwich assay, it was noticeable that the inhibitory effects of B. cereus on Vir07 was not as 
pronounced as its effect on the CV026 mutant (Fig. 2.1). This is due to the preference of 
lactonases for short chain (< 8 carbon atoms) AHL-degradation (Castillo-Juarez et al., 2017), 
as well as the general resilience of long chain AHLs as compared to their shorter-chained 
counterparts (Castillo-Juarez et al., 2017). This was taken into consideration when allocating 
the QSI rating of 0-4.  
It was observed that 88% (86/98) of sponge-associated bacteria were able to inhibit 
short chain signal transduction with a rating of 3 or 4. This was an improvement on results 
obtained by Saurav et al. (2016) who found that, upon screening 14 sponge species for QSI 
activity against C. violaceum CV026, only four isolates (28%) were QSI-positive. Similarly, both 
Singh et al. (2017) and Gutiérrez-Barranquero et al. (2018) observed that only 4% (2/56 and 
18/440, respectively) of their sponge-associated bacterial isolates possessed QSI activity 
against biosensor strains. Only 17% (17/98) of the sponge-associated bacteria tested in this 
study were able to achieve the same results for long chain QSI. These results were 
unsurprising due to the resilience of long chain AHLs to quenching. Of the 17, 16 could 
additionally inhibit short chain QS of C. violaceum.  
Following ethyl acetate extractions of 15 selected isolates using two production 
media, a total of 30 extracts were obtained for further QSI screening using the C. violaceum 
ATCC 12472 agar well assay. Of the 30 extracts, only four (Fig. 2.2) yielded a positive QSI result. 
Although all of the isolates had previously demonstrated long chain QSI activity, the reduction 
in activity was not a concern as it may be attributed to a potential lack of diffusion by the 
extracts. Another potential reason for the lack of activity was the high amount of violacein 
being produced by the C. violaceum cells, indicating an elevated level of AHL production. This 
high level was potentially too potent for the limited amount of extracted inhibitors to quench. 
This theory was given some precedence when the concentration of SP-AB2 (Mann) and SP2-
AB3 (5294) was increased from 1 mg/well to 2 mg/well, resulting in an increased violacein 
inhibition (Table 2.3). This was also taken as an indication that the effect of the QSI molecules 
present in some of the extracts may be concentration-dependent, which was further 
validated as SP2-W6 (Mann) and SP4-AB2 (Mann) caused increased zone diameters with 
increased concentration (Table 2.3). Musthafa et al. (2011) observed a similar concentration-
dependent effect when testing marine Bacillus spp. extracts on violacein production, 
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confirming the results of this study. Furthermore, Singh et al. (2017) obtained similar positive 
results via the spotting of their crude extracts directly onto the bacterial plate, as well as Mani 
et al. (2012) who observed inhibitions of between 7-11 mm upon incorporation of their crude 
Bacillus spp. extracts into discs, and so it is evident that a comparison of the efficacies of the 
various methodologies could prove beneficial in the future.  
Unlike in the case of the furanone control, however, no zones of cell death were 
observed for any of the extracts. A further observation made during the course of this assay 
was that 75% (3/4) of the positive extracts were obtained from the mannitol production 
medium. It was, therefore, hypothesised at this point that mannitol may be a better medium 
for long chain inhibitor production. 
Following the initial screening and identification, the ten extracts identified as 
belonging to Bacillus species were tested further as potential P. aeruginosa QSI agents. 
Gutiérrez-Barranquero et al. (2018) similarly took five sponge-associated Bacillus spp. isolates 
forward for testing against P. aeruginosa, following primary QSI screening. Based on the agar 
well diffusion assay, extracts were tested at 5 and 10 mg/well, with no antimicrobial activity 
being observed for any of the extracts. This was done to ensure that none of the QSI results 
observed in the upcoming assays would be as a result of cell death, as well as to ensure that 
the Bacillus spp. extracts would not induce resistance in the cells as a result of metabolic 
stress. Although this was confirmed through the antimicrobial assay, growth readings (OD600 
nm) were taken for each assay in order to continuously monitor the effects of the extracts on 
cell growth. 
The first virulence factor against which the extracts were screened was the production 
of the blue phenazine pigment, pyocyanin. Pyocyanin is commonly found to be present at 
significant levels in the sputum of CF patients, as well as in the urine of those chronically 
infected with P. aeruginosa and is, among other things, responsible for neutrophil apoptosis 
in mammalian hosts (Hall et al., 2016). Pyocyanin inhibition was screened in conjunction with 
the production of the siderophore pyoverdine. Both of these virulence factors are mediated 
by multiple QS systems, including the PQS and rhl QS networks. Even with the complexity of 
the systems governing production, 100% (10/10) of the sponge-associated Bacillus spp. 
extracts were able to inhibit pyocyanin production to some degree. Of these, however, only 
eight resulted in pyocyanin production of >30%, with none reaching inhibitions of 50%. Saurav 
et al. (2016), who tested sponge-associated bacterial extracts from the Mediterranean and 
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Red Seas, observed a similar frequency of positive results (94%; 16/17) with six of these 
resulting in >70% reduction in pyocyanin production at approximately 1 mg/ml of extract, 
which proved to be the most significant treatment concentration when using the Bacillus spp. 
extracts as well (p < 0.01).  In a similar study, Guendouze et al. (2017) achieved improved 
results, and was able to inhibit pyocyanin production in Pseudomonas spp. strains (96%; 
25/26) using a purified lactonase enzyme, with 20 of these being >50%, indicating the need 
for compound purification in the future, especially considering the known production of 
lactonase enzymes by Bacillus isolates.  
Of the sponge-associated bacterial extracts, the strongest inhibitor of pyocyanin 
production was SP5-AB7 (Mann), which exerted a primarily concentration-dependent effect 
on pyocyanin production, culminating in an inhibition of 39.36% at 750 µg/ml, after which 
inhibition decreased. This result was in line with those of Mani et al. (2012) who observed a 
maximal pyocyanin inhibition of 25% following exposure of P. aeruginosa to 1 ml of their 
crude Bacillus spp. extracts. Also utilizing a crude marine Bacillus spp. extract, Musthafa et al. 
(2011) observed a pyocyanin inhibition of approximately 40 % at 1 mg/ml, almost identical to 
that of sponge-associated bacterial extract SP5-AB7 (Mann). They further observed an 
increase in pyocyanin inhibition to 86% upon using 2 mg/ml of their extract (Musthafa et al., 
2011), indicating that in future a wider range of treatment concentrations may be advisable. 
Guendouze et al. (2017), however, achieved complete pyocyanin inhibition at 0.5 mg/ml, 
although this was done using a purified lactonase enzyme while the sponge-associated 
bacterial extracts are crude preparations of multiple secondary metabolites and enzymes.  
Patterns in inhibition such as the one observed for SP5-AB7 (Mann), where a dip in 
inhibition was observed at a higher treatment concentration, are potentially attributed to the 
hierarchical nature of the P. aeruginosa QS network. Unless both PQS and rhl systems are 
inhibited, PQS may serve to reactivate the rhl system (Chan et al., 2015; Kim and Lee, 2016). 
Similarly, if the las system is not inhibited the rhl system may also be activated (Welsh and 
Blackwell, 2016). This reactivation may occur at a higher concentration as at the point of 1 
mg/ml for the SP5-AB7 (Mann) extract the cells are experiencing stress due to the inactivation 
of the QS systems. It would be advisable then for extracts such as this not to be administered 
at doses where this effect is observed. Patterns such as these are difficult to compare to 
literature, however, as most virulence factor studies either employ purified compounds 
(which exert stronger QSI activities thus forming linear patterns) or they only test a single 
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concentration of their crude extracts, such as Singh et al. (2017) who achieved inhibition of 
50-70% pyocyanin production, but only tested 0.1 mg/ml thus eliminating any inhibition 
pattern formation. In terms of production media used, mannitol and medium 5294 resulted 
in inhibition of equal significance (p < 0.01 at 1000 µg/ml). However, as mannitol yielded an 
overall higher mean inhibition at 1000 µg/ml (31.95%), this may be selected as the ideal 
production medium for pyocyanin inhibition.  
Pyoverdine is a siderophore that acts both as a signalling molecule by obtaining iron 
for the bacterial cells and up-regulates the production of exotoxin A and endoprotease 
(Gellatly and Robert, 2013). Pyoverdine inhibition was tested in conjunction with pyocyanin 
inhibition, utilizing the known QS inhibitor cinnamaldehyde as a positive control. An overall 
significant decrease in pyoverdine inhibition was observed (p < 0.01) using the sponge-
associated bacterial extracts, and all extracts inhibited pyoverdine to some extent. Five of 
those were able to inhibit pyoverdine production by >30%, as compared to the eight extracts 
which inhibited pyocyanin production by the same amount. Although the production of both 
virulence factors is mediated in an analogous manner, iron levels and the efficacy of iron 
sequestration result in the las system being bypassed in favour of the rhl system (Guendouze 
et al., 2017). This system is then able to reactivate the PQS system, which could explain the 
lower inhibition values as any inhibition in iron sequestration, including the inhibition in 
siderophore production, would have this effect.  
Of the five isolates which inhibited pyoverdine production by >30%, SP-AB2 (Mann) 
proved to be the most effective with a maximum pyoverdine inhibition of 38.43% at 1 mg/ml. 
This was similar to the 32.63% pyocyanin inhibition exhibited by this organism, also at 1 
mg/ml and also in a concentration-dependent manner. This treatment concentration was 
determined to be the most effective for pyoverdine inhibition, as it achieved the most 
significant and highest mean inhibition (24.05%, p < 0.01). This result was not dissimilar to 
that of Chang et al. (2017) who, upon testing extracts of a marine Rhizobium species, obtained 
a maximum pyoverdine inhibition of 55.7%. However, the concentration of the extracts could 
not be compared as Chang et al. (2017) presented their values as volume of bacterial 
supernatant without quantifying the weight of the extract. Musthafa et al. (2011) similarly 
observed a concentration-dependent decrease in pyoverdine production by P. aeruginosa 
following treatment with 0.5-2 mg/ml of a crude marine Bacillus spp. extract, however they 
did not quantify this decrease. Overall, very few previously published studies which have 
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examined the effect of QSI agents on P. aeruginosa have included pyoverdine as a virulence 
factor, possibly as the effect of a pyoverdine deficiency on virulence is often quite modest 
(Granato et al., 2016). Overall medium 5294 was determined to be the ideal medium for 
pyoverdine inhibition.  
The las QS system of P. aeruginosa is the primary mediator of elastase production 
within this organism (Bandara et al., 2012). The most commonly studied P. aeruginosa 
elastase is LasB, which allows for bacterial invasion of host tissues (Mani et al., 2012). Overall 
60% (6/10) of the sponge-associated Bacillus spp. extracts caused a >30% inhibition in LasB 
production (p < 0.01). Three of the Bacillus spp. extracts were capable of >50% elastase 
inhibition at 1000 µg/ml, all of which were mannitol-derived, stressing the utility of mannitol 
as the ideal production medium for elastase reduction. The greatest of these was SP5-AB7 
(Mann) which caused a 71.32%, concentration-dependent inhibition at 1 mg/ml. Extracts 
from this isolate had already displayed promising activity against both pyocyanin and 
pyoverdine production, although none so high as 70%. This result was almost mirrored by 
that of Chang et al. (2017), who observed a 77.9% elastase inhibition after treatment with a 
5% aqueous Rhizobium extract (weight not quantified) and was an improvement on those of 
Mani et al. (2012) who obtained an elastase inhibition of 37% following treatment with 1 ml 
of their crude Bacillus spp. extracts. Similarly, utilizing a crude marine Bacillus spp. extract, 
Musthafa et al. (2011) observed a maximal decrease of 68% in elastase production at a 
treatment concentration of 2 mg/ml whereas SP5-AB7 (Mann) was able to achieve the same 
level of inhibition at only 1 mg/ml. It was unsurprising, however, that 30% of the extracts 
should show a >50% inhibition in LasB production. Extracts were obtained from isolates 
selected in a manner that gave preference to potential inhibitors of long chain AHLs, and the 
success of the extracts in terms of LasB inhibition only served to validate the results obtained 
in the initial, pre-screening stage of the study.  
Another virulence factor primarily controlled by the long chain las QS system is the 
production of proteases. Upon qualitative screening. 90% (9/10) of the Bacillus spp. extracts 
yielded putative protease inhibitory activity. Eight of these were then confirmed as exerting 
a >20% inhibition in protease production. This was similar to results observed by Guendouze 
et al. (2017) who, using their purified lactonase enzyme at 0.5 mg/ml, observed inhibition of 
protease in 93% (26/28) of Pseudomonas spp. strains. Four of the sponge-associated bacterial 
extracts resulted in a >50% protease reduction. This was in line with the results of a similar 
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assay performed by Singh et al. (2017), who observed a maximum protease inhibition of 24% 
following exposure of Pseudomonas to 0.1 mg/ml of their bacterial extract.  
While Mani et al. (2012) observed a maximal protease inhibition of 33% following 
exposure of P. aeruginosa to 1 ml of their crude Bacillus spp. extracts, of the sponge-
associated bacterial extracts B. pumilus extract SP2-W6 (5294) was most effective, with 
63.81% inhibition at 1000 µg/ml. The mannitol extract of the same organism also yielded long 
chain inhibitory results, inhibiting violacein production in the agar overlay assay. In addition 
to 63.81% protease inhibition, this extract had also displayed 34.41% reduction in LasB 
production at 1000 µg/ml. These results were comparable to those of Musthafa et al. (2011), 
who achieved a protease inhibition of 37% and 65% following treatment of P. aeruginosa with 
1 mg/ml and 2 mg/ml of their crude marine Bacillus spp. extract, respectively. The results for 
these two extracts were further comparable to those of Guendouze et al. (2017) who 
observed that their purified lactonase achieved an optimum protease inhibition of 90 and 
57% when tested at 0.5 mg/ml against P. aeruginosa PAO1 and PA14, respectively. This 
indicates that while purification of the extracts may improve their QSI results, the test strain 
of Pseudomonas also plays a role, making truly accurate inter-study comparisons a challenge 
as the susceptibility profiles of various strains differs considerably.   
While the las QS system was named for its regulation of elastase production, the rhl 
QS system was similarly named as it is the key regulator of rhamnolipid production by P. 
aeruginosa cells (Bandara et al., 2012). Rhamnolipids are key for swarming motility as well as 
biofilm formation in P. aeruginosa (Lee and Yoon, 2017). Of the 90% (9/10) of extracts 
exhibited inhibition of rhamnolipid production in the qualitative assay, seven of these were 
confirmed using the quantitative orcinol assay, as well as an additional extract bringing the 
total to 80% capable of >20% rhamnolipid inhibition. Six of these were capable of a >50% 
inhibition in rhamnolipid production, which was the highest rhamnolipid inhibition observed 
by Mani et al. (2012) upon treatment of P. aeruginosa with 1 ml of crude Bacillus spp. extracts. 
The ability of sponge-associated bacteria to inhibit short chain AHLs had been shown earlier 
as 88% of isolates tested had successfully inhibited violacein production by C. violaceum 
CV026 in the sandwich assay. As short chain AHLs offer less resistance to inhibition, are 
especially prone to degradation by Bacillus-produced lactonases, and rhamnolipid is under 
regulation by primarily only the one QS system, it was expected that many extracts should 
yield strong inhibition. The results of the orcinol assay served to validate these expectations.  
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The greatest of the rhamnolipid-inhibiting extracts were SP5-AB7 (Mann) and SP2-AB7 
(Mann) which caused rhamnolipid inhibition of 93.88% at 500 µg/ml and 86.03% at 250 µg/ml, 
respectively. Singh et al. (2017) demonstrated an 85% inhibition in rhamnolipid production 
following treatment of Pseudomonas aeruginosa PAO1 with 0.1 mg/ml of their marine-
derived bacterial extract. Although both production media yielded extracts with strong 
rhamnolipid-inhibitory abilities, medium 5294 was shown to be more significant and as such 
can be said to be the better of the two media in this regard.  
The motility of P. aeruginosa cells is vital for bacterial invasion and biofilm formation 
(Singh et al., 2017). While P. aeruginosa exhibits multiple forms of motility (including 
swimming, swarming and twitching) swimming and swarming motility were determined to be 
the ideal forms of motility to use as references for QSI activity as they are used during key 
cellular processes such as host colonization and biofilm formation (Singh et al., 2017). 
However, swimming and swarming motility have yet to be conclusively associated with a 
particular QS system in P. aeruginosa, with multiple external factors coming into play such as 
pili formation and rhamnolipid production (Steindler et al. 2009; Lee and Yoon, 2017). This in 
conjunction with the sensitivity of the swarming motility assay to environmental conditions 
such as miniscule variations in liquids on the surface of the agar plates as well as the humidity 
of the laboratory environment (Morales-Soto et al., 2015), resulted in only a few instances 
where the swarming results were quantitatively reproducible. This meant that significant 
inhibitions in swarming motility were only seen at 1000 µg/ml for the mannitol extracts and 
at ≥500 µg/ml for the medium 5294 Bacillus spp. extracts. Unlike the sponge-associated 
bacterial extracts tested by Gutiérrez-Barranquero et al. (2018), which were observed to have 
no impact on P. aeruginosa swimming motility, eighty percent of the extracts tested here 
showed a >30% inhibition in swimming motility, with one extract exceeding 50%. This was in 
comparison to the extracts’ effect on swarming motility, where 60% (6/10) of extracts were 
capable of >30% swarm inhibition, with three of these exceeding 50%. These results were 
comparable to those obtained by Gutiérrez-Barranquero et al. (2018), who observed that 
most of their marine sponge-associated bacterial extracts were capable of a qualitative 
inhibition in swarming motility, with three of the most promising extracts being Bacillus spp-
derived. Our swarm measurements in particular were comparable to those of Rekha et al. 
(2016) who observed a reduction in swarm motility from 64 mm (untreated) to 12 mm 
(81.25%), similar to the reduction from 39.5 mm to 16 mm (59.5%) observed after treatment 
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using SP2-AB7 (Mann). Rekha et al. (2016) failed, however, to test the sustainability of their 
results, whereas those of SP2-AB7 (Mann) were maintained for the full 72 h. Extract SP2-AB7 
(5294) similarly resulted in >50% inhibition for both swim and swarm motility. Overall, 
medium 5294 was shown to yield the most significant inhibitions in both motility assays, 
deeming it the ideal production media for motility inhibition.  
While each of these virulence factors may tell an intriguing story individually, quite 
often they culminate and cause an enhanced virulence effect in the form of a biofilm. Biofilm 
formation P. aeruginosa is a highly complex process, involving multiple variables such as 
virulence factor production, motility, EPS production as well as small molecule signals and 
sRNAs (Kim and Lee, 2016; Moradali et al., 2017). Therefore, while virulence factors do play a 
role, it was not expected than in many instances there would be a clear correlation between 
biofilm formation and the inhibition of other virulence factors such as pyocyanin production 
and rhamnolipid production. Due to the robustness of biofilm life, with cells being ×1000 
more resistant to any sort of chemical treatment than when in planktonic form (Lee and Yoon, 
2017), higher concentrations of extracts (0.5 - 10 mg/ml) were tested than with the previous 
assays.  
When screened against initial biofilm production, 50% (5/10) of the Bacillus spp. 
extracts resulted in an ≥40% reduction in initial biofilm formation. Gutiérrez-Barranquero et 
al. (2018) observed that a similar 61% (11/18) of their sponge-associated bacterial extracts 
caused a ≥50% reduction in biofilm formation, including Bacillus AF52. Three of the positive 
extracts tested in this study resulted in a >65% inhibition without causing cell death. Musthafa 
et al. (2011) similarly observed a strong inhibition in initial biofilm formation (88% at 2 mg/ml) 
when utilizing a marine Bacillus spp. extract, while Sayem et al. (2011) achieved a 90% initial 
biofilm inhibition of Pseudomonas fluorescens when utilizing an extract from sponge-
associated B. licheniformis, highlighting the QSI potential of these organisms. These results 
were also similar to those obtained by Pejin et al. (2014), who observed a 54% decrease in 
initial biofilm formation after treatment of P. aeruginosa with 15 µg/ml of a sponge-derived 
extract. The MIC of this extract, however, was determined to be 30 µg/ml. This suggests that 
while more concentrated, this extract may be cytotoxic when administered in a clinical dose 
whereas none of the sponge-associated bacterial extracts exhibited cytotoxicity during 
antimicrobial screening.  
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These results can be compared to the 88.1% (37/42) positive results obtained by 
Guendouze et al. (2017) following the exposure of the isolates to a purified lactonase enzyme 
as well as to those of Boopathi et al. (2017) who achieved biofilm inhibition of between 57 
and 90% using purified B. subtilis compound stigmatellin. This lower inhibition of initial biofilm 
formation by the sponge-associated bacterial extracts could be as a result of the high levels 
of rhamnolipid inhibition exhibited by the extracts, as rhamnolipid inhibition before the 
biofilms have reached maturation has been linked with increased initial biofilm formation 
(Kim and Lee, 2016) and rhl-deficient mutants have been shown to form robust initial biofilm 
structures (Musthafa et al., 2011). Furthermore, while a biofilm inhibitory study performed 
by Guendouze et al. (2017) showed higher inhibition of initial biofilm formation (90% for P. 
aeruginosa PAO1 and 60% for PA14), their results cannot be accurately compared with those 
obtained in this study as the authors used a purified lactonase enzyme and incubated their 
biofilms for 48 h (compared to our 24 h incubation).  
Mature biofilms are much harder to inhibit than initial biofilms, due to their complex 
EPS structures (Kim and Lee, 2016). All of the extracts were able to inhibit mature biofilm 
formation to some extent, with treatment concentrations as low as 0.5 mg/ml proving to be 
significant for both medium 5294 (p < 0.01) and mannitol (p < 0.05) extracts. Gutiérrez-
Barranquero et al. (2018) similarly observed significant decreases in mature biofilm formation 
for 72% (13/18) of their sponge-associated bacterial extracts. Only one extract tested here 
inhibited mature biofilm production by ≥50%, reaching an inhibition of 86.28%. Although few 
comparable studies were found in literature (i.e. those looking at the effect of QSI compounds 
on mature biofilm formation), this was a pleasing result as patients presenting with cystic 
fibrosis often possess mature bacterial biofilms as early as age 3 (Moradali et al., 2017). Due 
to the significance of the results, medium 5294 was determined to overall be a better medium 
for both initial and mature biofilm inhibition.  
While it has been shown that sponge-associated Bacillus spp. extracts possess 
immense QSI potential against all three QS systems of P. aeruginosa, extracts must be 
characterized, and individual components extracted in order to identify the mechanism of 
action. However, previous studies could provide some insight into the possible compounds 
responsible for the anti-virulence results observed. Extracts obtained from isolate SP2-W6, 
identified at B. pumilus, proved to amongst the top inhibitors of swimming motility as well as 
protease and pyocyanin production. Marine-derived Bacillus pumilus S8-07 similarly exhibited 
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AHL-QSI activity against P. aeruginosa PAO1, through the action of an AHL-acylase enzyme 
(Musthafa et al., 2011). Enzymatic inhibition of P. aeruginosa AHL-QS has been well 
documented, with Guendouze et al. (2017) achieving significant inhibition for a number of 
virulence factors using a purified lactonase enzyme, commonly produced by a variety of 
Bacillus species, including B. mycoides, B. cereus and B. thuringiensis (Boopathi et al., 2017). 
Each of these species fall into the B. cereus sub-group, with four of our five sponge-associated 
bacterial isolates falling into the same group. Isolate SP1-AB4 and SP-AB2 were both identified 
as strains of B. thuringiensis, and as such their position as top inhibitors of each of the 
virulence factors tested could be as a result of lactonase production (Fig. 2.7-2.10). 
While Musthafa et al. (2011) and Gutiérrez-Barranquero et al. (2018) did not identify 
the compounds responsible for the QSI activity of their marine-derived Bacillus spp. extracts, 
they did show that they were both non-enzymatic in nature. This lends precedence to the 
possibility that the QSI activity of the Bacillus spp. extracts tested here were similarly as a 
result of small molecule activity. Non-enzymatic compounds such as furanone and coumarin 
have been shown to be effective QSI agents in the past (Gutiérrez-Barranquero et al., 2018), 
however these often prove to be cytotoxic, whereas our extracts were not. A further 
possibility is Bacillus-produced subtilosin, which has been shown to bind to cell surface 
receptors through a net anionic charge, thereby disrupting biofilm formation (Algburi et al., 
2017). Similarly, observed QSI activity could be as a result of antimicrobial peptides or exo-
polysaccahrides, both of which have been shown to reduce P. aeruginosa virulence factor 
production (Sayem et al., 2011; Algburi et al., 2017). Finally, pyocyanin inhibition as a result 
of the sponge-associated bacterial extracts could be due to the production of stigmatellin Y 
or a similar compound, as this compound, produced by B. subtilis, acts as a cognate signal and 
binds with the PqsR receptor in P. aeruginosa (Boopathi et al., 2017).  
Due to the variety of QSI compounds discovered thus far, and the promising activity 
of the sponge-associated Bacillus spp. extracts examined in this study, it can be clearly seen 
that the marine environment, and sponge-associated bacteria in particular, may be an 
exciting potential source of novel treatment options to combat nosocomial and clinical 
pathogens such as P. aeruginosa. 
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CHAPTER 2 
SUPPLEMENTARY INFORMATION 
 
S2.1 Selected sponge-associated Bacillus spp. isolates 
 
 
 
 
 
 
Figure S2.1.1: Growth of selected Bacillus spp. isolates on GYM medium. Designated codes, from left to right, are: AB2-SP, SP1-AB4, SP2-W6, 
SP2-AB7 and SP5-AB7.  
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S2.2 Pyocyanin, pyoverdine and growth inhibitions following treatment with sponge-associated Bacillus spp. extracts 
 
 
 
 
 
 
 
 
Figure S2.2.1: Inhibition of pyocyanin and pyoverdine using cinnamaldehyde and 10% DMSO. Positive control cinnamaldehyde (A) resulted in 
≥40% growth inhibition from 750 µg/ml, contributing to the decrease in pyocyanin production and is not indicative of QSI. A steep increase in 
pyoverdine was also observed. Solvent 10% DMSO (B) had a negligible effect on cell growth, as well as pyocyanin and pyoverdine production (p 
> 0.05). Data reflects average results ±SD following experiments in triplicate on three separate occasions.  
 
 
 
 
 
 
 
Figure S2.2.2: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of isolate SP-AB2 extracts on growth, 
pyocyanin and pyoverdine production. (A) SP-AB2 (Mann) and (B) SP-AB2 (5294). Data reflects average results ±SD following experiments in 
triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
A B 
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Figure S2.2.3: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of isolate SP1-AB4 extracts on growth, 
pyocyanin and pyoverdine production. (A) SP1-AB4 (Mann) and (B) SP1-AB4 (5294). Data reflects average results ±SD following experiments in 
triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S2.2.4: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of isolate SP2-AB7 extracts on growth, 
pyocyanin and pyoverdine production. (A) SP2-AB7 (Mann) and (B) SP2-AB7 (5294). Data reflects average results ±SD following experiments in 
triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
A B 
A B 
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Figure S2.2.5: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of isolate SP2-W6 extracts on growth, 
pyocyanin and pyoverdine production. (A) SP2-W6 (Mann) and (B) SP2-W6 (5294). Data reflects average results ±SD following experiments in 
triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
Figure S2.2.6: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of isolate SP5-AB7 extracts on growth, 
pyocyanin and pyoverdine production. (A) SP5-AB7 (Mann) and (B) SP5-AB7 (5294). Data reflects average results ±SD following experiments in 
triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
A B 
A B 
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S2.3 Elastase and growth inhibitions following treatment with sponge-associated Bacillus spp. extracts 
 
 
 
 
 
 
 
Figure S2.3.1: Inhibition of elastase LasB using cinnamaldehyde and 10% DMSO. Positive control cinnamaldehyde (A) resulted in cytotoxic effects 
from 750 µg/ml, to which the decrease in elastase may be attributed. Solvent 10% DMSO (B) resulted in an increase in cell growth, but had a 
negligible effect on elastase production (p > 0.05). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. 
 
 
 
 
 
 
 
Figure S2.3.2: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of isolate SP-AB2 extracts on growth and elastase 
production. (A) SP-AB2 (Mann) and (B) SP-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A B 
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Figure S2.3.3: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of isolate SP1-AB4 extracts on growth and elastase 
production. (A) SP1-AB4 (Mann) and (B) SP1-AB4 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
Figure S2.3.4: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of isolate SP2-AB7 extracts on growth and elastase 
production. (A) SP2-AB7 (Mann) and (B) SP2-AB7 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A B 
A B 
112 
 
 
 
 
 
 
 
 
Figure S2.3.5: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of isolate SP2-W6 extracts on growth and elastase 
production. (A) SP2-W6 (Mann) and (B) SP2-W6 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S2.3.6: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of isolate SP5-AB7 extracts on growth and elastase 
production. (A) SP5-AB7 (Mann) and (B) SP5-AB7 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A B 
A B 
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S2.4 Quantitative protease and growth inhibitions following treatment with sponge-associated Bacillus spp. extracts 
 
 
 
 
 
 
 
 
Figure S2.4.1: Inhibition of protease using cinnamaldehyde and 10% DMSO. Positive control cinnamaldehyde (A) resulted in ≥40% growth 
inhibition from 750 µg/ml, contributing to the decrease in protease production and is not indicative of QSI. Solvent 10% DMSO (B) had a negligible 
effect on cell growth, however a significant effect on protease production (p < 0.05) which needs to be taken into consideration. Data reflects 
average results ±SD following experiments in triplicate on three separate occasions. 
 
 
 
 
 
 
 
Figure S2.4.2: Inhibition of protease using sponge-associated bacterial extracts. Effect of isolate SP-AB2 extracts on growth and protease 
production. (A) SP-AB2 (Mann) and (B) SP-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A 
A 
B 
B 
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Figure S2.4.3: Inhibition of protease using sponge-associated bacterial extracts. Effect of isolate SP1-AB4 extracts on growth and protease 
production. (A) SP1-AB4 (Mann) and (B) SP1-AB4 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
  
 
 
 
 
 
 
 
Figure S2.4.4: Inhibition of protease using sponge-associated bacterial extracts. Effect of isolate SP2-AB7 extracts on growth and protease 
production. (A) SP2-AB7 (Mann) and (B) SP2-AB7 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A 
A 
B 
B 
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Figure S2.4.5: Inhibition of protease using sponge-associated bacterial extracts. Effect of isolate SP2-W6 extracts on growth and protease 
production. (A) SP2-W6 (Mann) and (B) SP2-W6 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%.  
  
 
 
 
 
 
 
 
Figure S2.4.6: Inhibition of protease using sponge-associated bacterial extracts. Effect of isolate SP5-AB7 extracts on growth and protease 
production. (A) SP5-AB7 (Mann) and (B) SP5-AB7 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A 
A 
B 
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S2.5 Quantitative rhamnolipid and growth inhibitions following treatment with sponge-associated Bacillus spp. extracts 
 
 
 
 
 
 
 
Figure S2.5.1: Inhibition of rhamnolipids using furanone and 10% DMSO. Positive control furanone (A) did not result in P. aeruginosa cell death 
and inhibited rhamnolipid production insignificantly (p > 0.05) in a concentration independent manner. Solvent 10% DMSO (B) had a negligible 
effect on cell growth, as well as an insignificant effect on rhamnolipid production (p > 0.05). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. 
 
 
 
 
 
 
 
Figure S2.5.2: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of isolate SP-AB2 extracts on growth and rhamnolipid 
production. (A) SP-AB2 (Mann) and (B) SP-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A B 
A B 
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Figure S2.5.3: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of isolate SP1-AB4 extracts on growth and rhamnolipid 
production. (A) SP1-AB4 (Mann) and (B) SP1-AB4 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
   
 
 
 
 
 
 
 
Figure S2.5.4: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of isolate SP2-AB7 extracts on growth and rhamnolipid 
production. (A) SP2-AB7 (Mann) and (B) SP2-AB7 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A 
A 
B 
B 
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Figure S2.5.5: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of isolate SP2-W6 extracts on growth and rhamnolipid 
production. (A) SP2-W6 (Mann) and (B) SP2-W6 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S2.5.6: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of isolate SP5-AB7 extracts on growth and rhamnolipid 
production. (A) SP5-AB7 (Mann) and (B) SP5-AB7 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
A 
A 
B 
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S2.6 Inhibition in P. aeruginosa motility following treatment with sponge-associated Bacillus spp. extracts  
Table S.2.6.1: Inhibition of swarming motility following treatment with sponge-associated Bacillus spp. extracts. Readings were taken every 24 
h following incubation at 37 °C for 72 h. Readings taken at 72 h are reflected here as they were considered to reflect sustained QSI activity 
 Untreated 250 µg/ml 500 µg/ml   1000 µg/ml 
Extract code 
Zone of swarming 
(mm) ± SD* 
Zone of swarming 
(mm) ± SD* 
Swarming 
inhibition (%) 
Zone of swarming 
(mm) ± SD* 
Swarming 
inhibition (%) 
Zone of swarming 
(mm) ± SD* 
Swarming 
inhibition (%) 
Cinnamaldehyde$ 39.50 ± 0.50 22.50 ± 2.50 43.04 34.50 ± 3.50 12.66 42.75 ± 2.25 -8.23# 
10% DMSO 39.50 ± 0.50 62.50 ± 2.50 -58.23# 72.50 ± 2.50 -83.54# 59.00 ± 3.00 -49.37# 
SP-AB2 (Mannitol) 39.50 ± 0.50 32.00 ± 8.00 18.99 36.50 ± 0.00 7.59 34.25 ± 3.75 13.29 
SP-AB2 (5294) 39.50 ± 0.50 27.50 ± 8.50 30.38 21.25 ± 5.75 46.20 22.75 ± 4.75 42.41 
SP1-AB4 (Mannitol) 39.50 ± 0.50 28.50 ± 10.50 27.85 27.00 ± 10.50 31.65 37.25 ± 1.75 5.70 
SP1-AB4 (5294) 39.50 ± 0.50 17.00 ± 0.00 56.96 17.50 ± 0.00 55.70 19.00 ± 0.00  51.90 
SP2-AB7 (Mannitol) 39.50 ± 0.50 35.25 ± 1.75 10.76 16.00 ± 0.00 59.49 36.00 ± 0.00 8.86 
SP2-AB7 (5294) 39.50 ± 0.50 25.00 ± 0.00 36.71 17.50 ± 1.50 55.70 28.00 ± 0.00 29.11 
SP2-W6 (Mannitol) 39.50 ± 0.50 32.00 ± 2.00 18.99 40.00 ± 0.00 -1.27# 35.00 ± 0.00 11.39 
SP2-W6 (5294) 39.50 ± 0.50 46.75 ± 22.75 -18.35# 34.50 ± 1.00 12.66 21.50 ± 4.00 45.57 
SP5-AB7 (Mannitol) 39.50 ± 0.50 46.50 ± 4.00 -17.72# 37.50 ± 0.00 5.06 28.00 ± 0.00 29.11 
SP5-AB7 (5294) 39.50 ± 0.50 29.75 ± 0.25 24.68 31.50 ± 0.00 20.25 30.00 ± 4.00 24.05 
* All readings in swarming inhibition are given ± standard deviation. 
$ Swarming inhibition for cinnamaldehyde at 1000 µg/ml was the result of P. aeruginosa cell death. All other extracts tested had a growth inhibitory effect of <40% at all 
concentrations tested.  
# Negative values are indicative of an increase in swarming motility at this concentration. 
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Table S.2.6.2: Inhibition of swimming motility following treatment with sponge-associated Bacillus spp. extracts. Readings were taken every 24 
h following incubation at 37 °C for 72 h. Readings taken at 72 h are reflected here as they were considered to reflect sustained QSI activity 
 0 250 µg/ml 500 µg/ml 1000 µg/ml 
Extract code 
Zone of swimming 
(mm) ± SD* 
Zone of swimming 
(mm) ± SD* 
Swimming 
inhibition (%) 
Zone of swimming 
(mm) ± SD* 
Swimming 
inhibition (%) 
Zone of swimming 
(mm) ± SD* 
Swimming 
inhibition (%) 
Cinnamaldehyde$ 74.60 ± 1.00 37.00 ± 2.00  50.40 33.50 ± 1.50 55.09 41.50 ± 1.50 44.37 
10% DMSO 74.60 ± 1.00 61.25 ± 5.25 17.90 60.50 ±2.00 18.90 59.00 ± 0.00 20.91 
SP-AB2 (Mannitol) 74.60 ± 1.00 53.25 ± 4.75 20.52 56.50 ± 0.00 15.67 62.50 ± 0.50 6.72 
SP-AB2 (5294) 74.60 ± 1.00 55.50 ± 0.50 34.71 57.75 ± 0.75 32.06 53.25 ± 0.25 37.35 
SP1-AB4 (Mannitol) 74.60 ± 1.00 54.00 ± 3.50 19.40 53.50 ± 1.50 20.15 54.75 ± 0.25 18.28 
SP1-AB4 (5294) 74.60 ± 1.00 50.75 ± 2.75 40.29 61.50 ± 1.00 27.65 52.75 ± 2.75 37.94 
SP2-AB7 (Mannitol) 74.60 ± 1.00 54.00 ± 0.00 36.47 60.50 ± 0.50 28.82 61.00 ± 1.00 28.24 
SP2-AB7 (5294) 74.60 ± 1.00 37.50 ± 0.50 55.88 48.00 ± 0.00 43.53 42.00 ± 1.00 50.59 
SP2-W6 (Mannitol) 74.60 ± 1.00 55.50 ± 3.00 17.16 40.50 ± 0.50 39.55 43.50 ± 0.00 35.07 
SP2-W6 (5294) 74.60 ± 1.00 46.00 ± 4.50 31.34 50.50 ± 0.00 24.63 54.00 ± 0.00  19.40 
SP5-AB7 (Mannitol) 74.60 ± 1.00 57.00 ± 2.50 32.94 61.25 ± 3.75 27.94 65.00 ±0.00 23.53 
SP5-AB7 (5294) 74.60 ± 1.00 58.25 ± 0.25 13.06 57.00 ± 0.00 14.93 47.00 ± 1.00 29.85 
* All readings in swimming inhibition are given ± standard deviation. 
$ Swimming inhibition for cinnamaldehyde at 1000 µg/ml was the result of P. aeruginosa cell death. All other extracts tested had a growth inhibitory effect of <40% at all 
concentrations tested.  
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S2.7 Biofilm and growth inhibition following treatment with sponge-associated Bacillus 
spp. extracts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2.7.1: Effect of crude sponge-associated Bacillus spp. medium 5294 extracts on (A) 
bacterial growth and (B) initial biofilm formation of Pseudomonas aeruginosa ATCC 27583 as 
quantified by crystal violet staining in a microtiter plate assay. Cinnamaldehyde served as the 
positive control while volumes of 10% DMSO equivalent to those of the extracts tested were 
used to ensure that inhibitions observed were not as a result of the DMSO. 
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Figure S2.7.2: Effect of crude sponge-associated Bacillus spp. mannitol extracts on (A) 
bacterial growth and (B) mature biofilm formation of Pseudomonas aeruginosa ATCC 27583 
as quantified by crystal violet staining in a microtiter plate assay. Cinnamaldehyde served as 
the positive control while volumes of 10% DMSO equivalent to those of the extracts tested 
were used to ensure that inhibitions observed were not as a result of the DMSO. 
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Figure S2.7.3: Effect of crude sponge-associated Bacillus spp. medium 5294 extracts on (A) 
bacterial growth and (B) mature biofilm formation of Pseudomonas aeruginosa ATCC 27583 
as quantified by crystal violet staining in a microtiter plate assay. Cinnamaldehyde served as 
the positive control while volumes of 10% DMSO equivalent to those of the extracts tested 
were used to ensure that inhibitions observed were not as a result of the DMSO. 
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Figure S2.7.4: Effect of crude sponge-associated Bacillus spp. mannitol extracts on (A) 
bacterial growth and (B) mature biofilm formation of Pseudomonas aeruginosa ATCC 27583 
as quantified by crystal violet staining in a microtiter plate assay. Cinnamaldehyde served as 
the positive control while volumes of 10% DMSO equivalent to those of the extracts tested 
were used to ensure that inhibitions observed were not as a result of the DMSO. 
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CHAPTER THREE  
SPONGE-ASSOCIATED ACTINOMYCETE EXTRACTS AS QUORUM SENSING INHIBITORS OF 
PSEUDOMONAS AERUGINOSA 
 
Abstract 
Quorum sensing inhibition (QSI) has been proposed as a viable treatment option for 
Pseudomonas aeruginosa, as this nosocomial pathogen has become resistant to almost all 
classes of antibiotics available. Following primary QSI screening and isolate identification, ten 
sponge-associated Actinomycetes (nine Streptomyces spp. and Rhodococcus fascians) were 
selected for QSI screening against P. aeruginosa. Crude extracts were obtained from these 
ten isolates following shake-flask fermentation with two production media, mannitol and 
medium 5294, and ethyl acetate extractions.  Mannitol extracts yielded the most significant 
inhibition of pyocyanin, pyoverdine, elastase, rhamnolipid, swarming motility and mature 
biofilm formation, while medium 5294 extracts yielded the most significant inhibition of initial 
biofilm formation and protease production, thus indicating that mannitol may prove superior 
in terms of producing broad-spectrum QSI compounds from Actinomycete isolates. Extracts 
from Streptomyces spp. isolate SP4-AB2 yielded some of the highest inhibition of elastase, 
protease, and pyocyanin production (≥50%). Extracts of Streptomyces spp. SP3-AB22 and SP2-
AB6 exhibited similar broad-spectrum QSI activity, and these isolates should be studied 
further in the future. Overall, the Actinomycete extracts significantly decreased (p < 0.05) all 
virulence factors tested, with inhibitions as high as 82% being observed. Sponge-associated 
bacteria, therefore, possess the QSI potential necessary to serve as the solution to the 
antimicrobial resistance crisis and should be studied further to determine the metabolites 
responsible. 
 
3.1 Introduction 
The majority of sponges are found in salt water (Al-Massarani et al., 2015; Kurian and 
Elumalai, 2017), and adopt a filter feeding lifestyle, filtering up to 2000 litres of water a day 
(Kurian and Elumalai, 2017) whilst employing a wide variety of secondary metabolites in order 
to defend their fragile structure (García-Vilas et al., 2016). Microbes associated with marine 
sponges can produce a prolific range of secondary metabolites, with the prime bacterial 
producers of these bioactive substances belonging to the phylum Actinobacteria (Kurian and 
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Elumalai, 2017). Sponge-associated actinobacteria fall into three orders: Actinomycetales (the 
most abundant), Rubrobacteriales and Acidimicrobiales (Valliapan et al., 2014). These can 
then be further grouped into 39 families and 112 genera, 102 of which belong to the order 
Actinomycetales (Valliapan et al., 2014). Actinomycete strains usually contain many 
biosynthetic gene clusters, such as those for aromatic polyketide production, although the 
corresponding metabolites are only rarely discovered due to low expression levels under 
standard laboratory conditions (Sun et al., 2015).  
 Streptomyces is the most prominent Actinomycete genus, with 30% of sponge-
associated bacteria-derived compounds originating from this genus (Indraningrat et al., 
2016). Streptomyces spp. HB202 associated with sponge Halichondria panicea and 
Streptomyces spp. RV15 from Dysidea tupha are known producers of antimicrobial 
compounds, with efficacies against Gram-positive pathogenic bacteria and Chlamydia, 
respectively (Indraningrat et al., 2016), while Dendrilla nigra-associated Streptomyces dendra 
MSI051 produces phospholipases capable of broad spectrum antimicrobial activity 
(Bramhachari et al., 2016). Furthermore, sponge-associated Streptomyces hedaya produces 
the antifungal 5,7-dimethoxy-4-p-methoxylphenylcoumarin, and sponge-associated 
Streptomyces sp. 43, 11 and 21 produced anti-Leishmania and anti-Trypanosoma compounds 
valinomycin and butanolide (Indraningrat et al., 2016). Sponge-associated Streptomyces spp. 
also display antioxidant properties, such as the production of antioxidant and anti-chlamydial 
quinolone Ageloline A by Streptomyces spp. SBT345 (Kurian and Elumalai, 2017). However, of 
even greater importance is the ability of these organisms to produce quorum sensing 
inhibitory compounds. 
 Quorum sensing inhibition (QSI) is made possible through small molecules as well as 
enzymes such as acylases and lactonases (Guendouze et al., 2017). Streptomyces and 
Rhodococcus species are known producers of AHL acylases, capable of degrading AHL chains 
possessing more than six acyl chains (Banerjee and Ray, 2016; Devaraj et al., 2017). 
Streptomyces spp. as well as Rhodococcus strains may also produce AHL-lactonases (Banerjee 
and Ray, 2016), with Rhodococcus erythropolis W2 producing an AHL-degrading acylase and 
oxido-reductase enzymes (Park et al., 2006). Park et al. (2006) demonstrated that numerous 
Rhodococcus species, as well as members of the same species, often produce a highly variable 
range of AHL-degrading enzymes. While AHL lactonases are generally capable of broad 
spectrum lactolytic QSI activities, acylases are noted for their long chain QSI activities (Tang 
127 
 
and Zhang, 2014). It has been previously observed from metagenomic data that long chain 
inhibition (and therefore acylase activity) is more frequent in an ocean environment (Tang 
and Zhang, 2014). This is unsurprising as, although long acylated chains (with carbon lengths 
equal to or more than 8) are less prone to degradation, lactolysis is reversible in acidic pH, 
making it a less desirable QSI process (Castillo-Juarez et al., 2017). Additionally, while acylases 
prefer long chain AHLs, in some instances, such as in the case of Anabaena sp. PCC7120, they 
are capable of short chain AHL inhibition (Fetzner, 2015). Anabaena spp. are, therefore, 
capable of degrading C4-homoserine lactone, better known as the rhl system of P. aeruginosa 
(Fetzner, 2015). 
Pseudomonas aeruginosa, a highly virulent nosocomial pathogen, is an important 
target for QSI (Fetzner, 2015). Rhodococcus erythropolis secretes lactonase proteins AqdC1 
and AqdC2 capable of inhibiting the alkyl-quinolone-based QS system of P. aeruginosa (Müller 
et al., 2015).  Streptomyces strain M664 produces an AHL-degrading acylase enzyme capable 
of reducing the production of various P. aeruginosa virulence factors (Chang et al., 2017). This 
study, therefore, aimed at examining the effect of South African, sponge-derived 
actinobacterial extracts on the production of virulence factors by P. aeruginosa, in the hope 
that these extracts would exhibit a QSI effect on this organism.   
 
3.2 Methods and Materials 
Following primary screening and identification (Chapter 2), 10 sponge-associated isolates 
were identified as Actinomycetes (Table 3.1; Supp. 3.1). The 20 ethyl acetate extracts 
obtained following shake flask fermentations in mannitol medium and medium 5294 were 
then screened against various QSI-mediated virulence factors of P. aeruginosa.  
 
Table 3.1: Sponge-associated bacterial codes and corresponding identification following 16S 
rRNA amplification and sequencing  
Isolate code 16S rRNA identification* 
SP1-V4 Streptomyces spp. 
SP2-AB1 Streptomyces spp. 
SP2-AB2 Streptomyces spp. 
SP2-AB3 Streptomyces spp. 
SP2-AB6 Streptomyces spp. 
SP2-W3 Streptomyces spp. 
SP3-AB22 Streptomyces spp. 
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SP4-AB2 Streptomyces spp. 
SP4-AB6 Rhodococcus fascians 
SP6-AB5 Streptomyces spp. 
* Nearest match obtained following screening of the sequences against the NCBI-BLAST database. All matches 
obtained were ≥ 97%. 
 
3.2.1 Antimicrobial testing of bacterial extracts using agar-well diffusion method 
A P. aeruginosa ATTC 27853 inoculum, equivalent to a 0.5 McFarland standard, was used to 
prepare bacterial lawns. Agar wells (8 mm diameter) were prepared with the help of a 
sterilized stainless-steel cork-borer. Wells were loaded with 5 and 10 mg of the 20 
Actinomycete bacterial extracts (mannitol and medium 5294) and plates were incubated at 
37 °C for 24 h, after which they were examined for the presence of zones of inhibition (El-
Naggar and Abdelwahed, 2014). 
 
3.2.2 Screening of extracts against P. aeruginosa virulence factor production 
Pseudomonas broth (PB 3 ml) was inoculated with 100 µl of an overnight P. aeruginosa ATCC 
27853 culture, standardized to an OD600 nm of 1. Pseudomonas aeruginosa ATCC 27853 was 
then exposed to varying concentrations of the ethyl acetate extracts (0 – 1000 μg/ml) at 37 
°C overnight with agitation. Broth containing P. aeruginosa ATCC 27853 but no extract was 
used as a negative control while cinnamaldehyde, at concentrations corresponding to those 
of the bacterial extracts tested, was used as a positive control.  Growth readings were taken 
at 600 nm using a microtitre plate reader (Promega Glomax Multi+ Detection System), where 
inhibition in conjunction with a growth inhibition ≥40% were regarded as due to bacterial 
killing and not QSI. All assays were carried out in triplicate. The effect of identical volumes of 
10% DMSO without extract was assessed for all assays in order to confirm that the solvent 
had no effect on virulence factor production.  
The following virulence assays were conducted to assess the anti-virulence effects of 
extracts; i.e. pyocyanin, pyoverdine, elastase, protease, rhamnolipid, motility and biofilm 
formation.  
 
3.2.2.1 Inhibition of pyocyanin production  
Inhibition of pyocyanin was tested according to Ra’oof and Latif (2010), with minor 
modifications. Treated and untreated cells were centrifuged at 2500 rpm for 10 min, and 
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supernatants extracted. Chloroform (1.5 ml) was then added to 3 ml of the supernatant and 
vortexed for 30 s. The mixture was then centrifuged at 2000 rpm for 15 min to allow for the 
cell debris and aqueous phase to separate. A 1 ml volume of the organic, chloroform layer 
was carefully transferred to a fresh tube, with care having been taken to transfer none of the 
aqueous phase. The separated chloroform layer was mixed with 1 ml of 0.2 M HCl and 
vortexed for 30 s. It was expected that the chloroform fraction, if blue, should have turned 
clear and then pink due to the addition of HCl. This mixture was then centrifuged at 7 800 
rpm for 10 min, and the upper HCl layer removed and used to measure pyocyanin 
concentration. This was done using a microtitre plate reader (Promega Glomax Multi+ 
Detection System) at 560 nm, using 0.2 M HCl as a blank. OD560 was multiplied by 17.072 in 
order to obtain the pyocyanin concentration in μg/ml (Ra’oof and Latif, 2010). This value was 
further multiplied by a factor of 1.5, in order to account for the remaining organic 
chloroform/pyocyanin layer that remained unused. Concentrations of pyocyanin from the 
treated and untreated samples were then compared.  
 
3.2.2.2 Inhibition of pyoverdine production  
Pyoverdine was measured using a protocol described previously by Huerta et al. 
(2008).  Briefly, 0.04 ml of the aqueous phase from the pyocyanin assay was mixed with 1.96 
ml of 0.05 M Tris hydrochloride buffer (pH 7.4).  Fluorescence was determined by excitation 
at 365 nm and emission at 460 nm (Promega Glomax Multi+ Detection System), with values 
being given in relative fluorescence units (RFU).  These readings were then divided by the 
respective OD600 nm readings in order to account for the effect of growth on pyoverdine 
production. The percent pyoverdine inhibition was determined as follows: 
Pyoverdine inhibition =  
(Untreated RFU ÷  OD600 nm) − (Treated RFU ÷  OD600 nm) 
Untreated RFU ÷  OD600 nm 
 
 
3.2.2.3 Inhibition of LasB production  
Elastase activity of extracts was determined by the Elastin Congo-red (ECR) assay as described 
by George et al. (2005) with minor modifications. Samples were centrifuged at 12 000 rpm 
for 15 min. One ml of 0.5% elastin-Congo red (Sigma) in Tris-HCl (pH 7.4) was added to 200 μl 
of the cell-free supernatant and incubated at 37 °C for 24 h with agitation.  Samples were then 
vortexed and centrifuged at 1 200 rpm for 15 min to remove insoluble ECR.  The absorbance 
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of the supernatants from both controls and treatments were then determined at 494 
nm, using a Shimadzu 1800 UV spectrophotometer, as a measure of elastase B activity.  The 
percentage change in absorbance was then calculated from the absorbance values.   
 
3.2.2.4 Qualitative inhibition of casein hydrolysis  
 The effect of extracts on casein proteolytic activity was assessed using an agar well diffusion 
assay (Flemming et al., 2007) with modifications. A sample volume of 600 μl was centrifuged 
three times at 12 000 rpm for 15 min to remove cells and 100 μl of the supernatant inoculated 
into 9 mm wells within TYES agar (4 g tryptone, 0.4 g yeast extract, 0.2 g CaCl2, 0.5 g MgSO4, 
10 g agar) plates enriched with 1% skim milk. This was performed in duplicate, and incubated 
for 24 h at 37 °C.  Appearance of zones of clearance around the wells was taken as a positive 
result, whilst no zone formation after the 24 h period was classified as negative for proteolytic 
ability.  Zone diameters were measured and the percentage inhibition of caseinolytic activity 
determined as follows:  
Percentage inhibition
=  (
Zone diameter (untreated) − zone diameter (treated)
zone diameter (untreated)
) × 100 
(Zacaria et al., 2010).  
 
3.2.2.5 Quantitative inhibition of casein hydrolysis  
Casein hydrolysis was quantified using the azocasein assay (Guendouze et al., 2017) with 
modifications. Cell-free culture supernatants were prepared by centrifuging samples at 
12 000 rpm for 5 min. Protease activity was then determined using azocasein (Sigma, 
Germany) as a substrate (Guendouze et al., 2017). The reaction was performed in PBS solution 
(pH 7.0) with 50 µl of azocasein (30 mg/ml, dissolved in water) and 25 µl of culture 
supernatant to a final volume of 750 µl. Reaction tubes were incubated at 37 °C for 1 h and 
subsequently stopped by adding 125 µl of 20% (w/v) trichloroacetic acid. Reaction mixtures 
were centrifuged at 12 000 rpm for 5 min, after which absorbance was measured at 450 nm 
using a microtitre plate reader (Promega Glomax Multi+ Detection System) (Guendouze et al., 
2017). A blank control was prepared using only azocasein and PBS buffer, which was 
incubated at the same conditions as the sample tubes (Nicodème et al., 2005).  Proteolytic 
activity was defined as the difference between the absorbance at 450 nm of the treatments 
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and the blank. The proteolytic activity of the treated and untreated samples was then 
compared (Nicodème et al., 2005).  
 
3.2.2.6 Qualitative inhibition of rhamnolipid production  
Rhamnolipid production by P. aeruginosa was detected using M9-glutamate minimal medium 
(12.8 g Na2HPO4-7H2O, 3 g KH2PO4, 0.5 g NaCl, 1.0 g NH4Cl, 2 ml of 1M MgSO4, 20 g of glucose, 
100 µl of 1M CaCl2, 15 g of agar, 0.2 g cetyltrimethylammonium bromide and 5 mg methylene 
blue in 1 l of dH2O) agar plates. M9-glutamate minimal medium agar plates were inoculated 
with 200 µl of an overnight PB culture of Pseudomonas (Senturk et al., 2012). After an 
overnight incubation at 37 °C, the diameter of the clear zone around the bacterial colony was 
measured as evidence of rhamnolipid production using a UV-transilluminator lightbox 
(Senturk et al., 2012).  
 
3.2.2.7 Quantitative inhibition of rhamnolipid production  
 Rhamnolipid inhibition was quantified following the protocol of Koch et al. (1991) with 
modifications. Aliquots of the final culture supernatant (1 ml) were transferred to 1-dram 
glass vials and extracted twice with 1 ml of diethyl ether. The pooled organic fractions were 
evaporated to dryness, and the resulting residue reconstituted in 200 µl of de-ionized water. 
In a 2 ml plastic centrifuge tube, 75 µl of this extract was diluted into 675 µl of a solution of 
0.19% (w/v) orcinol in 50% (v/v) concentrated H2SO4. Tubes were vortexed thoroughly to mix 
and incubated in an 80 °C heating block for 30 min. After briefly cooling to room temperature, 
200 µl of the resulting yellow to yellow-orange solutions were transferred to a clear 96-well 
microtiter plate, and the absorbance at 421 nm measured (Multiskan Ascent plate reader, 
AEC Amersham). Media background absorbance (measured from a ‘‘no bacteria’’ control) was 
subtracted, the resulting growth values normalized by dividing by the final OD600. For this 
assay (Z-)-4-bromo-5-(bromoethylene)-2(5H)-furanone was used as a positive control at 
concentrations corresponding to 10% of the bacterial extracts tested.   
 
3.2.2.8 Inhibition of swimming and swarming motilities 
 The effect of extracts on swimming motility was conducted with swimming agar (10 g 
tryptone, 5 g NaCl and 0.3% bacteriological agar) (Rashid et al., 2000).  Swim plates were 
prepared 24 h in advance and allowed to dry overnight within a laminar flow.  Five microlitres 
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of the treated bacterial suspension was point-inoculated at the centre of the medium and 
plates incubated at 30 °C for 72 h. Swim diameters were read every 24 h in order to determine 
the effect of the extracts on swimming motility over time.  
Swarming motility was assessed with LB agar overlaid with 5 ml swarming soft 
agar (1% peptone, 0.5% NaCl, 0.5% agar) supplemented with 0.5% D-glucose (Packiavathy et 
al., 2012).  Five microlitres of treated P. aeruginosa bacterial suspension, was point-
inoculated at the centre of the swarm medium.  Plates were then incubated for 24 h at 37 °C 
followed by incubation at 30 °C and monitoring every 24 h over a 3 d period. The alteration 
in swimming and swarming migration was assessed by measuring the swim and swarm zones 
of the treated and untreated bacterial cells. 
 
3.2.2.9 Inhibition of biofilm production 
Extracts were tested against indicator organism P. aeruginosa ATTC 27853 for their effect on 
initial attachment and mature biofilm formation. Sixteen hour-old cultures were used to 
prepare cell suspensions which were standardized to an OD600 nm of 1. For the initial 
attachment studies, extracts were added at 0.5, 1, 5 and 10 mg/ml to 90 µl TSB and 10 µl of 
standardized cell suspension and incubated for 24 h at 37 °C with agitation (Basson et al., 
2008).  For pre-formed biofilm detachment assays, 24 h biofilms were established following 
addition of 90 µl TSB and 10 µl of standardized cell suspension to microtiter plate wells, which 
were incubated at 37 °C for 24 h. Microtitre plates were washed three times with sterile 
deionised water and allowed to air-dry. Following air-drying, 90 µl TSB as well as extracts at 
the relevant, respective concentrations were added to wells and microtitre plates incubated 
for 24 h with agitation at 37 °C. The negative control contained only broth, while positive 
controls contained cell suspensions with no extracts added.  
 After incubation, planktonic cells were removed by turning the plate over and shaking 
out the liquid. Thereafter, the plate was washed three times with 250 µl sterile dH20. Cells 
were fixed with 200 µl of methanol for 15 min and left to air dry. Staining was done by adding 
150 µl of 2% Huckers crystal violet for 5 min. Wells were gently rinsed under running water 
and allowed to air dry. Crystal violet was resolubilized with 150 µl of 33% (v/v) glacial acetic 
acid and the OD595 nm values determined using Promega at OD600 nm (Basson et al., 2008).  A 
measure of efficacy, termed percentage reduction, was calculated from the blank, control, 
and treated absorbance values (Pitt et al., 2003):  
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Percentage reduction =  (
(C − B) − (T − B)
C − B
) × 100 
where B denotes the average absorbance per well for blank wells (no biofilm, no treatment), 
C denotes the average absorbance per well for control wells (biofilm, no treatment), and T 
denotes the average absorbance per well for treated wells (biofilm and treatment). Wells 
containing TSB broth and P. aeruginosa ATCC 27853 but no extract was used as a growth 
control while cinnamaldehyde, at 0.5, 1, 5 and 10 mg/ml, was used as a positive control. The 
solvent, 10% DMSO, was used at identical volumes in order to confirm that it had no effect 
on bacterial motility. 
 
3.2.3 Statistical analyses 
Data was obtained after assays had been performed in either duplicate or triplicate, in order 
to ensure the validity of the results.  One-way ANOVA analyses were performed for each assay 
to determine the significance of inhibitions exacted by the Actinomycete extracts, as well as 
the mannitol and medium 5294 extracts separately. Following this, a number of two-tailed t-
tests were performed for each assay, examining the effects of the mannitol and medium 5294 
extracts at each concentration tested, both together and separately, in order to determine 
the significance of any inhibitions observed. The null hypothesis put forth was that there was 
no difference between the mean untreated inhibition and the mean inhibition observed at 
each concentration. For all tests a p-value of <0.05 was taken to be significant, such that the 
null hypothesis may be rejected. All statistical analyses were performed using Microsoft Excel 
following the installation of Real Statistics Add-In software.  
 
3.3 Results 
3.3.1 Antimicrobial testing of sponge-associated Actinomycete extracts against 
Pseudomonas aeruginosa ATCC 27853 
To ensure that any QSI activity against P. aeruginosa observed would not be as a result of cell 
death, antimicrobial agar well diffusion testing was performed with all 20 Actinomycete 
extracts at 5 and 10 mg. No cell death was observed for any of the extracts tested. 
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3.3.2 Actinomycete extracts and P. aeruginosa pyocyanin production 
The first virulence factor against which the extracts were screened was the production of the 
blue phenazine pigment, pyocyanin. Production of pyocyanin is primarily mediated through 
the Pseudomonas quinolone system (PQS), with contributions from the rhl system (Müller et 
al., 2015). All 20 sponge-associated Actinomycete extracts displayed pyocyanin inhibitory 
capabilities to some extent, with inhibitions ranging from -0.88% to 57.53% and cell death not 
exceeding 40% (Supp. Fig. S3.2.1 – S3.2.11). Of these, 65% (13/20) of extracts were able to 
inhibit pyocyanin production by >30% (Table 3.2), with one extract achieving >50% inhibition. 
Furthermore, the Actinomycete extracts as a whole were found to result in a significant 
overall decrease in pyocyanin production (p < 0.01). Each treatment concentration 
additionally resulted in a significant decrease (p < 0.01), with the average pyocyanin inhibition 
at 1000 µg/ml proving to be the most significant.  
 
Table 3.2: Effect of sponge-associated Actinomycete extracts on pyocyanin production by P. 
aeruginosa ATCC 27853. Percentage pyocyanin inhibition of both mannitol and medium 5294 
extracts were assessed at 250-1000 µg/ml 
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
# Negative values indicate an increase in pyocyanin production. 
$Pyocyanin inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
Exposure to medium 5294 extracts resulted in an overall significant decrease in 
pyocyanin production (p < 0.01) as well as significant decreases at each individual treatment 
concentration. However, a semi-concentration dependent effect was observed in this regard, 
with 750 and 1000 µg/ml achieving more significant inhibitions than the lower concentrations 
 Percentage pyocyanin inhibition 
 250 µg/ml** 500 µg/ml** 750 µg/ml** 1000 µg/ml** 
Extract code Mann** 5294** Mann** 5294** Mann** 5294** Mann** 5294** 
SP1-V4 32.48 19.69 7.73 15.33 23.85 14.08 23.32 25.86 
SP2-AB1 16.02 20.16 15.82 5.02 14.51 20.15 23.54 10.96 
SP2-AB2 27.54 15.56 31.32 24.14 25.97 29.90 28.85 29.09 
SP2-AB3 15.79 17.65 16.76 15.31 34.82 21.33 25.34 31.23 
SP2-AB6 -0.88# 7.33 10.06 6.10 15.28 12.47 37.44 25.65 
SP2-W3 21.11 13.88 21.32 14.78 29.92 21.50 12.76 24.27 
SP3-AB22 22.66 9.67 24.39 30.49 25.36 29.88 41.05 30.92 
SP4-AB2 -0.36# 4.76 43.34 9.56 41.99 9.77 57.53 30.60 
SP4-AB6 31.62 31.44 31.52 43.86 32.48 41.10 38.95 44.89 
SP6-AB5 21.25 28.71 26.59 30.51 37.10 30.56 37.52 30.34 
Cinnamaldehyde 9.79  12.89  37.34$  79.53$  
10% DMSO 17.43  -6.13#  10.79  0.59  
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(Table 3.2). This concentration-dependent pyocyanin inhibition could be observed for a 
number of individual extracts, such as SP2-AB6 (Mann) (Supp. Fig. S3.2.6A) and SP6-AB5 
(Mann) (Supp. Fig. S3.2.11A). However, this effect was only semi-concentration dependent as 
a concentration of 250 µg/ml proved to be more significant than 500 µg/ml, with mean 
inhibitions of 16.89% and 19.51%, respectively. For medium 5294, 1000 µg/ml proved to be 
the most significant concentration, with a mean pyocyanin inhibition of 28.38%.  
Mannitol, while yielding significant inhibitions overall (p < 0.01), gave slightly different 
results (Table 3.2). Although 1000 µg/ml yielded the highest mean pyocyanin inhibition 
(32.63%), 750 µg/ml yielded the most significant mean inhibition of 28.13%. However, both 
carried a significance level of p < 0.01. As mannitol yielded higher mean pyocyanin inhibition, 
and both media yielded inhibition of equal significance, it may be said that mannitol may 
prove the preferable production medium for effective pyocyanin inhibition.   
Examining the Actinomycete extracts at an isolate level, Streptomyces spp. SP4-AB2 
(Mann) yielded the highest inhibition in pyocyanin production, with a decrease of 57.53% at 
1000 µg/ml (Supp. Fig. S3.2.9A). This extract consistently yielded the highest inhibitions of all 
the mannitol extracts at concentration ≥500 µg/ml. Extract SP4-AB2 (Mann) was followed by 
Rhodococcus fascians SP4-AB6 (5294), which resulted in pyocyanin inhibition ranging from 
31.44% at 250 µg/ml to 44.89% at 1000 µg/ml. This narrow range of inhibition suggests using 
a lower treatment concentration may prove viable, making this an extract of interest. Also of 
note was SP1-V4 (Mann), which resulted in a maximal pyocyanin inhibition of 32.48% at only 
250 µg/ml. As lower treatment concentrations are to be desired, this extract may also prove 
worthy of further study.  
Cinnamaldehyde was used as positive control, at 250-1000 µg/ml. However, unlike the 
extracts, cinnamaldehyde was cytotoxic, resulting in a maximum pyocyanin inhibition of 
12.89% at 500 µg/ml (Supp. Fig. S3.2.1A). In order to determine the effect of 10% DMSO, 
without bacterial extract, on pyocyanin production it was tested using equivalent volumes to 
that of the extracts (Supp. Fig. S3.2.1B). No significant inhibition in pyocyanin production 
resulted, indicating that the inhibition arising from treatment with the Actinomycete extracts 
was independent to the 10% DMSO.  
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3.3.3 Actinomycete extracts and P. aeruginosa pyoverdine production 
Pyoverdine is a siderophore utilized by P. aeruginosa for iron sequestration (Müller et al., 
2015), and its production is mediated in a manner similar to that of pyocyanin (although the 
role of rhl is not as defined). Following treatment with the sponge-associated Actinomycete 
extracts, inhibition of between -42,99% and 37.43% was observed, with 95% (19/20) of 
extracts inhibiting pyoverdine to some extent and 50% (10/20) inhibiting pyoverdine 
production by >30%. The failure of these extracts to exert inhibition of ≥50% on pyoverdine 
production, while only one had inhibited previously inhibited pyocyanin production by >50%, 
may be indicative of a lack of PQS-QSI ability.  
Actinomycete extracts were able to exert an overall significant inhibitory effect on 
pyoverdine production (p < 0.01), with this same significance being seen at each treatment 
concentration (250 µg/ml, p < 0.05) (Table 3.3). Overall, 1000 µg/ml yielded the highest mean 
pyoverdine inhibition (22.53%, p < 0.01), while no significant cell death was observed for any 
of the extracts at the concentrations tested (Supp. S3.2).  
 
Table 3.3: Effect of sponge-associated Actinomycete extracts on pyoverdine production by P. 
aeruginosa ATCC 27853. Percentage pyoverdine inhibition of both mannitol and medium 
5294 extracts were assessed at 250-1000 µg/ml 
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
# Negative values indicate an increase in pyoverdine production at this concentration. 
$Pyoverdine inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
Medium 5294 yielded significant inhibition at each concentration ≥500 µg/ml (p < 
0.05), with the most significant inhibition occurring at 1000 µg/ml (p < 0.01) (Table 3.3). The 
 Percentage pyoverdine inhibition 
 250 µg/ml* 500 µg/ml** 750 µg/ml** 1000 µg/ml** 
Extract code Mann 5294 Mann 5294* Mann** 5294* Mann** 5294** 
SP1-V4 34.41 30.27 36.31 36.22 33.90 36.27 35.78 37.43 
SP2-AB1 9.89 20.09 12.86 28.23 11.85 30.13 16.56 30.17 
SP2-AB2 23.47 21.48 19.09 20.60 24.34 22.05 23.52 21.61 
SP2-AB3 20.92 20.76 29.85 35.74 31.59 33.46 32.41 27.40 
SP2-AB6 1.54 31.41 11.04 32.07 15.40 26.09 31.37 24.42 
SP2-W3 -2.64# 2.85 28.20 10.40 30.39 15.77 35.13 23.74 
SP3-AB22 -5.74# 17.84 -7.24# 18.42 23.81 19.27 28.50 19.07 
SP4-AB2 22.44 4.49 29.26 17.89 29.24 23.21 26.52 33.85 
SP4-AB6 -27.00# -16.37# -29.93# 0.24 -7.25# 25.48 15.11 31.70 
SP6-AB5 1.95 -24.40# 1.03 -37.98# 7.89 -42.99# 7.86 -33.36# 
Cinnamaldehyde -41.39  -57.07  -205.22$  -932.37$  
10% DMSO 13.33  15.30  12.65  18.09  
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mean pyoverdine inhibition at this concentration was 21.60%, as compared to 16.18% and 
18.87% at 500 and 750 µg/ml, respectively. Mean pyoverdine inhibition by medium 5294 
extracts was, therefore, concentration-dependent, and this can be further seen in individual 
isolates SP1-V4 (5294) and SP2-AB1 (5294) (Supp. Fig. 3.2.2B and 3.2.4B, respectively). As with 
medium 5294, treatment of the P. aeruginosa cells with mannitol extracts resulted in a 
significant overall decrease in pyoverdine production (p < 0.01). However, mannitol only 
yielded significant mean pyoverdine inhibition at 750 and 1000 µg/ml of 18.99% and 23.48%, 
respectively. The effects of mannitol extracts were, therefore, also concentration-dependent, 
which can be further seen in extracts SP2-AB3 (Mann) and SP2-AB6 (Mann) (Supp. Fig. 3.2.5A 
and 3.2.6A, respectively). However, as the overall mean inhibition was higher for mannitol at 
1000 µg/ml, it may be suggested that this medium be employed at this concentration if 
effective inhibition of P. aeruginosa pyoverdine production is to be achieved.  
At the individual isolate level, the extract with the highest pyoverdine inhibition was 
Streptomyces spp. SP1-V4 (5294), achieving pyoverdine inhibitions of between 30.27% at 250 
µg/ml and 37.43% at 1000 µg/ml (Supp. Fig. S3.2.2B). The mannitol extract of the same 
organism also yielded promising pyoverdine inhibitory results, with inhibitions ranging from 
33.90% at 750 µg/ml to 36.31% at 500 µg/ml. As the maximum inhibition of the mannitol 
extract was only 1% lower than that of the medium 5294 extract, but at half the treatment 
concentration, SP1-V4 (Mann) appears to be the most promising extract. Streptomyces spp.  
extract SP6-AB5 (5294) was the only extract incapable of pyoverdine, resulting instead in 
increased pyoverdine production at each treatment concentration (Supp. Fig. S3.2.11B).  
The effect of 10% DMSO on pyoverdine inhibition overall proved to be insignificant (p 
> 0.05), ruling out the possibility that the efficacy of the bacterial extracts may be attributed 
to the 10% DMSO used as the solvent. Pyoverdine inhibition as a result of the positive control 
cinnamaldehyde resulted in increased pyoverdine production, possibly as a result of cell 
death at 750 and 1000 µg/ml, since growth was factored into the pyoverdine inhibition 
calculation (Supp Fig. S2.2.1A). 
 
3.3.4 Actinomycete extracts and P. aeruginosa elastase production 
Mediated via the long-chain AHL las QS system, elastase LasB is key in P. aeruginosa virulence 
(Müller et al., 2015; Guendouze et al., 2017). Following treatment of P. aeruginosa with 
extracts, an elastase inhibition range of -15.40% to 61.77% was observed (Table 3.4), with 
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70% (14/20) of extracts resulting in LasB inhibition of ≥30% (Supp. S3.3). Mean elastase 
inhibition as a result of treatment with extracts proved to be significant (p < 0.01), with this 
significance being carried through to each of the three individual concentrations tested (Table 
3.4). The average inhibition observed at 250 µg/ml was 14.46%, at 500 µg/ml 25.32% and 
32.04% at 1000 µg/ml. This same concentration-dependent effect can be seen in individual 
extracts such as SP1-V4 (5294) and SP2-AB1 (5294) (Supp. Fig. S3.3.2B and S3.3.3B). 
  
Table 3.4: Effect of sponge-associated Actinomycete extracts on elastase production by P. 
aeruginosa ATCC 27853. Percentage elastase inhibition of both mannitol and medium 5294 
extracts were assessed at 250-1000 µg/ml 
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
# Negative values indicate an increase in elastase production.  
$Elastase inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
Examining the extracts based on their individual production media, it can be observed 
that elastase inhibition exerted by both media was significant at each concentration (Table 
3.4). Inhibition by medium 5294 extracts was most significant at 500 µg/ml, however, 
inhibition was concentration-dependent, with the highest mean inhibition observed at 1000 
µg/ml (30.10%). Inhibition by the mannitol extracts was also concentration-dependent, with 
1000 µg/ml yielding both the most significant and highest mean elastase inhibition (33.97%). 
The ideal conditions for maximal LasB inhibition can, therefore, be said to be through the use 
of the mannitol production medium at 1000 µg/ml of extract. 
Examining the results in terms of the individual extracts, it was previously noted that 
70% of the extracts reduced LasB production by ≥30%. However, in comparison to 
 Percentage elastase inhibition 
 250 µg/ml** 500 µg/ml** 1000 µg/ml** 
Extract code Mann* 5294** Mann** 5294** Mann** 5294** 
SP1-V4 -5.22# 7.42 -2.19# 23.55 34.13 38.07 
SP2-AB1 -15.40# 21.22 4.60 29.35 11.97 35.98 
SP2-AB2 11.14 7.32 24.48 11.79 23.88 25.00 
SP2-AB3 20.04 6.05 41.83 15.88 35.10 25.54 
SP2-AB6 38.71 -0.56# 26.17 52.60 41.69 2.51 
SP2-W3 31.32 21.10 37.40 38.92 34.07 36.55 
SP3-AB22 5.70 4.36 13.07 21.06 44.12 53.60 
SP4-AB2 16.18 3.54 41.34 19.88 61.77 4.81 
SP4-AB6 22.64 34.72 31.50 33.62 34.25 36.14 
SP6-AB5 39.64 19.28 9.38 32.11 18.71 42.83 
Cinnamaldehyde 38.30  42.67  67.45$  
10% DMSO 7.51  7.28  12.81  
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cinnamaldehyde, where inhibition of 42.67% was observed before the compound became 
cytotoxic (Supp. Fig. S3.3.1A), only extracts capable of >50% inhibitions were considered to 
be meaningful. Three of the Streptomyces spp. extracts were capable of this, viz. SP2-AB6 
(5294) which caused an inhibition of 52.6% at 500 µg/ml (Supp. Fig. S3.3.6B), SP3-AB22 (5294) 
which caused an inhibition of 53.6% at 1000 µg/ml (Supp. Fig. S3.3.8B) and SP4-AB2 (Mann) 
which resulted in 61.77% inhibition at 1000 µg/ml (Supp. Fig. S3.3.9A).  
 
3.3.5 Actinomycete extracts and P. aeruginosa protease production 
A further virulence factor primarily mediated via the long chain las QS system is the 
production of protease (Guendouze et al., 2017). In order to determine if exposure to the 
extracts reduced the ability of P. aeruginosa to produce proteases, two separate assays were 
performed: the qualitative casein agar well diffusion assay and the qualitative azocasein 
spectrophotometric assay. The first assay allowed visual determination of protease 
production through a reduction in zones of casein hydrolysis as compared to the untreated 
control. Cinnamaldehyde was used as the positive control, with clear inhibition being visible 
(Fig. 3.1A), however, the reduction in casein hydrolysis at 1 mg/ml was a result of cell death 
(Table 3.5). No visible decrease in protease production was observed with 10% DMSO. 
Nineteen of the extracts (95%) resulted in a >10% reduction in casein hydrolysis (Table 3.5), 
including SP4-AB2 (Mann) (Fig. 3.1B).  
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Inhibition in protease production was determined through the comparison of skim 
milk agar hydrolysis zones of the untreated versus treated sample. (A) Positive control 
cinnamaldehyde. (B) Sponge-associated Streptomyces spp. extract SP4-AB2 (Mann) 
demonstrated decreased zones of hydrolysis at each concentration. 
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Table 3.5: Qualitative protease inhibition following treatment with sponge-associated Actinomycete extracts. Zones of hydrolysis on casein agar 
plates following 24 h incubation at 37 °C are given with the calculated percentage inhibition for each extract treatment 
 Untreated 250 µg/ml 500 µg/ml 1000 µg/ml 
Extract code 
Zone of hydrolysis 
(mm) ± SD* 
Zone of hydrolysis 
(mm) ± SD* 
Protease 
inhibition (%)** 
Zone of hydrolysis 
(mm) ± SD* 
Protease 
inhibition (%)** 
Zone of hydrolysis 
(mm) ± SD* 
Protease 
inhibition (%)** 
Cinnamaldehyde$ 25.14 ± 0.71 20.50 ± 0.71 18.46 18.00 ± 0.00 28.40 11.50 ± 0.71 54.26 
10% DMSO 25.14 ± 0.71 23.50 ± 0.71 6.52 23.00 ± 1.41 8.51 23.50 ± 0.71 6.52 
SP1-V4 (Mannitol) 25.14 ± 0.71 18.50 ± 0.71 26.41 20.00 ± 0.00 20.45 20.00 ± 0.00 20.45 
SP1-V4 (5294) 25.14 ± 0.71 21.00 ± 2.12 16.47 21.50 ± 1.80 14.48 22.75 ± 0.35 9.51 
SP2-AB1 (Mannitol) 25.14 ± 0.71 21.75 ± 0.35 13.48 20.75 ± 0.35 17.46 22.75 ± 0.35 9.51 
SP2-AB1 (5294) 25.14 ± 0.71 20.88 ± 0.18 16.96 21.13 ± 0.18 15.97 20.63 ± 0.18 17.96 
SP2-AB2 (Mannitol) 25.14 ± 0.71 18.25 ± 1.77 27.41 21.25 ± 0.35 15.47 21.50 ± 0.00 14.48 
SP2-AB2 (5294) 25.14 ± 0.71 19.50 ± 1.06 22.43 19.25 ± 1.77 23.43 18.25 ± 1.06 27.41 
SP2-AB3 (Mannitol) 25.14 ± 0.71 21.63 ± 1.94 13.98 24.50 ± 0.71 2.55 23.75 ± 0.35 5.53 
SP2-AB3 (5294) 25.14 ± 0.71 24.00 ± 0.00 4.53 18.13 ± 0.88 27.90 19.63 ± 1.59 21.94 
SP2-AB6 (Mannitol) 25.14 ± 0.71 24.75 ± 1.06 1.55 24.25 ± 0.35 3.54 22.50 ± 0.00 10.50 
SP2-AB6 (5294) 25.14 ± 0.71 25.50 ± 0.71 -1.43# 24.00 ± 0.00 4.53 23.17 ± 1.76 7.85 
SP2-W3 (Mannitol) 25.14 ± 0.71 20.13 ± 0.18 19.95 19.13 ± 0.18 23.93 19.75 ± 0.35 21.44 
SP2-W3 (5294) 25.14 ± 0.71 19.00 ± 0.00 24.42 21.00 ± 0.00 16.47 20.75 ± 0.35 17.46 
SP3-AB22 (Mannitol) 25.14 ± 0.71 22.25 ± 0.35 11.50 20.25 ± 0.35 19.45 20.25 ± 0.35 19.45 
SP3-AB22 (5294) 25.14 ± 0.71 20.50 ± 0.71  18.46 20.00 ± 1.41 20.45 20.50 ± 0.71 18.46 
SP4-AB2 (Mannitol) 25.14 ± 0.71 21.25 ± 0.35 15.47 21.38 ± 0.53 14.98 19.50 ± 0.71 22.43 
SP4-AB2 (5294) 25.14 ± 0.71 22.13 ± 0.18 11.99 22.25 ± 0.35 11.50 21.63 ± 0.18 13.98 
SP4-AB6 (Mannitol) 25.14 ± 0.71 21.00 ± 2.83 16.47 20.38 ± 2.65 18.95 20.63 ± 2.30 17.96 
SP4-AB6 (5294) 25.14 ± 0.71 22.50 ± 0.71 10.50 21.50 ± 0.00 14.48 22.25 ± 0.35 11.50 
SP6-AB5 (Mannitol) 25.14 ± 0.71 19.13 ± 0.18 23.93 19.00 ± 0.35 24.42 18.25 ± 0.35 27.41 
SP6-AB5 (5294) 25.14 ± 0.71 19.50 ± 0.50 22.43 18.38 ± 0.53 26.91 18.00 ± 0.00 28.40 
**Protease activity is expressed based on the diameter of the hydrolysis zone. QS inhibitory compounds should reduce protease activity of P. aeruginosa ATCC 27853, and thus, in their 
presence, the hydrolysis zone should be of smaller dimensions than in the untreated control (<20.71 mm). 
* Average of casein hydrolysis zones ± standard deviation. 
$ Protease inhibition for cinnamaldehyde at 1000 µg/ml is as a result of P. aeruginosa cell death. All other extracts tested had a growth inhibitory effect of <40%.  
# Negative values are indicative of an increase in protease production at this concentration.
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Using the quantitative azocasein assay, 18 of these extracts, with an additional extract 
which failed to give activity in the qualitative assay, were confirmed to quench protease 
production by >20%. Five of the 19 positive extracts (26%) yielded inhibition ≥50% (Table 3.6). 
No cell death (>40%) was observed following treatment with any of the sponge-associated 
Actinomycete extracts (Supp. S3.4). The extracts did, however, cause a significant average 
decrease in protease production (p < 0.01), and this same level of significance was seen at 
each individual treatment concentration (Table 3.6). 
 
Table 3.6: Effect of sponge-associated Actinomycete extracts on protease production by P. 
aeruginosa ATCC 27853. Both mannitol and medium 5294 extracts were tested at 250-1000 
µg/ml and the percentage protease inhibition at each concentration determined  
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
# Negative values indicate an increase in protease production. 
$Protease inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
Medium 5294 yielded significant inhibition at each treatment concentration, in a 
concentration-dependent manner, while the mannitol extracts yielded significant mean 
inhibition only at ≥500 µg/ml, also in a concentration-dependent manner. Even though the 
mean protease inhibition for both media was quite similar, medium 5294 yielded significant 
inhibition at all treatment concentrations, and is thus the preferable production medium for 
protease inhibition when using sponge-associated Actinomycetes. 
Examining individual extracts’ protease inhibitory potential, extract SP4-AB2 (Mann) 
yielded the best inhibition profile in a concentration-dependent manner (Supp. Fig. S3.4.9A), 
achieving a minimum inhibition of 32.58% at 250 µg/ml and a maximum inhibition of 71.95% 
 Percentage protease inhibition 
 250 µg/ml** 500 µg/ml** 750 µg/ml** 1000 µg/ml** 
Extract code Mann 5294** Mann** 5294** Mann** 5294** Mann** 5294** 
SP1-V4 7.67 19.60 35.53 40.79 41.71 39.93 44.34 39.94 
SP2-AB1 5.57 21.22 41.50 26.12 44.20 39.14 46.49 39.70 
SP2-AB2 27.57 30.14 28.61 30.79 38.28 38.62 50.66 40.06 
SP2-AB3 36.15 7.93 36.53 28.70 37.26 30.95 39.65 42.95 
SP2-AB6 18.56 15.37 38.27 28.49 42.28 39.05 52.79 39.96 
SP2-W3 21.43 11.66 33.14 12.47 40.48 11.73 52.23 20.16 
SP3-AB22 -14.97# 41.06 -5.55# 49.66 -5.93# 47.15 -1.95# 47.98 
SP4-AB2 32.58 -4.27# 37.77 21.82 56.60 22.63 71.95 69.76 
SP4-AB6 -3.37# 1.13 14.71 2.29 22.52 40.03 30.38 44.72 
SP6-AB5 -11.98# 12.78 16.44 23.56 24.58 27.39 25.90 30.84 
Cinnamaldehyde 22.38  95.23  109.72$  111.91$  
10% DMSO 3.80  6.33  10.13  12.66  
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at 1000 µg/ml. Extracts SP2-AB2 (Mann), SP2-AB6 (Mann), SP2-W3 (Mann) and SP4-AB2 
(5294) additionally yielded promising protease inhibitory activities of >50%. No growth 
inhibition was observed as a result of any of the extracts, and 10% DMSO without bacterial 
extract was found to increase the production of P. aeruginosa protease production (Supp. Fig. 
S3.4.1B). Cinnamaldehyde resulted in a significant (p < 0.05) decrease in protease production 
(Supp. Fig. S3.4.1A).  
 
3.3.6 Actinomycete extracts and P. aeruginosa rhamnolipid production 
The qualitative rhamnolipid test was the CTAB agar test, where the cationic CTAB binds to the 
anionic rhamnolipids, forming blue halos. Any inhibition of these zones can then be observed 
visually (Fig. 3.2), however, zones of growth are subtracted as varying diameters of growth 
may skew the results. The positive control cinnamaldehyde caused rhamnolipid inhibition at 
all concentrations tested, although at 1000 µg/ml this was as a result of cell death. The 10% 
DMSO solvent, however, had no noticeable effect on P. aeruginosa rhamnolipid production 
(Table 3.7). It was observed that 100% (20/20) of the extracts produced some degree of 
rhamnolipid inhibition (Table 3.7). Following quantitative analysis of the rhamnolipid 
inhibitory effects of the Actinomycete extracts, 70% (14/20) were confirmed to have an anti-
rhamnolipid activity of >20%, six of which were >50% (Table 3.7).  
 
 
 
 
 
 
 
Figure 3.2: Rhamnolipid production using the qualitative CTAB agar assay. Rhodococcus 
fascians extract SP4-AB6 (Mann) yielded a positive result in the qualitative CTAB agar 
rhamnolipid inhibition assay. Blue halos observed under UV light (A and B) were indicative of 
rhamnolipid production. Inhibition of these zones, more easily observable under greyscale (C 
and D) were taken as a positive for potential rhamnolipid inhibitions. The four cultured spots 
from left to right represent P. aeruginosa after treatment with 0, 250, 500 and 1000 µg/ml of 
extract.  
 
A B C D 
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Table 3.7: Qualitative rhamnolipid inhibition following treatment with sponge-associated Actinomycete extracts. Zones of rhamnolipid 
production on CTAB agar plates following 24 h incubation at 37 °C are given with percentage inhibition for each extract treatment 
 0 250 µg/ml 500 µg/ml 1000 µg/ml 
Extract code 
Rhamnolipid production 
(mm)** ± SD* 
Rhamnolipid production 
(mm)** ± SD* 
Rhamnolipid 
inhibition (%) 
Rhamnolipid production 
(mm)** ± SD* 
Rhamnolipid 
inhibition (%) 
Rhamnolipid production 
(mm)** ± SD* 
Rhamnolipid 
inhibition (%) 
Cinnamaldehyde$ 20.71 ± 0.35 19.25 ± 0.35 7.05 13.50 ± 0.71 34.81 9.50 ± 0.71 54,13 
10% DMSO 20.71 ± 0.35 20.75 ± 0.35 -0.19# 20.75 ± 0.35 -0.19# 21.00 ± 0.00 -1,40# 
SP1-V4 (Mannitol) 20.71 ± 0.35 11.63 ± 5.13 43.87 12.75 ± 5.30 38.44 13.25 ± 2.47 36,02 
SP1-V4 (5294) 20.71 ± 0.35 13.13 ± 4.42 36.62 11.00 ± 3.54 46.89 12.50 ± 4.24 39,64 
SP2-AB1 (Mannitol) 20.71 ± 0.35 13.25 ± 0.35  36.02 13.13 ± 3.36 36.62 17.25 ± 3.18 16,71 
SP2-AB1 (5294) 20.71 ± 0.35 14.00 ± 3.54 32.40 13.00 ± 3.54 37.23 14.50 ± 5.66 29,99 
SP2-AB2 (Mannitol) 20.71 ± 0.35 13.75 ± 5.30 33.61 14.00 ± 2.83 32.40 13.75 ± 4.60 33,61 
SP2-AB2 (5294) 20.71 ± 0.35 14.25 ± 3.89 31.19 14.25 ± 5.30 31.19 15.50 ± 5.66 25,16 
SP2-AB3 (Mannitol) 20.71 ± 0.35 9.00 ± 0.00 56.54 7.50 ± 1.41 63.79 6.75 ± 1.06 67,41 
SP2-AB3 (5294) 20.71 ± 0.35 8.88 ± 0.53 57.15 9.50 ± 1.41 54.13 8.75 ± 0.35 57,75 
SP2-AB6 (Mannitol) 20.71 ± 0.35 13.00 ± 4.24 37.23 8.25 ± 0.35 60.16 7.25 ± 0.35 64,99 
SP2-AB6 (5294) 20.71 ± 0.35 8.50 ± 0.71 58.96 7.50 ± 2.12 63.79 7.50 ± 2.12 63,79 
SP2-W3 (Mannitol) 20.71 ± 0.35 14.00 ± 4.24 32.40 14.88 ± 5.48 28.17 15.50 ± 3.54 25,16 
SP2-W3 (5294) 20.71 ± 0.35 14.00 ± 2.12 32.40 13.13 ± 4.77 36.62 11.75 ± 4.60 43,26 
SP3-AB22 (Mannitol) 20.71 ± 0.35 13.25 ± 3.89 36.02 11.75 ± 4.60 43.26 11.00 ± 4.24 46,89 
SP3-AB22 (5294) 20.71 ± 0.35 13.00 ± 4.24 37.23 13.25 ± 5.30 36.02 13.00 ± 4.24 37,23 
SP4-AB2 (Mannitol) 20.71 ± 0.35 13.75 ± 5.30 33.61 12.75 ± 5.30 38.44 11.50 ± 2.83 44,47 
SP4-AB2 (5294) 20.71 ± 0.35 12.75 ± 5.30 38.44 12.50 ± 4.95 39.64 11.50 ± 3.54 44,47 
SP4-AB6 (Mannitol) 20.71 ± 0.35 12.63 ± 5.13 39.04 12.13 ± 4.07 41.45 11.50 ± 3.54 44,47 
SP4-AB6 (5294) 20.71 ± 0.35 13.00 ± 4.24 37.23 10.00 ± 1.41 51.71 12.50 ± 3.54 39,64 
SP6-AB5 (Mannitol) 20.71 ± 0.35 12.50 ± 4.95 39.64 11.50 ± 4.24 44.47 13.25 ± 3.89 36,02 
SP6-AB5 (5294) 20.71 ± 0.35 19.25 ± 0.35 7.05 13.50 ± 0.71 34.81 9.50 ± 0.71 54,13 
** Rhamnolipid production is expressed based on the diameter of the rhamnolipid hydrolysis zone – bacterial growth diameter. QS inhibitory compounds should reduce rhamnolipid production 
of P. aeruginosa ATCC 27853, and thus, in their presence, the hydrolysis zone should be of smaller dimensions than in the untreated control (<20.71 mm). 
* All readings of rhamnolipid production are given ± standard deviation. 
$ Rhamnolipid inhibition for cinnamaldehyde at 1000 µg/ml is as a result of P. aeruginosa cell death. All other extracts tested had a growth inhibitory effect of <40% at all concentrations tested.  
# Negative values are indicative of an increase in protease production at this concentration.
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Following statistical analysis, the mean rhamnolipid inhibition resulting from 
treatment with the Actinomycete extracts was significant (p < 0.05). When examining 
individual treatment concentrations, significant mean inhibitions were exacted by the 
extracts at all treatment concentrations, in a concentration-dependent manner (Table 3.8).  
 
Table 3.8: Effect of sponge-associated Actinomycete extracts on rhamnolipid production by 
P. aeruginosa ATCC 27853. Both mannitol and medium 5294 extracts were tested at 250-1000 
µg/ml and the percentage rhamnolipid inhibition at each concentration determined 
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Rhamnolipid inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
# Negative values indicate an increase in rhamnolipid production. 
 
Mannitol-derived extracts yielded a significant mean inhibition (p < 0.05) at 500 µg/ml, 
while the medium 5294 extracts did not yield significant inhibition at any of the individual 
treatment concentrations (Table 3.8). This was due to the wide range of inhibitions observed 
at each treatment concentration, and it was determined that separate statistical analysis 
needed to be run on the top-performing extracts.  
Individually, the strongest inhibitors of rhamnolipid production were SP2-AB6 (Mann) 
(Supp. Fig. 3.5.6A), SP6-AB5 (5294) (Supp. Fig. 3.5.11B), and SP4-AB2 (5294) (Supp. Fig. 
3.5.10B), all achieving >60% rhamnolipid inhibition without exerting cytotoxic effects. SP2-
AB6 (Mann) resulted in a minimum rhamnolipid inhibition of 21.74% at 250 µg/ml and a 
maximum inhibition of 82.53% at 1000 µg/ml (p < 0.05). Extract SP6-AB5 (5294) yielded a 
minimum inhibition of 39.49% at 250 µg/ml and a maximum inhibition of 67.31% at 1000 
µg/ml (p < 0.01) and SP4-AB2 (5294) resulted in a minimum rhamnolipid inhibition of 23.73% 
 Percentage rhamnolipid inhibition 
 250 µg/ml* 500 µg/ml* 750 µg/ml** 1000 µg/ml** 
Extract code Mann 5294 Mann* 5294 Mann 5294 Mann 5294 
SP1-V4 44.29 6.74 38.20 33.11 37.82 33.60 45.43 34.48 
SP2-AB1 15.67 -14.93# 25.85 -12.70# 24.54 -13.35# 24.56 1.10 
SP2-AB2 -5.22# -5.86# -15.11# -6.73# -15.21# 0.24 -11.05# -0.79# 
SP2-AB3 -5.31# -10.33# -2.39# -1.24# -0.11# 12.88 8.68 -8.71 
SP2-AB6 21.74 37.46 44.97 37.96 48.65 41.55 82.53 48.92 
SP2-W3 16.85 62.00 38.77 10.03 47.18 51.69 28.61 46.47 
SP3-AB22 35.15 27.60 38.64 31.48 40.16 31.53 52.99 18.32 
SP4-AB2 -17.47# 23.73 -25.17# 36.17 -34.04# 40.76 -59.41#$ 61.31 
SP4-AB6 2.11 44.71 17.32 44.74 7.19 19.91 25.67 32.39 
SP6-AB5 31.32 39.49 41.36 46.67 46.62 47.99 59.58 67.31 
Furanone 26.96  23.90  24.37  28.90  
10% DMSO 26.90  28.39  25.75  20.88  
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at 250 µg/ml and a maximum inhibition of 61.31% at 1000 µg/ml (p < 0.05). Therefore, 
mannitol extracts yielded overall more significant inhibitions, and individually the strongest 
inhibitor was mannitol-derived. As a result, a conclusion regarding the ideal production 
medium for rhamnolipid inhibition can tentatively be made as being mannitol.  
Furanone was used as a positive control for this assay at concentrations of 2.5, 5, 7.5 
and 10 µg/ml, and was found to have an insignificant effect on rhamnolipid production, 
achieving a maximum inhibition of 29.3% at 5 µg/ml (p > 0.05). The 10% DMSO solvent 
without bacterial extract was found to have a similarly insignificant effect on P. aeruginosa 
rhamnolipid production, thereby ruling out any added effect of the solvent on the inhibitions 
observed above. Neither effected cell growth (Supp. Fig. S3.5.1).  
 
3.3.7 Actinomycete extracts and P. aeruginosa swimming motility 
The effects of each extract, at varying concentrations, on swimming motility was monitored 
for 3 d. However, only inhibitory effects which were maintained for the full 72 h were taken 
as positive results, such as those of SP4-AB2 (Mann) and SP2-W3 (5294) (Fig. 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Effect of sponge-associated bacterial extracts on swimming motility of P. 
aeruginosa ATCC 27853. Positive extracts for motility inhibition were those with a sustained 
reduction in swim zones after 72 h. (A) Clear reduction in swimming motility was observed 
after treatment of the cells with sponge-associated Streptomyces spp. extract SP4-AB2 
(Mann). (B) Positive motility inhibition as a result of treatment with Actinomycete extract SP2-
W3 (5294). In each instance cells were treated with 0, 250, 500 and 1000 µg/ml of bacterial 
extract (from left to right).  
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Statistically, the sponge-associated Actinomycete extracts exerted a significant (p < 
0.01) mean reduction in P. aeruginosa swimming motility after 72 h. This same level of 
significance was maintained at each individual treatment concentration and remained the 
same, even when examining the separate production media (Table 3.9). The mannitol extracts 
yielded average swim inhibition of 24.83%, 34.10% and 32.91% at 250, 500 and 1000 µg/ml, 
respectively, thereby indicating that 500 µg/ml would be the ideal treatment concentration 
when employing mannitol extracts. Medium 5294 resulted in highly similar mean inhibition 
of 27.25%, 30.09% and 36.60% at 250, 500 and 1000 µg/ml, respectively. Therefore, no 
statement can be made regarding the ideal production medium for P. aeruginosa swimming 
inhibition. Overall, 80% of the extracts (16/20) resulted in a >30% inhibition in swim motility, 
while three of these were capable of >50% inhibition (Table 3.9).  
 
Table 3.9: Effect of sponge-associated Actinomycete extracts on P. aeruginosa ATCC 27853 
swimming motility. Both mannitol and medium 5294 extracts were tested at 250-1000 µg/ml 
and the percentage swimming inhibition at each concentration determined 
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
# Negative values indicate an increase in swimming motility at this concentration.  
$Swimming inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
The strongest inhibitor of swimming motility at 72 h was R. fascians SP4-AB6 (5294), 
which resulted in a maximum swimming inhibition of 57.77% at only 250 µg/ml. Also 
achieving a maximum swim inhibition of >50% were Streptomyces spp. extracts SP3-AB22 
(5294), which resulted in a maximum inhibition of 55.76% at 1000 µg/ml, and SP4-AB2 (Mann) 
an inhibition of 51.07% at 1000 µg/ml. No growth inhibition was observed with any of the 
 Percentage swimming inhibition 
 250 µg/ml** 500 µg/ml** 1000 µg/ml** 
Extract code Mann** 5294** Mann** 5294** Mann** 5294** 
SP1-V4 28.28 20.24 26.94 25.94 49.73 25.60 
SP2-AB1 34.65 -5.90 31.64 22.25 30.97 22.25 
SP2-AB2 11.53 37.00 26.94 38.34 32.31 32.31 
SP2-AB3 45.04 41.02 38.47 25.60 32.98 42.36 
SP2-AB6 10.86 18.23 42.02 32.98 6.17 37.67 
SP2-W3 30.29 35.99 36.33 30.29 19.57 39.01 
SP3-AB22 24.26 45.04 39.68 52.41 42.36 55.76 
SP4-AB2 15.55 -0.54 34.32 34.65 51.07 41.02 
SP4-AB6 25.60 57.77 43.70 45.71 48.39 42.36 
SP6-AB5 22.25 23.59 20.91 -7.24 15.55 27.61 
Cinnamaldehyde 50.40  55.09  44.37$  
10% DMSO 17.90  18.90  20.91  
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extracts, and 10% DMSO without bacterial extract was found to result in an insignificant (p > 
0.05) inhibition of P. aeruginosa swimming motility (Supp. Table S3.6.2). Cinnamaldehyde 
resulted in a >50% decrease in swimming motility but was found to be insignificant due to 
high variances as well as cytotoxicity at 1000 µg/ml (Supp. Table S3.6.2).  
 
3.3.8 Actinomycete extracts and P. aeruginosa swarming motility 
The effects of each sponge-associated Actinomycete extract on P. aeruginosa swarming 
motility, at varying concentrations, was monitored for 3 d. However, while swarm readings 
for the sponge-associated bacterial extracts were taken every 24 h for 72 h, the results at 72 
h indicated a sustained inhibitory effect on cells (Fig. 3.4).  
 
 
 
 
 
 
 
 
Figure 3.4 Effect of sponge-associated bacterial extracts on P. aeruginosa ATCC 27853 
swarming motility. Positive extracts for motility inhibition were those with a sustained 
reduction in swarm zones after 72 h. A clear reduction in swimming motility was observed 
after treatment of the cells with sponge-associated Streptomyces spp. extract SP4-AB2 
(Mann). 
 
The sponge-associated Actinomycete extracts resulted in a significant (p < 0.05) mean 
reduction in P. aeruginosa swarming motility at 72 h, as well as at all three treatment 
concentrations (p < 0.01) (Table 3.10). Mannitol resulted in significant inhibition in swarming 
motility at concentrations ≥500 µg/ml (p < 0.05) while medium 5294 extracts only resulted in 
significant inhibition at 250 µg/ml (p < 0.01), possibly due to the large variance in the results 
obtained (Table 3.10).  
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Table 3.10: Effect of sponge-associated Actinomycete extracts on P. aeruginosa ATCC 27853 
swarming motility. Both mannitol and medium 5294 extracts were tested at 250-1000 µg/ml 
and the percentage swarming inhibition at each concentration determined. 
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Swarming inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
# Negative values indicate an increase in swarming motility. 
 
The mannitol extracts yielded a significant average swim inhibition of 20.63% at 500 
µg/ml and 17.84% at 1000 µg/ml, while medium 5294 resulted in significant mean inhibitions 
of 18.8% at 250 µg/ml. As the average swarm inhibition exerted by the mannitol extracts were 
both greater and significant at a wider range of concentrations, mannitol can be proposed as 
the preferred medium for swarming inhibition.  
Overall, 50% (10/20) of extracts reduced swarming motility by >30%, with three of 
these exceeding 50% inhibition. Examining the isolates individually, the strongest inhibitor of 
swarming motility at 72 h was Streptomyces spp. extract SP1-V4 (Mann), which resulted in a 
maximum swarming inhibition of 67.09% at 250 µg/ml. Rhodococcus fascians extract SP4-AB6 
(5294) also exhibited promising swarming inhibitory effects, resulting in inhibitions ranging 
from 54.43% at 250 µg/ml to 58.23% at 1000 µg/ml, indicating a low treatment concentration 
may be used. Furthermore, SP3-AB22 (Mann) resulted in 53.16% swarming inhibition at 500 
µg/ml. No growth inhibition was observed as a result of any of the extracts, and 10% DMSO 
without bacterial extract was found to result in an insignificant (p > 0.05) inhibition of P. 
aeruginosa swarming motility (Supp. Table S3.6.1). Cinnamaldehyde resulted in a >50% 
decrease in swarming motility, but was found to be insignificant due to high variances as well 
as cytotoxicity effect of the compound at 1000 µg/ml. 
 Percentage swarming inhibition 
 250 µg/ml** 500 µg/ml** 1000 µg/ml** 
Extract code Mann 5294** Mann* 5294 Mann* 5294 
SP1-V4 67.09 17.09 26.58 25.32 37.97 39.24 
SP2-AB1 -3.8# 25.32 10.13 10.13 21.52 -5.06# 
SP2-AB2 -17.72# 3.8 15.19 -13.92# 5.06 0 
SP2-AB3 18.99 15.19 34.81 -13.92# 6.33 -5.7# 
SP2-AB6 24.68 -7.59# 48.1 -6.33# -10.13# -10.13# 
SP2-W3 15.19 37.97 36.08 7.59 22.15 11.39 
SP3-AB22 20.25 11.39 53.16 46.84 50 35.44 
SP4-AB2 27.85 14.56 11.39 17.72 0 5.06 
SP4-AB6 -21.52# 54.43 13.92 56.96 44.3 58.23 
SP6-AB5 25.95 18.35 -43.04# 44.3 1.27 22.78 
Cinnamaldehyde 43.04  12.66  -8.23#$  
10% DMSO -58.23#  -83.54#  -49.37#  
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3.3.9 Actinomycete extracts and P. aeruginosa initial biofilm formation 
The effect of the sponge-associated Actinomycete extracts on P. aeruginosa initial biofilm 
formation was tested at 0, 0.5, 1, 5 and 10 mg/ml. Initial biofilm inhibition ranged from -
23.95% to 55.43%. Overall 20% (4/20) of the Actinomycete extracts resulted in an ≥40% 
reduction in initial biofilm formation, with only one of these further resulting in a >50% 
inhibition without causing cell death. While one extract achieved a >70% initial biofilm 
reduction, this was due to the cytotoxic effects of the extract at those concentrations (Table 
3.11, Supp. S3.7). 
 
Table 3.11: Effect of sponge-associated Actinomycete extracts on initial biofilm formation by 
P. aeruginosa ATCC 27853. Both mannitol and medium 5294 extracts were tested at 0.5, 1, 5 
and 10 mg/ml and the biofilm reduction at each concentration determined 
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Swarming inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
# Negative values indicate an increase in swarming motility. 
 
Statistically the sponge-associated Actinomycete extracts were found to result in a 
significant overall decrease in P. aeruginosa initial biofilm formation (p < 0.01). However, 
upon further examination it was observed that individually 0.5 and 1 mg/ml proved to be 
insignificant, while both 5 and 10 mg/ml resulted in significant average initial biofilm 
inhibition (p < 0.01). Furthermore, when examining each concentration for the individual 
production media (mannitol and medium 5294), mannitol was found to overall yield 
significant average inhibition only at 10 mg/ml (p < 0.05), with medium 5294 extracts also 
yielding significant mean inhibition at this concentration only (p < 0.01) (Table 3.11). This lack 
 Percentage initial biofilm inhibition 
 0.5 mg/ml 1 mg/ml 5 mg/ml** 10 mg/ml** 
Extract code Mann 5294 Mann 5294 Mann 5294 Mann* 5294** 
SP1-V4 3.48 11.57 4.14 -18.37# 8.50 -18.93# 9.41 -20.88# 
SP2-AB1 2.66 1.61 21.77 9.22 23.39 13.65 40.76 40.96 
SP2-AB2 -23.95# -0.67# -23.87# 5.37 -23.30# 7.58 -23.05# 14.73 
SP2-AB3 2.41 1.68 2.53 4.51 14.67 18.43 22.39 33.01 
SP2-AB6 1.97 3.49 -0.06# 3.18 0.29 3.33 1.72 45.66 
SP2-W3 6.20 2.29 7.99 3.08 24.39 23.82 36.50 9.57 
SP3-AB22 -21.19# 3.87 -15.71# 3.87 4.04 3.92 14.64 25.60 
SP4-AB2 7.48 17.76 9.07 11.91 9.99$ 2.30 72.36$ -1.16# 
SP4-AB6 0.52 -1.32# 3.41 -0.74# 5.12 2.81 39.29$ 34.19 
SP6-AB5 4.37 3.46 12.81 25.55 13.61 30.72 13.62 55.43 
Cinnamaldehyde -22.50#  -21.12#  70.25$  70.19$  
10% DMSO -23.36#  -21.12#  -18.47#  -18.52#  
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of significance could, however, be attributed to the large variances seen between the 
different bacterial extracts of each production media at each treatment concentration.  
The best inhibitors each resulted in a >40% reduction in initial biofilm formation at 10 
mg/ml of extract. These were SP6-AB5 (5294) which resulted in a decrease of 55.43%, SP2-
AB6 (5294) with a 45.66% inhibition, SP2-AB1 (5294) which resulted in a 40.96% inhibition 
and SP2-AB1 (Mann) with an inhibition of 40.76% (Table 3.11). However, none of these 
yielded a significant mean decrease in initial biofilm inhibition, and thus should not be used 
at concentrations below 10 mg/ml.  
No growth inhibition was observed as a result of any of the extracts unless indicated 
(Table 3.11), and 10% DMSO without bacterial extract actually resulted in an increase in initial 
biofilm formation (Supp. Fig. S3.7.1 and S3.7.2). Cinnamaldehyde resulted in an insignificant 
average effect on initial biofilm production due to the cell death observed at both 5 and 10 
mg/ml.  
 
3.3.10 Actinomycete extracts and P. aeruginosa mature biofilm formation 
The sponge-associated Actinomycete extracts were also screened at 0, 0.5, 1, 5 and 10 mg/ml 
for their effect on P. aeruginosa mature biofilm formation. Mature biofilm inhibition ranged 
from 5.82% to 53.16% with no killing being observed for any of the extracts (Supp. Fig. S3.7.3A 
and S3.7.4A). Overall three of the Actinomycete extracts resulted in an ≥40% reduction in 
initial biofilm formation, reaching a maximum inhibition of 53.16% (Table 3.12). Statistically, 
the sponge-associated Actinomycete extracts resulted in a significant overall decrease in P. 
aeruginosa mature biofilm formation (p < 0.01), as well as for all treatment concentrations (p 
< 0.01). Furthermore, when examining each concentration for the individual production 
media, the results were found to remain significant for both media (p < 0.01) (Table 3.12). In 
terms of the medium 5294 extracts, an average inhibition of 12.89% was achieved at 0.5 
mg/ml, 13.36% at 1 mg/ml, 14.41% at 5 mg/ml and 18.47% at 10 mg/ml. The mannitol extracts 
achieved an average inhibition of 16.32% at 0.5 mg/ml, 16.84% at 1 mg/ml, 16.51% at 5 mg/ml 
and 19.52% at 10 mg/ml. Due to the low mean inhibition range observed for both production 
media, a lower treatment concentration (such as 1 mg/ml) may be suggested without losing 
treatment efficacy, with mannitol being the production media of choice. 
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Table 3.12: Effect of sponge-associated Actinomycete extracts on mature biofilm formation 
by P. aeruginosa ATCC 27853. Both mannitol and medium 5294 extracts were tested at 0.5, 
1, 5 and 10 mg/ml and the percent mature biofilm reduction at each concentration 
determined 
* Values carry a significance of p < 0.05. 
** Values carry a significance of p < 0.01. 
$Swarming inhibition as a result of ≥40% growth inhibition, and therefore not regarded as QSI. 
 
In terms of the individual extracts, Streptomyces spp. extracts SP2-W3 (5294) and SP3-
AB22 (Mann) were the only extracts to yield a >50% mature biofilm inhibition, reaching 
maximum inhibitions of 53.16% at 10 mg/ml and 50.64% at 1 mg/ml, respectively. Although 
SP3-AB22 (Mann) yielded the lower inhibition of the two, due to the lower treatment 
concentration needed this extract may prove preferable in future treatment trials.  
No growth inhibition was observed as a result of any of the extracts, and 10% DMSO 
without bacterial extract was found to result in a significant mean decrease of 12% (p < 0.05) 
in mature biofilm formation (Supp. Fig. S3.7.3 and S3.7.4). As a result, those extracts yielding 
a lower (<12%) mature biofilm inhibition should be further tested to ensure that the 
inhibitions observed were not as result of the solvent used. Cinnamaldehyde resulted in a 
significant average decrease of 29.7% on mature biofilm production (p < 0.05), however, the 
cell death observed at 10 mg/ml as a result of this compound should be taken into account.  
 
3.3.11 Sponge-associated Actinomycete extracts as inhibitors of specific P. 
aeruginosa QS systems 
The P. aeruginosa QS network can be broken down into three distinct QS systems (excluding 
the newly integrated IQS network) (Rekha et al., 2016; Lee and Yoon, 2017). In order to see if 
 Percentage mature biofilm inhibition 
 0.5 mg/ml** 1 mg/ml** 5 mg/ml** 10 mg/ml** 
Extract code Mann** 5294** Mann** 5294** Mann** 5294** Mann** 5294** 
SP1-V4 11.35 38.01 11.38 38.66 12.75 37.55 17.80 36.28 
SP2-AB1 12.93 12.54 12.87 13.03 14.08 15.80 15.66 17.91 
SP2-AB2 37.49 12.57 37.59 14.05 38.49 14.90 39.16 15.56 
SP2-AB3 12.41 11.88 12.82 14.40 14.64 16.29 20.63 17.05 
SP2-AB6 11.23 12.14 11.40 11.47 11.68 12.73 45.89 17.50 
SP2-W3 12.71 11.66 13.21 11.44 14.07 15.14 15.94 53.16 
SP3-AB22 36.22 11.18 50.64 11.94 48.94 15.59 40.54 16.71 
SP4-AB2 31.65 12.69 18.49 13.22 11.48 14.24 9.75 14.58 
SP4-AB6 9.22 10.90 12.47 11.31 10.86 11.12 5.82 11.17 
SP6-AB5 10.77 13.30 11.02 12.64 11.11 10.85 11.14 10.47 
Cinnamaldehyde 38.85  38.55  45.39  46.43$  
10% DMSO 14.63  15.48  18.16  21.03  
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there was any correlation between the results obtained for certain extracts and the QS system 
inhibited, the best three inhibitors of each the virulence factors were grouped according to 
their QS control. Virulence factors primary under control of the rhl system are rhamnolipid 
production (Moradali et al., 2017) and, due to the influence of rhamnolipids on this process, 
mature biofilm formation (Moradali et al., 2017) while the las system mediates the 
production of elastase LasB and protease (Guendouze et al., 2017). Pyocyanin and pyoverdine 
production receive their influence primarily through the PQS system (Müller et al., 2015), 
although not exclusively, while the exact QS control mechanism in regard to swimming and 
swarming motility as well as initial biofilm formation remains to be fully elucidated, as they 
may be mediated by multiple QS systems simultaneously as well as outside factors such as 
cyclic-di-GMP (Moradali et al., 2017).  
In terms of the short chain rhl-AHL QS system, maximal inhibitions of between 62% 
and 82% were observed for rhamnolipid production while maximal inhibitions of between 
45% and 63% were observed for mature biofilm inhibition (Fig. 3.5).  
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Three of the best inhibitors of rhamnolipid and mature biofilm production which 
are primarily mediated through the short chain rhl system in P. aeruginosa. Streptomyces spp. 
extract SP2-AB6 (Mann) was identified as the lead inhibitor of rhamnolipid production 
(82.53%) while medium 5294 extract of the same isolate inhibited mature biofilm formation 
by >40%. SP2-W3 (5294) similarly inhibited both rhamnolipid production (62%) in addition to 
being the best inhibitor of mature biofilm formation (53.16%). Streptomyces spp. extracts 
SP6-AB5 (5294) and SP3-AB22 (Mann) were also amongst the top inhibitors of rhamnolipid 
production (67.31%) and mature biofilm production (50.64%), respectively.  
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Streptomyces spp. extract SP2-W3 (5294) exhibited both rhamnolipid inhibitory 
potential (62%) as well as the highest mature biofilm inhibition (53.16%), possibly due to its 
ability to inhibit rhamnolipid production. The medium 5294 extract of SP2-AB6 was the 
strongest inhibitor of rhamnolipid inhibition (82.53%) while the mannitol extract of the same 
isolate proved to be capable of mature biofilm inhibition (45.89%), indicating that this 
organism as a whole may be capable of short chain rhl inhibition. Similarly extract SP3-AB22 
(Mann) inhibited mature biofilm formation by 50.64%, which may be tied to its ability to 
inhibit rhamnolipid production by 53% at 1000 µg/ml (Supp. Fig. 3.5.8A). Although extract 
SP6-AB5 (5294) strongly inhibited rhamnolipid production, it was not a strong inhibitor of 
mature biofilm formation. This indicates that while these two virulence factors may often 
prove to be linked, this is not always the case. 
When examining the results for long-chain QSI of the las system, Streptomyces spp. 
SP4-AB2 immediately stands out as a strong inhibitor. The SP4-AB2 (Mann) extract was the 
best inhibitor of both elastase and protease production, resulting in inhibition of 61.77% and 
71.95%, respectively (Fig. 3.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Three of the best inhibitors of elastase and protease production, which are 
primarily mediated through the long chain las system in P. aeruginosa. Streptomyces spp. 
extract SP4-AB2 (Mann) was identified as the lead inhibitor of both elastase (61.77%) and 
protease (71.95%) production. The medium 5294 extract of the same isolate was further able 
to inhibit protease production by 69.76%. Both the mannitol and medium 5294 extracts from 
Streptomyces spp. SP3-AB22 were able to inhibit elastase production by 44.12% and 53.6%, 
respectively.  Streptomyces spp. extract SP2-AB6 (Mann) inhibited protease production by 
52.79%. 
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Additionally, the medium 5294 extract of the same isolate resulted in a 69.76% 
reduction in protease production. These results, paired with SP4-AB2 (Mann) being the 
strongest inhibitor of C. violaceum violacein production in the agar overlay well diffusion 
assay, suggests that this isolate should be investigated further for long chain QSI production. 
Making a reappearance was Streptomyces spp. SP3-AB22, which in addition to its 
rhamnolipid and mature biofilm inhibitory potential discussed above, resulted in elastase 
inhibition, with the mannitol extract inhibiting elastase production by 44.12% and the 
medium 5294 extract by 53.6%. Additionally, although not a top inhibitor, SP3-AB22 (5294) 
resulted in a 49% reduction in protease production at 500 µg/ml, highlighting this isolate’s 
potential as an inhibitor of both short and long chain AHLs. Similarly, SP2-AB6 (Mann) was 
one of the top inhibitors of mature biofilm formation, in addition to inhibiting protease 
production by 52.79%, suggesting a potential broad spectrum QSI ability of this organism.  
For the quinolone-based PQS system in P. aeruginosa, similar trends in inhibition were 
observed. Extract SP4-AB2 (Mann) was the top inhibitor of both elastase and protease 
production, as well as pyocyanin production (57.53%) (Fig. 3.7). This is in addition to short 
chain QSI by this organism, highlighting it definitively as one worthy of further QSI 
investigations.  
Pyocyanin inhibition by SP4-AB2 (Mann) was followed by that of SP4-AB6 (5294), 
which resulted in a decrease of 44.89%, and SP3-AB22 (Mann), with an inhibition of 41.05%. 
This extract had been observed to inhibit both long and short chain P. aeruginosa QS, 
suggesting that it may exhibit broad spectrum QSI abilities. Isolate SP1-V4 was the best 
inhibitor of pyoverdine production, with both the medium 5294 and mannitol extracts 
resulting in pyoverdine inhibition (36.31% and 37.43%, respectively). This extract was not a 
top inhibitor of any of the previously discussed virulence factors, suggesting its QSI potential 
may be specific to the PQS system. This was similarly true of SP2-AB3 (5294), which reduced 
pyoverdine production by 35.74%, but was not a top inhibitor of any of the other virulence 
factors.  
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Figure 3.7: Three of the best inhibitors of pyocyanin and pyoverdine production, which are 
primarily mediated through the quinolone-based PQS system in P. aeruginosa. Streptomyces 
spp. extract SP4-AB2 (Mann) was identified as the lead inhibitor of pyocyanin production 
(57.53%). The top inhibitor of pyoverdine production was SP1-V4, with SP1-V4 (5294) 
inhibiting pyoverdine production by 37.43% and SP1-V4 (Mann) by 36.31%. Rhodococcus 
fascians SP4-AB6 (5294) inhibited pyocyanin production by 44.89%, followed by SP3-AB22 
(5294) with an inhibition of 41.05%. Extract SP2-AB3 inhibited pyoverdine production by 
35.74%. 
 
While the QS systems primarily mediating many of the P. aeruginosa virulence factors 
are well understood, in some instances there are too many systems with influence over the 
production of a virulence factor for the correlations to be clear. Swimming and swarming 
motility as well as initial biofilm production are examples of such virulence factors (Fig. 3.8), 
although the PQS system has been putatively suggested to play a role in initial biofilm 
formation (Boopathi et al., 2017).  
Although unelucidated, it can be said that swimming and swarming motility are clearly 
linked, as the same three extracts were the top inhibitors of both virulence factors. 
Rhodococcus fascians extract SP4-AB6 (5294) was the best inhibitor of swimming motility, 
with an inhibition of 55.77%, in addition to inhibiting swarming motility by 58.23%. This 
extract also showed a pyocyanin inhibition of 44.89%, indicating pyocyanin and motility may 
be linked in terms of QS control. This was further suggested as isolate SP3-AB22 produced 
extracts capable of both swimming and swarming inhibition (Fig. 3.8) as well as a pyocyanin 
inhibition of 41.05%. This isolate showed potential in all four QS categories, and so should 
undoubtedly be studied further. SP1-V4 (Mann) inhibited both swimming (51.07%) and 
swarming (67.09%), as well as pyoverdine production. This indicated the link may not be 
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between swimming and pyocyanin production but rather between motility and the PQS 
system. 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: The mediation of swimming and swarming motility as well as initial biofilm 
formation are closely intertwined, however, the exact QS influence of these three virulence 
factors is not yet completely understood. They are either not known or highly variable. Here 
the best three inhibitors each of swimming, swarming and initial biofilm production are 
indicated. Rhodococcus fascians extract SP4-AB6 (5294) was the best inhibitor of swimming 
motility (55.77%) as well as inhibiting swarming motility (58.23%). Streptomyces spp. extract 
SP3-AB22 additionally showed motility-inhibitory potential, with SP3-AB22 (5294) inhibiting 
swimming (55.76%) and SP3-AB22 (Mann) inhibiting swarming (53.16%). Extract SP1-V4 
(Mann) showed similar motility inhibition, inhibiting swimming by 51.07% and swarming by 
67.09%. The inhibitors of initial biofilm formation were SP6-AB5 (5294), Sp2-AB6 (5294) and 
SP2-AB1 (5294), resulting in inhibitions of 55.43%, 45.66% and 40.96%, respectively. 
 
In terms of initial biofilm inhibition, SP6-AB5 (5294) resulted in the highest reduction 
of initial biofilm formation (55.43%). This extract also showed rhamnolipid-inhibitory 
potential. This was similar to SP2-AB6 (5294), which inhibited initial biofilm production 
(45.66%) as well as rhamnolipid production, while the mannitol extract of this isolate inhibited 
mature biofilm formation. These results indicate that there may be a link between the P. 
aeruginosa rhl QS system and initial biofilm production. 
 
3.4 Discussion 
Amidst a rising increase in antibiotic resistance, marine sponges and their associated bacteria 
have arisen as one of the major sources of novel bioactive metabolites (Gutiérrez-
Barranquero et al., 2018).  Following previous primary screening and identification, 20 
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extracts from sponge-associated Actinomycetes were tested as potential P. aeruginosa QSI 
agents. The large number of positive QSI Actinomycete isolates was in contrast to Hassan et 
al. (2016) who, upon screening 65 soil Streptomyces spp. isolates only identified three with 
positive QSI against C. violaceum 12472, or Miao et al. (2017) who observed that only five of 
their 56 marine Actinomycetes yielded positive QSI activity against the same organism. 
Similarly, Devaraj et al. (2017) observed that only eight of their 147 tropical soil-derived 
Actinomycetes exhibited QSI activity against C. violaceum CV026. This highlights the potential 
of Actinomycete strains isolated from sponges in comparison to those of terrestrial origin. 
In order to ensure that none of the QSI positive sponge-associated Actinomycete 
extracts were bactericidal against P. aeruginosa, antimicrobial testing was done using the agar 
well diffusion method. Extracts were tested at 5 and 10 mg, with no antimicrobial activity 
being observed for any of the Actinomycete extracts. This was done to ensure that none of 
the QSI results observed in the upcoming assays would be as a result of cell death, as well as 
to ensure that the extracts would not induce resistance in the cells as a result of metabolic 
stress. Although this was confirmed through the antimicrobial assay, growth readings (OD600 
nm) were taken for each P. aeruginosa assay in order to continuously monitor the effects of 
the extracts on cell growth. 
 The first virulence factor against which the extracts were screened was the production 
of the blue phenazine pigment, pyocyanin. This redox-active pigment is required for full P. 
aeruginosa virulence, as it generates reactive oxygen species thereby interfering with 
eukaryotic cell functions (Müller et al., 2015; Devaraj et al., 2017). Pyocyanin inhibition was 
screened in conjunction with the production of the siderophore pyoverdine. Both of these 
virulence factors are mediated by multiple QS systems, including the PQS and rhl QS networks. 
Even with the complexity of the systems governing production, 100% (20/20) of the sponge-
associated Actinomycete extracts were able to inhibit pyocyanin production to varying 
degrees. Of these, however, only 13 (65%) resulted in pyocyanin production of >30%, with 
only one extract reaching an inhibition of 50%. These results were comparable to those of 
Naik et al. (2013) who observed pyocyanin inhibition of 34-45% following treatment with 0.1 
mg/ml sponge-associated Streptomyces spp. extracts, while being only moderately lower 
than those of Saurav et al. (2016) who, upon testing Mediterranean sponge-associated 
bacterial extracts, observed a 94% frequency (16/17 extracts) of positive results. At 1 mg/ml 
of butanone extract, Saurav et al. (2016) found six extracts capable of >70% pyocyanin 
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inhibition, whereas the maximal inhibition observed for the Actinomycete extracts was 
57.53%, also at 1 mg/ml. This treatment concentration proved to yield the highest significant 
mean pyocyanin inhibition when using the sponge-associated Actinomycete extracts, with the 
results obtained by Saurav et al. (2016) confirming the efficacy of crude sponge-associated 
extracts at this concentration. Similarly, although a treatment concentration was not 
specified, Gutiérrez-Barranquero et al. (2018) also observed that 22% (4/18) of their sponge-
associated bacterial extracts were capable of a >50% pyocyanin reduction, highlighting the 
QSI potential of sponge-associated bacterial extracts.   
 The strongest inhibitor of pyocyanin production was the mannitol extract of 
Streptomyces spp. SP4-AB2, resulting in a 57.53% inhibition at 1 mg/ml of extract. These 
results were superior to those of the R. erythropolis PQS dioxygenase AqdC1, which achieved 
an inhibition of only 28% (Müller et al., 2015). Methanolic extracts from a marine sponge 
Ochridaspongia rotunda (Pejin et al., 2014), which resulted in a 49.90% pyocyanin reduction, 
and acetone extracts of the same sponge which resulted in a 42.44% pyocyanin reduction 
were similar to the results obtained in the present study. Streptomyces spp. extract SP4-AB2 
(Mann) was followed by SP4-AB6 (5294) with an inhibition of 44.89% and SP3-AB22 (Mann) 
with an inhibition of 41.05%, each at 1000 µg/ml, suggesting that this may be proposed as an 
ideal treatment concentration when subjecting P. aeruginosa to extracts which have yet to 
be purified, although purified compounds such as enzymes and flavonoids in various studies 
(Rekha et al., 2016; Guendouze et al., 2017) have been used effectively to completely 
eradicate pyocyanin production at half this concentration.  
Guendouze et al. (2017) achieved >50% pyocyanin inhibition in 77% of Pseudomonas 
strains using an engineered lactonase enzyme. As pyocyanin is mediated via the PQS system, 
it is likely that there may be PQS-degrading oxidoreductase activity in some of the extracts in 
need of purification. Two PQS dioxygenases, AqdC1 and AqdC2, are produced by R. 
erythropolis (Müller et al., 2015). Isolate SP4-AB6, identified as R. fascians, and its medium 
5294 extract proved to be the second strongest inhibitor of pyocyanin production (44.89% 
inhibition). It is possible that this activity was a result of the production of a PQS-degrading 
enzyme, and requires further investigation. 
Extracts from the present study, similar to those of Guendouze et al. (2017) and the 
enzymes used by Müller et al. (2015) resulted in no significant P. aeruginosa cell death. In 
terms of production media used, mannitol and medium 5294 resulted in inhibition of equal 
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significance (p < 0.01 at 1000 µg/ml). However, as mannitol yielded an overall higher mean 
inhibition at 1000 µg/ml (32.63%), this may be selected as the ideal production medium for 
pyocyanin inhibition. It was not possible to compare this to literature as no studies could be 
found which utilized either of these production media. Results in this study were an 
improvement, however, on those obtained by Devaraj et al. (2017). They observed that while 
their soil-derived Actinomycete extracts were capable of P. aeruginosa PAO1 pyocyanin 
inhibition, all of the inhibitions observed were statistically insignificant. This highlights the 
potential of marine Actinomycete strains in comparison to their terrestrial counterparts. 
Pyoverdine is the primary P. aeruginosa siderophore, both in obtaining iron for the 
bacterial cells and up-regulating the production of exotoxin A and endoprotease (Gellatly and 
Robert, 2013; Müller et al., 2015). Pyoverdine inhibition was tested in conjunction with 
pyocyanin inhibition, utilizing the known QS inhibitor cinnamaldehyde as a positive control. A 
significant mean decrease in pyoverdine production was achieved (p < 0.01) following 
treatment with the sponge-associated Actinomycete extracts. Most isolates (19/20) inhibited 
pyoverdine to some extent, while 50% of the isolates inhibited pyoverdine production by 
>30%. This result was slightly lower than that of pyocyanin, where 65% of extracts resulted in 
inhibition of >30%. This could be explained as, although the production of both virulence 
factors is primarily through the PQS and rhl systems, iron levels and the efficacy of iron 
sequestration result in the las system being bypassed in favour of the rhl system (Guendouze 
et al., 2017). The las QS system the reactivates the PQS system, which could explain the lower 
inhibition values as any inhibition in iron sequestration, including the inhibition in siderophore 
production, would have this effect.  
 The two greatest inhibitors of pyoverdine production were the medium 5294 and 
mannitol extracts of SP1-V4, which resulted in 37.43% pyoverdine inhibition at 1000 µg/ml 
and 36.31% pyoverdine inhibition at 500 µg/ml respectively. These results were lower than 
those of Chang et al. (2017), who observed a pyoverdine inhibition of 55.7% with marine 
Rhizobium extracts. However, the concentration of the extracts could not be compared as 
Chang et al. (2017) presented their values as volume of bacterial supernatant without 
quantifying the weight of the extract. The extracts tested did compare to those of Müller et 
al. (2015) who demonstrated an inhibition of 41% following 24 h treatment of P. aeruginosa 
with Rhodococcus PQS dioxygenase AqdC2. Overall, however, very few previously published 
studies which have examined the effect of QSI agents on P. aeruginosa have included 
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pyoverdine as a virulence factor, possibly as the effect of a pyoverdine deficiency on virulence 
is less than that of other virulence factors such as pyocyanin (Granato et al., 2016). 
Furthermore, in terms of patients chronically infected with cystic fibrosis, pyoverdine 
production within the airways is often down-regulated (Granato et al., 2016), and so studies 
on other virulence factors are favoured.  Due to the mean inhibition and significance of results 
for each concentration tested, mannitol medium at 1000 µg/ml of extract was determined to 
be the most efficient for pyoverdine production.  
The las QS system of P. aeruginosa is the primary mediator of elastase production 
within this organism (Bandara et al., 2012). Elastase LasB is the most studied P. aeruginosa 
elastase and results in host tissue damage through the degradation of immunoglobulins, 
cytokines and elastin (Müller et al., 2015). Overall, 70% (14/20) of the sponge-associated 
Actinomycete extracts resulted in elastase inhibition of >30% (p < 0.01). Three of these 
extracts further resulted in >50% elastase inhibition. Even though two of these were medium 
5294-derived, due to the total mean inhibition and significance of results observed for each 
media, mannitol was determined as the ideal production medium for elastase inhibition, with 
the ideal treatment concentration being 1000 µg/ml.  
The greatest inhibitor of elastase production was SP4-AB2 (Mann), inhibiting elastase 
production by 61.77% at 1000 µg/ml. This extract was also the strongest inhibitor of 
pyocyanin production, as well as a strong inhibitor of pyoverdine production. This suggests 
that Streptomyces spp. SP4-AB2 may be a QSI isolate worthy of further study. This result was 
only slightly below that of Chang et al. (2017), who observed a 77.9% elastase inhibition 
following treatment of P. aeruginosa with a 5% aqueous Rhizobium extract. Extract SP4-AB2 
(Mann) was followed by SP3-AB22 (5294) and SP3-AB22 (Mann) which resulted in LasB 
inhibitions of 53.6% and 44.12%, respectively. Each of these was an improvement on the 
results obtained by Singh et al. (2017), who achieved a maximal elastase inhibition of 35% 
when 0.1 mg/ml of marine extract was used. However, as this was the only concentration 
tested it was not possible to determine if Singh et al. (2017) would have obtained results 
similar to those in the present study at a higher concentration.  
Although achieving a 35% reduction in elastase production, Müller et al. (2015) 
observed that this effect of their Rhodococcus dioxygenase enzyme was only sustainable for 
8 h, after which elastase production was restored. This may be a result of the dioxygenase 
primarily targeting the PQS system, whilst elastase is mediated through the las QS system. 
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The extracts tested here may have presented a sustained inhibition as Actinomycetes are 
known producers of acylase enzymes, which target long chain QS systems (Fetzner, 2015). 
Streptomyces strain M664 was found to produce such an acylase, resulting in a 43% reduction 
in P. aeruginosa elastase production (Chang et al., 2017), which closely mirrored the results 
of this study.  
Highlighting the importance of purifying the key active components within the crude 
extracts, our results at 1 mg/ml of extract were much lower than those of Rekha et al. (2016) 
who achieved a 90% reduction in elastase production using only 0.2 mg/ml of their plant-
derived flavonoid or Hassan et al. (2016) who observed a 96% and 91.8% decrease in elastase 
production following treatment with soil-derived actinomycete compound 1H-pyrrole-2-
carboxylic acid and docosanoic acid, respectively. It was unsurprising, however, that 95% of 
the extracts should show an inhibition in LasB production, even if these results were lower 
than that of purified compounds. Isolate selection for extraction was biased towards potential 
inhibitors of long chain AHLs, and the success of the extracts in terms of LasB inhibition only 
served to validate the results obtained in the initial, pre-screening stage of the study. 
Similar to elastase production, protease production is mediated via the long chain QS 
system.  Utilizing the qualitative casein agar diffusion assay, 19 extracts yielded definitive 
protease activity. Using a similar assay, Saurav et al. (2016) observed a maximal decrease from 
casein hydrolysis from 20 mm to 15 mm when using sponge-associated bacterial isolates. 
Using the maximal concentration tested (1000 µg/ml), we observed similar results for most 
isolates, with zones decreasing from approximately 25 mm to between 11 mm and 19 mm 
(Supp. Table S3.4.1).   
Eighteen of the positive isolates in the qualitative assay were confirmed via the 
azocasein quantitative assay, in addition to SP2-AB6 (5294) which failed to give positive 
results during the qualitative assay. This extract may not have exhibited initial activity as a 
result of a lack of diffusion of the extract through the media, possibly due to particulates 
present in the extract, and highlights the need for validation of qualitative results with 
quantitative methods. Nineteen out of 20 sponge-associated Actinomycete extracts were, 
therefore, confirmed to exhibit protease inhibitory potential. This was similar to results 
observed by Guendouze et al. (2017) who, using their purified lactonase enzyme at 0.5 mg/ml, 
observed inhibition of protease in 93% (26/28) of Pseudomonas strains. While Actinomycetes 
isolates are known producers of acylase enzymes, various Streptomyces and Rhodococcus 
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spp. strains have been shown to produce lactonase enzymes (Banerjee and Ray, 2016), 
making the results in the present study comparable to these.  
The three best inhibitors of protease production were SP4-AB2 (Mann), SP4-AB2 
(5294) and SP2-AB6 (Mann), which resulted in protease inhibition of 71.95%, 69.76% and 
52.79%, respectively. The latter was similar to the results obtained following treatment of P. 
aeruginosa with an AHL-acylase produced by Streptomyces spp. M664, which resulted in a 
total protease reduction of 60% (Chang et al., 2017). Similarly, although not yet purified, the 
inhibition exerted by SP4-AB2 (Mann) equalled that of the purified soil-derived Streptomycete 
metabolite 1H-pyrrole-2-carboxylic acid, which resulted in a 74% protease inhibition (Hassan 
et al., 2016). Furthermore, the inhibitory effects of all three of the best sponge-associated 
Actinomycete extracts surpassed that of purified, soil-derived docosanoic acid, which resulted 
in a 46.1% decrease in protease production (Hassan et al., 2016). Protease inhibition in the 
present study failed to compare with those obtained with purified lactonase (Guendouze et 
al., 2017) where a maximum protease inhibition of 90 and 57% was obtained when tested at 
0.5 mg/ml against P. aeruginosa PAO1 and PA14, respectively. This indicates that purification 
of the extracts, and any QSI enzymes specifically, may improve the inhibitory potential. It also 
indicates that the test strain of Pseudomonas also plays a role, making truly accurate inter-
study comparisons a challenge as the susceptibility and virulence profiles of various P. 
aeruginosa strains differs considerably.   
The rhl QS system was named for its regulation of rhamnolipid production in P. 
aeruginosa cells as it is the major contributor to this process (Bandara et al., 2012; Welsh and 
Blackwell, 2016). Rhamnolipids are key for swarming motility as well as biofilm formation in 
P. aeruginosa (Lee and Yoon, 2017). Furthermore, rhamnolipids enhance the solubility of PQS 
while inhibiting normal tracheal ciliary function (Müller et al., 2015). Using the qualitative 
CTAB agar assay, a preliminary 100% of extracts (20/20) exhibited inhibitions in rhamnolipid 
production. Fourteen of these were confirmed using the quantitative orcinol assay as being 
capable of >20% rhamnolipid inhibition. Inconsistencies between the qualitative and 
quantitative assays could be ascribed to the large volume of treated culture spotted onto the 
CTAB plates; as 0.2 ml of liquid was spotted and the plates then transferred to incubation, the 
cultures often did not maintain their shape and this spreading of the culture made the results 
more difficult to accurately interpret in comparison to those of the spectrophotometric 
163 
 
orcinol assay. In both assays, however, growth readings remained constant and no substantial 
inhibition in growth were observed. 
Six of the positive extracts further inhibited rhamnolipid production by >50%. The 
ability of sponge-associated bacteria to inhibit short chain AHLs had been shown earlier as 
88% of isolates tested had successfully inhibited violacein production by C. violaceum CV026. 
In general, short chain AHLs are more prone to degradation, especially by enzymes such as 
lactonases which Actinomycetes such as Streptomyces spp. and Rhodococcus have been 
shown to produce (Banerjee and Ray, 2016), although not to the extent of Bacillus.  Therefore, 
as rhamnolipid is regulated primarily by the rhl QS system, it was expected that many extracts 
should yield strong inhibition and the orcinol assay data served to validate these expectations.  
The strongest inhibitors of rhamnolipid production were SP2-AB6 (5294), SP6-AB5 
(5294) and SP2-W3 (5294) which resulted in rhamnolipid inhibition of 82.53%, 67.31% and 
62%, respectively. This range of positive results was in alignment with those achieved by Naik 
et al. (2013) who observed 47-71% rhamnolipid inhibition following treatment with sponge-
derived Streptomyces spp. extracts. Furthermore, the results of extracts SP6-AB5 (5294) and 
SP2-W3 (5294) specifically were similar to those obtained by Müller et al. (2015), who 
observed a 65% decrease in rhamnolipid production 24 h after treatment of P. aeruginosa 
with Rhodococcus-produced dioxygenase AqdC1. The inhibition observed as a result of extract 
SP2-AB6 (5294) was more similar to those obtained by Singh et al. (2017), who obtained a 
rhamnolipid inhibition of 85% following treatment of the P. aeruginosa cells with 0.1 mg/ml 
of their marine-derived bacterial extract. The similarity of these results, although at varying 
concentrations, once again highlights the strong QSI potential of marine bacterial extracts.  
Mannitol was identified as the more suitable medium for rhamnolipid inhibition, due 
to the higher significance of the mean inhibitory results. Furanone, used as a positive control, 
had an insignificant effect on rhamnolipid production (p > 0.05). Even though positive results 
were obtained using furanone, with no significant cell death, application of this compound is 
restricted due to high cytotoxicity at treatment concentrations required in vivo (Castillo-
Juarez et al., 2017), once again highlighting the need for novel, non-toxic QSI compounds.  
The motility of P. aeruginosa cells is vital for bacterial invasion and biofilm formation 
(Singh et al., 2017), with motile phenotypes being attributed to increased virulence within the 
host (Moradali et al., 2017). Furthermore, reductions in motility often lead to decreases in 
other phenotypic behaviour and bacterial virulence towards the host (Kazmierczak et al., 
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2015). While P. aeruginosa exhibits multiple forms of motility (including swimming, swarming 
and twitching) swimming and swarming motility were determined to be the ideal forms of 
motility to use as references for QSI activity as these methods are used during key cellular 
processes such as host colonization and biofilm formation (Singh et al., 2017).  
A total of 80% of the extracts (16/20) showed a >30% inhibition in swimming motility, 
with three extracts exceeding 50%. This was similar to the extracts’ effect on swarming 
motility, where 50% (10/20) of extracts were capable of >30% swarming inhibition, with three 
of these exceeding 50%, suggesting a correlation between the QS systems mediating each 
form of motility.  This was further emphasized as extracts from the same three isolates proved 
to be the best inhibitors of both swimming and swarming motility. The swarm measurements 
in particular were comparable to those of Rekha et al. (2016) who observed a reduction in 
swarming motility from 64 mm (untreated) to 12 mm (81.25%), similar to the reduction from 
39.5 mm to 13 mm (67.09%) observed after treatment using SP1-V4 (Mann). Rekha et al. 
(2016) failed, however, to test the sustainability of their results, whereas those of SP2-AB7 
(Mann) were maintained for the full 72 h. Our results were further comparable to those of 
Naik et al. (2013) who observed all three sponge-associated bacterial extracts tested to inhibit 
swarming motility by ≥65%. While extracts from R. fascians SP4-AB6 proved to be amongst 
the strongest inhibitors of swimming and swarming motility, Devaraj et al. (2017) found that 
although their tropical soil-derived Rhodococcus sp. H54 extract exhibited strong QSI 
potential against many P. aeruginosa PAO1 virulence factors, it had no noticeable effect on 
motility.  
However, swimming and swarming motility have yet to be conclusively associated 
with a particular QS system in P. aeruginosa, with multiple external factors coming into play 
such as pili formation and rhamnolipid production (Steindler et al. 2009; Lee and Yoon, 2017). 
This in conjunction with the sensitivity of the swarming assay to environmental conditions 
such as miniscule variations in liquids on the surface of the agar plates as well as the humidity 
of the laboratory environment (Morales-Soto et al., 2015), resulted in only a few instances 
where the swarming results were quantitatively reproducible. This meant that while the 
extracts resulted in significant overall swarming inhibition at each treatment concentration, 
in terms of individual production media significant inhibition in swarming motility was seen 
only at 250 µg/ml for the medium 5294 extracts and at ≥500 µg/ml for the mannitol extracts.  
The results for swimming inhibition, in contrast, were both more reproducible and were 
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observed to be significant both overall and at each individual treatment concentration for 
both production media (p < 0.01). While no definitive conclusion could be made regarding the 
ideal production for inhibition of swimming motility, it was determined that the use of 
mannitol was more effective for the inhibition of swarming motility. Due to the variability of 
the swarming assay and lack of reproducibility, it may be preferable to regard this assay as 
qualitative rather than quantitative. Singh et al. (2017) took a similar approach, presenting 
the inhibition of P. aeruginosa PAH and PAO1 swimming and swarming motility observed after 
treatment with their bacterial extract as qualitative in comparison to an untreated control, 
instead of reporting quantitative colony measurements. 
The ability of a bacterial isolate to form a robust biofilm structure is often related to 
the secretion of a number of other virulence factors, such as rhamnolipids and motility.  
Pseudomonas aeruginosa biofilms are commonly observed on medical devices, putting 
patients at risk of systemic infections (Lee and Yoon, 2017). Currently the only treatment for 
device-associated biofilms is to remove and replace the medical device (Lee and Yoon, 2017). 
Biofilm formation P. aeruginosa is a highly complex process, involving multiple variables such 
as virulence factor production, motility, EPS production as well as small molecule signals and 
sRNAs (Kim and Lee, 2016; Moradali et al., 2017). Due to the robustness of biofilm life, with 
cells being ×1000 more resistant to any sort of chemical treatment than when in planktonic 
form (Lee and Yoon, 2017), higher concentrations of extracts were tested than with the 
previous assays (0, 0.5, 1, 5 and 10 mg/ml).  
When screened against initial biofilm production, 20% (4/20) of the Actinomycete 
extracts resulted in an ≥40% reduction in initial biofilm formation, with only one of these 
further resulting in a >50% inhibition without causing cell death. This was similar to the results 
observed by Otton et al. (2017), who observed a decrease in initial biofilm formation in 30% 
of the isolates tested, following exposure to QSI compound furanone. The best sponge-
associated Actinomycete inhibitor of initial biofilm formation was SP6-AB5 (5294), which 
resulted in a 55.43% reduction in initial biofilm formation at 10 mg/ml. This was similar to 
results obtained by Pejin et al. (2014) who observed a 54% decrease in initial biofilm 
formation after treatment of P. aeruginosa with 15 µg/ml of a sponge-derived extract, a 
concentration much lower than our own. The MIC of this extract, however, was determined 
to be 30 µg/ml. This suggests that while more concentrated, this extract may be cytotoxic 
when administered in a clinical dose whereas none of the sponge-associated bacterial 
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extracts exhibited cytotoxicity during antimicrobial screening. Our initial biofilm result was 
more similar then to those obtained by Miao et al. (2017) who observed a maximal initial 
biofilm inhibition of <50% following treatment with an ethyl acetate Streptomyces parvulus 
extract.  
When compared further to the 88.1% (37/42) positive biofilm-inhibitory results 
obtained by Guendouze et al. (2017) following exposure to a purified lactonase enzyme, the 
sponge-associated Actinomycete extracts were found to perform less effectively. This lower 
degree of initial biofilm inhibition by the sponge-associated bacterial extracts could be as a 
result of the high levels of rhamnolipid inhibition exhibited by the extracts, as rhamnolipid 
inhibition before biofilms have reached maturation has been linked with increased initial 
biofilm formation (Kim and Lee, 2016). Although Guendouze et al. (2017) showed higher 
inhibition of initial biofilm formation (90% for P. aeruginosa PAO1 and 60% for PA14), these 
results cannot be accurately compared with those obtained in the present study as they used 
a purified lactonase enzyme, incubated their biofilms for 48 h (compared to our 24 h 
incubation) and employed biofilm weight measurements to calculate inhibition as opposed 
to the staining and absorbance readings performed in this assay. Their results do serve to 
highlight the efficacy of enzymatic QSI agents however, and this should be explored further 
when the sponge-associated bacterial extracts are purified in the future.  
Mature biofilms often prove more difficult to inhibit than initial attachment, due to 
the additional time they are afforded to build their EPS structures (Kim and Lee, 2016). All of 
the extracts were able to inhibit mature biofilm formation to some extent (p < 0.01), with all 
treatment concentrations, for both production media, resulting in a significant mean mature 
biofilm inhibition (p < 0.01).  Furthermore, three extracts were capable of >40% mature 
biofilm inhibition. Although no comparable studies were found in literature (i.e. those looking 
at the effect of QSI compounds on mature biofilm formation), this was a promising result as 
patients presenting with CF often possess mature bacterial biofilms as early as age 3 (Moradali 
et al., 2017). Due to the mean inhibition observed, mannitol was the more effective of the 
two production media for mature biofilm formation inhibition.  
During the formation of the mature biofilm structure, rhamnolipids are key in allowing 
motile cells to reach the centre of the biofilm (Lee and Yoon, 2017) such that the mature 
structure may be stable and that, when ideal, the cells may disperse to form new biofilms 
(Kim and Lee, 2016). Therefore, rhamnolipid inhibition is a great hindrance to the formation 
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of mature biofilms, with rhl-deficient mutants forming thinner biofilms and being more 
susceptible to antibiotic treatment (Moradali et al., 2017). This was seen in the present study, 
as two of the best inhibitors of rhamnolipid production were additionally two of the best 
inhibitors of mature biofilm formation. Extract SP2-W3 (5294) resulted in both a 62% 
rhamnolipid inhibition as well as a 53.16% reduction in mature biofilm formation. Similarly, 
extract SP2-AB6 (5294) resulted in an 82.53% reduction in rhamnolipid production, while the 
mannitol extract of the same organism resulted in 45.89% reduction in mature biofilm 
formation. In addition, extract SP3-AB22 (5294) and SP3-AB22 (Mann) both exhibited motility 
inhibition, while SP3-AB22 (Mann) resulted in a 50.64% mature biofilm inhibition. This could 
be explained as pathogenic microorganisms such as P. aeruginosa have been shown to switch 
from a planktonic to biofilm lifestyle as a means of avoiding stressors and adverse conditions 
(Moradali et al., 2017). Interestingly, one of the top inhibitors of rhamnolipid production, SP6-
AB5 (5294) which resulted in a 67.31% rhamnolipid inhibition, was only able to inhibit mature 
biofilm formation by 13%. However, this was thought to be as a result of the myriad of factors 
involved in the formation of mature biofilms, as stated earlier. For example, this extract did 
not exhibit strong protease inhibition. As a result, cells may use protease to release nutrients 
as well as eDNA into the biofilm, thereby bolstering the strength of the mature biofilm 
structure (Kim and Lee, 2016). It has also been proposed, however, that biofilm formation 
may rely less on QS than initially thought, and that the role of QS on this process could be 
influenced by environmental sources such as carbon source (Otton et al., 2017). This will need 
to be investigated further in future.  
Although the active compounds within the extracts have yet to be purified, 
speculations can be made regarding their mode of action based off similar studies. For 
instance, Streptomyces spp. M664 was shown to produce an AHL-degrading acylase which 
resulted in P. aeruginosa elastase and protease inhibition (Musthafa et al., 2011). 
Rhodococcus erythropolis and Rhodococcus sp. strain W2 have also been shown to produce 
both lactonase and acylase enzymes (Devaraj et al., 2017). As many of the extracts showed 
similar activity, including R. fascians SP4-AB6, it is possible that the QSI activity observed may 
be enzymatic.  
Actinomycetes have been shown to produce many non-enzymatic compounds 
capable of P. aeruginosa quorum-sensing inhibition (Gutiérrez-Barranquero et al., 2018). 
Rhodococcus fascians was shown to produce QSI streptomycin (Boopathi et al., 2017), it is 
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possible that QSI activity observed using SP4-AB6 extracts may be as a result of streptomycin 
production or other small molecules present. Antimicrobial proteins have also exhibited 
extensive QSI capabilities, especially anti-biofilm activities as a result of rhamnolipid inhibition 
and the binding of eDNA (Algburi et al., 2017). Extracts such as SP2-W3 (5294) which exhibited 
both rhamnolipid-inhibitory as well as anti-biofilm activity may have done so as a result of the 
production of antimicrobial proteins. Many Actinomycetes have also been shown to produce 
actinomycin D (Miao et al., 2017). Initially identified from a Streptomyces isolate in 1940, the 
QSI activity of this metabolite had been neglected until recently and has since been shown to 
be effective against P. aeruginosa (Miao et al., 2017). Similarly, Streptomyces-produced 
tobramycin was also shown to inhibit P. aeruginosa pyocyanin production and swarming 
motility (Devaraj et al., 2017), suggesting that the sponge-associated bacterial activity 
observed in this study may be as a result of low concentrations of Streptomyces-derived 
antimicrobial compounds.  
Given the importance of QS in mediating P. aeruginosa virulence, QSI has been 
proposed as a suitable alternative to antimicrobial therapies (Musthafa et al., 2011; Miao et 
al., 2017; Gutiérrez-Barranquero et al., 2017). The sponge-associated Actinomycete extracts 
tested in this study have shown immense promise as quorum-sensing inhibitors, and as such 
should be studied further to identify the active agents as well as to determine their future 
clinical potential.  
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CHAPTER 3 
SUPPLEMENTARY INFORMATION 
 
S3.1 Selected sponge-associated Actinomycete isolates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.1.1: Growth of selected Actinomycete isolates on GYM medium. Designated codes, from left to right, are: SP1-V4, SP2-AB1, SP2-AB2, 
SP2-AB3, SP2-AB6 (top row) and SP2-W3, SP3-AB22, SP4-AB2, SP4-AB6, SP5-AB6 (bottom row). 
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S3.2 Pyocyanin, pyoverdine and growth inhibitions following treatment with sponge-associated Actinomycete extracts 
 
 
 
 
 
 
 
 
Figure S3.2.1: Inhibition of pyocyanin and pyoverdine using cinnamaldehyde and 10% DMSO. Positive control cinnamaldehyde (A) resulted in 
≥40% growth inhibition from 750 µg/ml, contributing to the decrease in pyocyanin production and is not indicative of QSI. A steep increase in 
pyoverdine was also observed. Solvent 10% DMSO (B) had a negligible effect on cell growth, as well as pyocyanin and pyoverdine production (p 
> 0.05). Data reflects average results ±SD following experiments in triplicate on three separate occasions.  
 
 
 
 
 
 
 
Figure S3.2.2: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP1-V4 extracts on 
growth, pyocyanin and pyoverdine production. (A) SP1-V4 (Mann) and (B) SP1-V4 (5294). Data reflects average results ±SD following experiments 
in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.2.3: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB1 extracts 
on growth, pyocyanin and pyoverdine production. (A) SP2-AB1 (Mann) and (B) SP2-AB1 (5294). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.2.4: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB2 extracts 
on growth, pyocyanin and pyoverdine production. (A) SP2-AB2 (Mann) and (B) SP2-AB2 (5294). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
A B 
A B 
176 
 
 
 
 
 
 
 
 
 
 
Figure S3.2.5: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB3 extracts 
on growth, pyocyanin and pyoverdine production. (A) SP2-AB3 (Mann) and (B) SP2-AB3 (5294). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.2.6: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB6 extracts 
on growth, pyocyanin and pyoverdine production. (A) SP2-AB6 (Mann) and (B) SP2-AB6 (5294). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.2.7: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-W3 extracts 
on growth, pyocyanin and pyoverdine production. (A) SP2-W3 (Mann) and (B) SP2-W3 (5294). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.2.8: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP3-AB22 extracts 
on growth, pyocyanin and pyoverdine production. (A) SP3-AB22 (Mann) and (B) SP3-AB22 (5294). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.2.9: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP4-AB2 extracts 
on growth, pyocyanin and pyoverdine production. (A) SP4-AB2 (Mann) and (B) SP4-AB2 (5294). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.2.10: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Rhodococcus fascians SP4-AB6 
extracts on growth, pyocyanin and pyoverdine production. (A) SP4-AB6 (Mann) and (B) SP4-AB6 (5294). Data reflects average results ±SD 
following experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.2.11: Inhibition of pyocyanin and pyoverdine using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP6-AB5 extracts 
on growth, pyocyanin and pyoverdine production. (A) SP6-AB5 (Mann) and (B) SP6-AB5 (5294). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. Growth inhibition for both extracts was ≤40%. 
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S3.3 Elastase and growth inhibitions following treatment with sponge-associated Actinomycete extracts 
 
 
 
 
 
 
 
 
Figure S3.3.1: Inhibition of elastase LasB using cinnamaldehyde and 10% DMSO. Positive control cinnamaldehyde (A) resulted in ≥40% growth 
inhibition from 750 µg/ml, contributing to the decrease in elastase production and is not indicative of QSI.  Solvent 10% DMSO (B) resulted in an 
increase in cell growth but had a negligible effect on elastase production (p > 0.05). Data reflects average results ±SD following experiments in 
triplicate on three separate occasions. 
 
 
 
 
 
 
 
Figure S3.3.2: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP1-V4 extracts on growth and 
elastase production. (A) SP1-V4 (Mann) and (B) SP1-V4 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.3.3: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp.SP2-AB1 extracts on growth and 
elastase production. (A) SP2-AB1 (Mann) and (B) SP2-AB1 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.3.4: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB2 extracts on growth and 
elastase production. (A) SP2-AB2 (Mann) and (B) SP2-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.3.5: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB3 extracts on growth and 
elastase production. (A) SP2-AB3 (Mann) and (B) SP2-AB3 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.3.6: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB6 extracts on growth and 
elastase production. (A) SP2-AB6 (Mann) and (B) SP2-AB6 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.3.7: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-W3 extracts on growth and 
elastase production. (A) SP2-W3 (Mann) and (B) SP2-W3 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.3.8: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP3-AB22 extracts on growth 
and elastase production. (A) SP3-AB22 (Mann) and (B) SP3-AB22 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.3.9: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP4-AB2 extracts on growth and 
elastase production. (A) SP4-AB2 (Mann) and (B) SP4-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.3.10: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of R. fascians SP4-AB6 extracts on growth and 
elastase production. (A) SP4-AB6 (Mann) and (B) SP4-AB6 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.3.11: Inhibition of elastase LasB using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP6-AB5 extracts on growth 
and elastase production. (A) SP6-AB5 (Mann) and (B) SP6-AB5 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
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S3.4 Quantitative protease and growth inhibitions following treatment with sponge-associated Actinomycete extracts 
 
 
 
 
 
 
 
 
Figure S3.4.1: Inhibition of protease using cinnamaldehyde and 10% DMSO. Positive control cinnamaldehyde (A) resulted in ≥40% growth 
inhibition from 750 µg/ml, contributing to the decrease in protease production and is not indicative of QSI. Solvent 10% DMSO (B) had a negligible 
effect on cell growth, however a significant effect on protease production (p < 0.05) which needs to be taken into consideration. Data reflects 
average results ±SD following experiments in triplicate on three separate occasions. 
 
 
 
 
 
 
 
Figure S3.4.2: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP1-V4 extracts on growth and 
protease production. (A) SP1-V4 (Mann) and (B) SP1-V4 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.4.3: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB1 extracts on growth and 
protease production. (A) SP2-AB1 (Mann) and (B) SP2-AB1 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.4.4: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB2 extracts on growth and 
protease production. (A) SP2-AB2 (Mann) and (B) SP2-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.4.5: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB3 extracts on growth and 
protease production. (A) SP2-AB3 (Mann) and (B) SP2-AB3 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.4.6: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB6 extracts on growth and 
protease production. (A) SP2-AB6 (Mann) and (B) SP2-AB6 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.4.7: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-W3 extracts on growth and 
protease production. (A) SP2-W3 (Mann) and (B) SP2-W3 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.4.8: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP3-AB22 extracts on growth and 
protease production. (A) SP3-AB22 (Mann) and (B) SP3-AB22 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.4.9: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP4-AB2 extracts on growth and 
protease production. (A) SP4-AB2 (Mann) and (B) SP4-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.4.10: Inhibition of protease using sponge-associated bacterial extracts. Effect of R. fascians SP4-AB6 extracts on growth and protease 
production. (A) SP4-AB6 (Mann) and (B) SP4-AB6 (5294). Data reflects average results ±SD following experiments in triplicate on three separate 
occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.4.11: Inhibition of protease using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP6-AB5 extracts on growth and 
protease production. (A) SP6-AB5 (Mann) and (B) SP6-AB5 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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S3.5 Quantitative rhamnolipid and growth inhibitions following treatment with sponge-associated Actinomycete extracts 
 
 
 
 
 
 
 
 
Figure S3.5.1: Inhibition of rhamnolipids using furanone and 10% DMSO. Positive control furanone (A) did not result in P. aeruginosa cell death 
and inhibited rhamnolipid production insignificantly (p > 0.05) in a concentration independent manner. Solvent 10% DMSO (B) had a negligible 
effect on cell growth, as well as an insignificant effect on rhamnolipid production (p > 0.05). Data reflects average results ±SD following 
experiments in triplicate on three separate occasions. 
 
 
 
 
 
 
 
Figure S3.5.2: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP1-V4 extracts on growth and 
rhamnolipid production. (A) SP1-V4 (Mann) and (B) SP1-V4 (5294). Data reflects average results ±SD following experiments in triplicate on three 
separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.5.3: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB1 extracts on growth and 
rhamnolipid production. (A) SP2-AB1 (Mann) and (B) SP2-AB1 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.5.4: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB2 extracts on growth and 
rhamnolipid production. (A) SP2-AB2 (Mann) and (B) SP2-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
A 
A 
B 
B 
194 
 
 
 
 
 
 
 
 
 
 
Figure S3.5.5: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB3 extracts on growth and 
rhamnolipid production. (A) SP2-AB3 (Mann) and (B) SP2-AB3 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.5.6: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-AB6 extracts on growth and 
rhamnolipid production. (A) SP2-AB6 (Mann) and (B) SP2-AB6 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.5.7: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP2-W3 extracts on growth and 
rhamnolipid production. (A) SP2-W3 (Mann) and (B) SP2-W3 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
Figure S3.5.8: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP3-AB22 extracts on growth 
and rhamnolipid production. (A) SP3-AB22 (Mann) and (B) SP3-AB22 (5294). Data reflects average results ±SD following experiments in triplicate 
on three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.5.9: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp.SP4-AB2 extracts on growth and 
rhamnolipid production. (A) SP4-AB2 (Mann) and (B) SP4-AB2 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition exceeded 40% for SP4-AB2 (Mann) at 1000 µg/ml, the remainder of the extracts resulted in growth 
inhibition ≤40%. 
 
 
 
 
 
 
 
Figure S3.5.10: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of R. fascians SP4-AB6 extracts on growth and 
rhamnolipid production. (A) SP4-AB6 (Mann) and (B) SP4-AB6 (5294). Data reflects average results ±SD following experiments in triplicate on 
three separate occasions. Growth inhibition for both extracts was ≤40%. 
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Figure S3.5.11: Inhibition of rhamnolipids using sponge-associated bacterial extracts. Effect of Streptomyces spp. SP6-AB5 extracts on growth 
and rhamnolipid production. (A) SP6-AB5 (Mann) and (B) SP6-AB5 (5294). Data reflects average results ±SD following experiments in triplicate 
on three separate occasions. Growth inhibition for both extracts was ≤40%. 
 
 
 
 
 
 
 
 
 
 
A B 
198 
 
S3.6 Inhibition in P. aeruginosa motility following treatment with sponge-associated Actinomycete extracts  
 
Table S.3.6.1: Inhibition of swarming motility following treatment with sponge-associated Actinomycete extracts. Readings were taken every 24 
h following incubation at 37 °C for 72 h. Readings taken at 72 h are reflected here as they were considered to reflect sustained QSI activity 
 Untreated 250 µg/ml 500 µg/ml   1000 µg/ml 
Extract code 
Zone of swarming 
(mm) ± SD* 
Zone of swarming 
(mm) ± SD* 
Swarming 
inhibition (%) 
Zone of swarming 
(mm) ± SD* 
Swarming 
inhibition (%) 
Zone of swarming 
(mm) ± SD* 
Swarming 
inhibition (%) 
Cinnamaldehyde$ 39.50 ± 0.50 22.50 ± 2.50 43.04 34.50 ± 3.50 12.66 42.75 ± 2.25 -8.23 
10% DMSO 39.50 ± 0.50 62.50 ± 2.50 -58.23 72.50 ± 2.50 -83.54 59.00 ± 3.00 -49.37 
SP1-V4 (Mannitol) 39.50 ± 0.50 13.00 ± 0.00 67.09 29.00 ± 8.00 26.58 24.50 ± 6.00 37.97 
SP1-V4 (5294) 39.50 ± 0.50 32.75 ± 3.75 17.09 29.50 ± 5.50 25.32 24.00 ± 6.50 39.24 
SP2-AB1 (Mannitol) 39.50 ± 0.50 41.00 ± 0.00 -3.80# 35.25 ± 0.25 10.76 30.50 ± 0.50 22.78 
SP2-AB1 (5294) 39.50 ± 0.50 29.50 ± 1.00 25.32 35.50 ± 0.00 10.13 40.75 ± 0.75 -3.16# 
SP2-AB2 (Mannitol) 39.50 ± 0.50 46.25 ± 0.25 -17.09# 33.50 ± 2.50 15.19 37.50 ± 0.00 5.06 
SP2-AB2 (5294) 39.50 ± 0.50 37.75 ± 0.25 4.43 44.50 ± 0.50 -12.66# 39.25 ± 0.25 0.63 
SP2-AB3 (Mannitol) 39.50 ± 0.50 32.00 ± 0.00 18.99 25.75 ± 2.25 34.81 37.00 ± 7.00 6.33 
SP2-AB3 (5294) 39.50 ± 0.50 33.50 ± 3.00 15.19 45.00 ± 2.50 -13.92# 41.75 ± 3.25 -5.70# 
SP2-AB6 (Mannitol) 39.50 ± 0.50 29.50 ± 9.50 24.68 20.50 ± 0.00 48.10 43.25 ± 0.25 -10.13# 
SP2-AB6 (5294) 39.50 ± 0.50 42.50 ± 4.00 -7.59# 42.00 ± 3.50 -6.33# 43.50 ± 3.50 -10.13# 
SP2-W3 (Mannitol) 39.50 ± 0.50 33.50 ± 4.00 15.19 25.25 ± 8.75 36.08 30.75 ± 3.25 22.15 
SP2-W3 (5294) 39.50 ± 0.50 24.50 ± 0.00 37.97 36.50 ± 0.00 7.59 35.00 ± 0.00 11.39 
SP3-AB22 (Mannitol) 39.50 ± 0.50 31.50 ± 1.50 20.25 18.50 ± 0.00  53.16 19.75 ± 4.25 50.00 
SP3-AB22 (5294) 39.50 ± 0.50 35.00 ± 0.00 11.39 20.50 ± 0.50 46.84 25.25 ± 0.25 35.44 
SP4-AB2 (Mannitol) 39.50 ± 0.50 28.25 ± 0.25 27.85 34.50 ± 0.50 11.39 39.50 ± 0.00 0.00 
SP4-AB2 (5294) 39.50 ± 0.50 33.75 ± 4.25 14.56 32.50 ± 0.00 17.72 37.50 ± 0.75 5.06 
SP4-AB6 (Mannitol) 39.50 ± 0.50 48.00 ± 4.00 -21.52# 34.00 ± 1.00 13.92 22.00 ± 2.50 44.30 
SP4-AB6 (5294) 39.50 ± 0.50 18.00 ± 0.00 54.43 17.00 ± 0.75 56.96 16.50 ± 1.00 58.23 
SP6-AB5 (Mannitol) 39.50 ± 0.50 29.25 ± 1.25 25.95 56.50 ± 0.50 -43.04# 39.00 ± 0.00 1.27 
SP6-AB5 (5294) 39.50 ± 0.50 32.25 ± 0.75 18.35 22.00 ± 0.00 44.30 30.50 ± 0.50 22.78 
* All readings in swarming inhibition are given ± standard deviation. 
$ Swarming inhibition for cinnamaldehyde at 1000 µg/ml was the result of P. aeruginosa cell death. All other extracts tested had a growth inhibitory effect of <40% at all 
concentrations tested.  
# Negative values are indicative of an increase in swarming motility at this concentration. 
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Table S.3.6.2: Inhibition of swimming motility following treatment with sponge-associated Actinomycete extracts. Readings were taken every 
24 h following incubation at 37 °C for 72 h. Readings taken at 72 h are reflected here as they were considered to reflect sustained QSI activity 
 0 250 µg/ml 500 µg/ml 1000 µg/ml 
Extract code 
Zone of swimming 
(mm) ± SD* 
Zone of swimming 
(mm) ± SD* 
Swimming 
inhibition (%) 
Zone of swimming 
(mm) ± SD* 
Swimming 
inhibition (%) 
Zone of swimming 
(mm) ± SD* 
Swimming 
inhibition (%) 
Cinnamaldehyde$ 74.60 ± 1.00 37.00 ± 2.00 50.40 33.50 ± 1.50 55.09 41.50 ± 1.50  44.37 
10% DMSO 74.60 ± 1.00 61.25 ± 5.25 17.90 60.50 ± 2.00 18.90 59.00 ± 0.00 20.91 
SP1-V4 (Mannitol) 74.60 ± 1.00 53.50 ± 4.50 28.28 54.50 ± 0.50 26.94 37.50 ± 0.00 49.73 
SP1-V4 (5294) 74.60 ± 1.00 59.50 ± 1.50 20.24 55.25 ± 0.75 25.94 55.50 ± 2.00 25.60 
SP2-AB1 (Mannitol) 74.60 ± 1.00 48.75 ± 0.25 34.65 51.00 ± 0.00 31.64 51.50 ± 0.00 30.97 
SP2-AB1 (5294) 74.60 ± 1.00 79.00 ± 0.00 -5.90# 58.00 ± 0.50 22.25 58.00 ± 1.00 22.25 
SP2-AB2 (Mannitol) 74.60 ± 1.00 66.00 ± 0.50 11.53 54.50 ± 0.50 26.94 50.50 ± 0.50 32.31 
SP2-AB2 (5294) 74.60 ± 1.00 47.00 ± 0.00 37.00 46.00 ± 2.00 38.34 50.50 ± 0.00 32.31 
SP2-AB3 (Mannitol) 74.60 ± 1.00 41.00 ± 0.50 45.04 45.90 ± 1.60 38.47 50.00 ± 2.00 32.98 
SP2-AB3 (5294) 74.60 ± 1.00 44.00 ± 2.00 41.02 55.50 ± 0.25 25.60 43.00 ± 0.50 42.36 
SP2-AB6 (Mannitol) 74.60 ± 1.00 66.50 ± 0.00 10.86 43.25 ± 0.25 42.02 70.00 ± 1.00 6.17 
SP2-AB6 (5294) 74.60 ± 1.00 61.00 ± 0.25 18.23 50.00 ± 0.00 32.98 46.50 ± 0.00 37.67 
SP2-W3 (Mannitol) 74.60 ± 1.00 52.00 ± 0.25 30.29 47.50 ± 2.00 36.33 60.00 ± 3.00 19.57 
SP2-W3 (5294) 74.60 ± 1.00 47.75 ± 2.25 35.99 52.00 ± 0.00 30.29 45.50 ± 5.50 39.01 
SP3-AB22 (Mannitol) 74.60 ± 1.00 56.50 ± 0.00 24.26 45.00 ± 2.25  39.68 43.00 ± 0.00 42.36 
SP3-AB22 (5294) 74.60 ± 1.00 41.00 ± 0.50 45.04 35.50 ± 0.00 52.41 33.00 ± 1.00 55.76 
SP4-AB2 (Mannitol) 74.60 ± 1.00 63.00 ± 0.00 15.55 49.00 ± 0.50 34.32 36.50 ± 0.00 51.07 
SP4-AB2 (5294) 74.60 ± 1.00 75.00 ± 2.25 -0.54# 48.75 ± 4.25 34.65 44.00 ± 0.00  41.02 
SP4-AB6 (Mannitol) 74.60 ± 1.00 55.50 ± 0.00  25.60 42.00 ± 0.00 43.70 38.50 ± 2.25 48.39 
SP4-AB6 (5294) 74.60 ± 1.00 31.50 ± 0.00 50.40 40.50 ± 1.50 55.09 43.00 ± 1.25 44.37 
SP6-AB5 (Mannitol) 74.60 ± 1.00 58.00 ± 2.25 17.90 59.00 ± 2.00 18.90 63.00 ±0.00 20.91 
SP6-AB5 (5294) 74.60 ± 1.00 57.00 ± 3.00 28.28 80.00 ± 5.00 26.94 54.00 ± 1.50 49.73 
* All readings in swimming inhibition are given ± standard deviation. 
$ Swimming inhibition for cinnamaldehyde at 1000 µg/ml was the result of P. aeruginosa cell death. All other extracts tested had a growth inhibitory effect of <40% at all 
concentrations tested.  
# Negative values are indicative of an increase in swimming motility at this concentration. 
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S3.7 Biofilm and growth inhibition following treatment with sponge-associated 
Actinomycete extracts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.7.1: Effect of crude sponge-associated Actinomycete spp. medium 5294 extracts on 
(A) bacterial growth and (B) initial biofilm formation of Pseudomonas aeruginosa ATCC 27583 
as quantified by crystal violet staining in a microtiter plate assay. Cinnamaldehyde served as 
the positive control while volumes of 10% DMSO equivalent to those of the extracts tested 
were used to ensure that inhibitions observed were not as a result of the DMSO. 
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Figure S3.7.2: Effect of crude sponge-associated Actinomycete spp. mannitol extracts on (A) 
bacterial growth and (B) initial biofilm formation of Pseudomonas aeruginosa ATCC 27583 as 
quantified by crystal violet staining in a microtiter plate assay. Cinnamaldehyde served as the 
positive control while volumes of 10% DMSO equivalent to those of the extracts tested were 
used to ensure that inhibitions observed were not as a result of the DMSO. 
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Figure S3.7.3: Effect of crude sponge-associated Actinomycete spp. medium 5294 extracts on 
(A) bacterial growth and (B) mature biofilm formation of Pseudomonas aeruginosa ATCC 
27583 as quantified by crystal violet staining in a microtiter plate assay. Cinnamaldehyde 
served as the positive control while volumes of 10% DMSO equivalent to those of the extracts 
tested were used to ensure that inhibitions observed were not as a result of the DMSO. 
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Figure S3.7.4: Effect of crude sponge-associated Actinomycete spp. mannitol extracts on (A) 
bacterial growth and (B) mature biofilm formation of Pseudomonas aeruginosa ATCC 27583 
as quantified by crystal violet staining in a microtiter plate assay. Cinnamaldehyde served as 
the positive control while volumes of 10% DMSO equivalent to those of the extracts tested 
were used to ensure that inhibitions observed were not as a result of the DMSO. 
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CHAPTER FOUR 
SHORT COMMUNICATION ON SOUTH AFRICAN SPONGE-ASSOCIATED BACTERIAL 
EXTRACTS AS POTENTIAL INHIBITORS OF HIV REVERSE TRANSCRIPTASE 
 
Abstract  
While much research has been done using terrestrial natural products as HIV-1 inhibitors, 
very little work has examined the anti-HIV potential of sponge-associated bacteria, with the 
majority of studies having focussed on sponge-associated fungi. Thirty South African sponge-
associated extracts were screened for their anti-HIV reverse transcriptase (RT) activity. It was 
observed that 13 of the 30 extracts yielded RT-inhibitions of >90%; higher than that of the 
positive control nevirapine. Of these, eight were Actinomycete-derived extracts while only 
five were Bacillus-derived. Neither the fermentation medium used (either mannitol or 
medium 5294) nor the microbial source (Bacillus or actinomycete) was observed to 
significantly affect the inhibition of reverse transcriptase activity. Due to the high percentage 
of RT inhibition observed, sponge-associated bacterial extracts should indeed be further 
screened for their anti-HIV potential, especially those belonging to the genus Bacillus and the 
family Actinomycetes.     
 
4.1 Introduction 
Viral infections can have devastating effects on livestock, the marine environment, agriculture 
as well as human health (Cheung et al., 2014; Janardhan et al., 2015). One such problematic 
virus is the human immunodeficiency virus, or HIV, which develops into acquired 
immunodeficiency syndrome (AIDS) (Moghadamtousi et al., 2015). The number of HIV-
infected individuals continues to increase, surpassing 35 million in 2013 (O’Rourke et al., 
2016) and reaching 36.7 million as of the end of 2016 (UNAIDS, 2017). This member of the 
Retroviridae family (Moghadamtousi et al., 2015) has become a global public health concern, 
especially in Africa, where it one of the leading causes of death (Ellithey et al., 2014; 
Mthethwa et al., 2014). In 2016, 7 million South Africans were living with HIV, with the 
prevalence of infection for individuals aged 15-49 being 19% of the population (UNAIDS, 
2017). This virus often leads to secondary, life threatening disease, such as tuberculosis and 
cervical cancer, due to decreased CD4+ lymphocytes (and therefore immunity) within the 
infected host (Ellithey et al., 2014; Gómez-Cansino et al., 2015). Additionally, even with anti-
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retroviral treatment, women with HIV are more likely to have a recurrence of pre-cervical 
cancer (Ellithey et al., 2014).  
HIV-inhibitors can be classified into various groups, viz. protease inhibitors, integrase 
inhibitors, entry inhibitors, non-nucleoside reverse transcriptase (RT) inhibitors and 
nucleoside RT inhibitors (Moghadamtousi et al., 2015; O’Rourke et al., 2016). Reverse 
transcriptase is a critical enzyme in the HIV life cycle and, therefore, disease progression 
(Zhang et al., 2014), and was identified early on as an important potential target for anti-HIV 
therapies (Ellithey et al., 2014). Non-nucleoside RT inhibitors are considered to be an 
especially important component of highly active antiretroviral therapy (Wang et al., 2015), 
which combines at least two of the different anti-HIV drug classes (O’Rourke et al., 2016). 
While various RT inhibitors have already been approved by the Food and Drug Administration, 
due to drug resistance and toxicity, new RT inhibitors are still needed due to an increase in 
drug resistant-retroviruses (Cheung et al., 2014; Zhang et al., 2014; O’Rourke et al., 2016). 
In the search for new antiviral compounds, the marine environment is of interest 
(Ellithey et al., 2014) due to the specific conditions within this niche and the tremendous 
biodiversity found there (Cheung et al., 2014; Agrawal et al., 2016). The marine world contains 
approximately half of all species (Moghadamtousi et al., 2015), and marine organisms such as 
corals, sponges and microorganisms produce unique, potent bioactive compounds (Cheung 
et al., 2014) which can be divided into various chemical classes. Within the marine 
environment, sponges are prolific producers of bioactive secondary metabolites (García-Vilas 
et al., 2016; Indraningrat et al., 2016), including the production of antiviral spongothymidine 
and spongouridine, derived from Tethya crypta and the basis for Ara-A, active against herpes 
simplex virus (HSV) (Indranigrat et al., 2016). Other sponge-derived antiviral compounds 
include Stylissa carteri-derived hymenialdisine which lowered HIV infection by 40% (O’Rourke 
et al., 2016) and aeroplysinin-1 from sponge Aplysina sp. which effectively inhibited HIV-RT 
activity (García-Vilas et al., 2016). 
Although sponges contribute to nearly 30% of all marine natural compounds (Kurian 
and Elumalai, 2017), it is unfeasible to harvest these metabolites directly from sponges as the 
large amount of biomass needed in order to gain a significant quantity of metabolite is often 
unobtainable (Agrawal et al., 2016; Indraningrat et al., 2016). As some of these metabolites 
are only synthesized in the presence of associated microorganisms (García-Vilas et al., 2016), 
whilst many others are actually produced by the associated microorganisms and not the 
206 
 
sponge itself (Jagadeesan and Balaiah, 2015; Agrawal et al., 2016; Indraningrat et al., 2016), 
the screening for active secondary metabolites from microorganisms has gained preference 
(Jagadeesan and Balaiah, 2015). This is because they are easier to cultivate, cheaper, their 
enzymes easier to control than animal enzymes (Jagadeesan and Balaiah, 2015) and they offer 
a potentially unlimited supply of the desired metabolite (Agrawal et al., 2016).  
Indeed, while many studies have examined the potential of sponge- and plant-derived 
extracts to inhibit HIV (Cheung et al., 2014; Ellithey et al., 2014; Larson et al., 2014; Mthethwa 
et al., 2014; Zhang et al., 2014; Gómez-Cansino et al., 2015; Kadokura et al., 2015; Agrawal et 
al., 2016; O’Rourke et al., 2016; Kurian and Elumalai, 2017), few looked at the potential of 
sponge-associated bacteria (SPAB), choosing instead to focus on sponge-associated fungi 
such as Stachybotris charatum derived from sponge Xestospongia testudinaris, which 
produces stachybotrin D, a potent inhibitor of HIV RT activity (Moghadamtousie et al., 2015; 
Wang et al., 2015; Indraningrat et al., 2016; Kurian and Elumalai, 2017). In sponges, 
microorganisms can comprise more than 40% of the total body mass through highly specific 
and often symbiotic associations (García-Vilas et al., 2016; Kurian and Elumalai, 2017).  Among 
these, Actinobacteria are responsible for 48.8% of sponge-associated bacterial-derived 
antimicrobial compounds (Indraningrat et al., 2016). While the corresponding antiviral 
statistic is unknown, an example of an Actinomycete-derived antiviral compound is penta-
lactone, extracted following fermentation of Streptomyces M-2719, which are active against 
several DNA viruses (Janardhan et al., 2015).  
 However, SPAB with antiviral potentials have been observed. Alteromonas sp., 
isolated from a Bermudian sponge showed anti-HIV potential as a RT inhibitor (Jagadeesan 
and Balaiah, 2015), while 2-undecyl-4-quinolone, isolated from Homophymia sp.-associated 
Pseudomonas sp. 1531-E7, showed in vitro activity against HIV-1 and Plasmodium falciparum 
(Indraningrat et al., 2016; Bramhachari et al., 2016). Furthermore, sponge-associated 
actinomycete-produced menzamine A exhibited, among other properties, anti-HIV effects 
(Santos-Gandelman et al., 2014). Sponge-associated bacterial extracts have additionally been 
screened against other viruses. Petromica citrina-associated Bacillus-derived extracts showed 
strong activity against hepatitis C (Kurian and Elumalai, 2017), while benzastatin C from 
Streptomyces nitrosporeus showed dose-dependent antiviral activity against HSV and 
vesicular stomatitis virus (Janardhan et al., 2015), indicating the potential of these remarkable 
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microorganisms.This study focussed on investigating the anti-HIV potential of selected 
sponge-associated bacterial extracts by targeting the reverse transcriptase of HIV-1.  
 
4.2 Methods and materials 
4.2.1 Ethyl acetate extract preparation 
Fifteen previously screened quorum-sensing inhibitory sponge-associated isolates were 
cultured in 5 ml of ISP2 broth for 2 d at 30 °C with shaking at 200 rpm. Thereafter, cultures 
were inoculated into 250 ml of Mannitol and Medium 5924 broth in 1 l glass flasks and 
incubated with shaking at 200 rpm at 30 °C for 7 d. Samples were then centrifuged at 7000 
rpm for 15 min in order to pellet cells, and supernatants collected. An equal volume (1:1) ethyl 
acetate was added to each supernatant, and then agitated at 30 °C for 1 h. The organic ethyl 
acetate layer was collected, and the remaining aqueous layer subjected to a second extraction 
of 1:1 volume ethyl acetate, with agitation at 30 °C overnight. The ethyl acetate layer was 
again collected, and the combined organic layers completely evaporated in a rotary 
evaporator (ILMVAC RObath, AVT Services) at 40 °C. The dry extract was then resuspended in  
 4̴ ml methanol and collected, after which the methanol was allowed to evaporate. Extracts 
were then resuspended in 5 ml of 10% dimethyl sulfoxide (DMSO) and standardized to a final 
concentration of 50 mg/ml for further use (Baltes et al., 1998). 
 
4.2.2 HIV-1 retroviral transcriptase (RT) assay 
Non-radioactive HIV-1 reverse transcriptase activities were evaluated using an HIV-1 RT non-
radioactive assay kit (Roche Diagnostics GmbH, Germany). Briefly, 20 µl of the reaction 
mixture containing a homogenous template/primer hybrid, poly(A) × oligo(dT)15 and a 
triphosphate substrate, dUTP/dTTP, were added to the wells of a streptavidine-coated 
microtiter plate that contained 20 µl of test extract solution (equivalent to 16.67 mg/ml; 50 
mg/ml stock) and 4 ng of the HIV-1 RT in 20 µl of lysis buffer. Final concentrations of the 
template/primer hybrid and triphosphate substrate (dUTP/dTTP) were 750 mA260 nm /ml and 
10 µM, respectively. The reaction was carried out at 37 °C for 1 h, followed by the addition of 
200 µl of anti-digoxigenin-peroxide, and ABTS [2,29-azino-bis-(3-ethyl benzothiazoline-6-
sulfonic acid) diammonium salt] substrate for colouring reaction. The absorbance of each well 
was recorded at 405 nm with the reference wavelength at 490 nm (Multiskan Ascent plate 
reader, AEC Amersham). Nevirapine (Viramune, Boehringer-Ingelheim Pharma KG, Germany) 
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was used as a reference compound at the same concentration (Ahn et al., 2004). The effect 
of the extract on RT activity was calculated as follows: 
Percentage RT inhibition =  100 − ((
Absorbance of sample with extract
Absorbance of reference compound
) × 100) 
(Kannan et al., 2012).  
 
4.2.3 Statistical analysis 
A two-tailed t-test was performed, comparing the effects of the mannitol and medium 5294 
extracts on overall RT inhibition, with the null hypothesis being that there was no difference 
between the two media used. A similar test was done to compare the RT-inhibitory effects 
exerted by the Bacillus-derived extracts in comparison to those derived from Actinomycete 
isolates. The statistical significance of the Bacillus and Actinomycete extracts was determined 
using a two-tailed t-test to compare the RT-inhibitory effects exerted by the mannitol-derived 
Bacillus extracts compared to those from medium 5294, followed by the same test being 
performed using the Actinomycete mannitol and medium 5294 extracts. For all tests a p-value 
of <0.05 was taken to be significant, such that the null hypothesis may be rejected. All 
statistical analyses were performed using Microsoft Excel following the installation of Real 
Statistics Add-In software.  
 
4.3 Results 
Fifteen quorum-sensing inhibitory, distinct isolates were selected, and 30 ethyl acetate 
extracts were obtained following shake flask fermentation.  Of these isolates, five belonged 
to the genus Bacillus (Fig 4.1A) while ten were Actinomycetes (Fig 4.1B). These isolates were 
fermented in two different production media, namely mannitol and medium 5294, in order 
to obtain the 30 extracts to be tested. All Bacillus isolates were butyrous in nature, with pale 
pigmentation. Almost all actinomycete isolates were sporulating, with spores ranging from 
white to dark grey. The exception was isolate SP4-AB6, identified as Rhodococcus fascians, 
which exhibited an orange-yellow, non-sporulating morphology. 
The 30 sponge-associated bacterial extracts were then screened for their potential 
anti-RT activity. Nevirapine, which was used as the positive control, caused an 82.6% 
reduction in RT activity. Therefore, only extracts which resulted in an inhibition of >83% were 
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considered to be effective to a degree warranting further investigation. Thirteen extracts had 
such an inhibitory effect, resulting in inhibition of   ̴91.7 - 96.93%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Thirty sponge-associated bacterial isolates selected for extract production. (A) 
Selected Bacillus isolates. Designated codes, from left to right, are: AB2-SP, SP1-AB4, SP2-W6, 
SP2-AB7 and SP5-AB7. (B) Selected actinomycete isolates. Designated codes, from left to right 
are: SP1-V4, SP2-AB1, SP2-AB2, SP2-AB3, SP2-AB6 (top row) and SP2-W3, SP3-AB22, SP4-AB2, 
SP4-AB6, SP5-AB6 (bottom row).  
 
Of these 13 extracts, six were Mannitol-derived (Fig. 4.2A) and seven medium 5294-derived 
(Fig. 4.2B). Furthermore, only five were Bacillus extracts (AB2-SP (Mann and 5294), SP2-W6 
(Mann and 5294) and SP5-AB7 (5294)) while eight were Actinomycete extracts. Overall the 
three greatest inhibitors of HIV RT were Bacillus sp. AB2-SP (Mann) and actinomycete sp. SP1-
V4 (5294) and SP2-AB6 (5294) which resulted in RT inhibitions of 96.93%, 96.85% and 96.58%, 
respectively. 
After examining the activity of all 30 extracts, and in particular the 13 extracts which 
gave activity superior to that of the positive control, it was observed that the production 
medium had no significance on the anti-HIV potential of the extracts (p = 0.72). The bacterial 
origin was also not observed to have a significant impact on RT-inhibition, either overall (p = 
0.57) or when individually comparing the mannitol (p = 0.73) or medium 5294 (p = 0.21) 
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extracts for each group. We were, therefore, unable to reject any of the null hypotheses put 
forth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Reverse transcriptase inhibitory effects of 30 sponge-associated bacterial extracts 
(A) Mannitol-derived extracts; (B) medium 5294-derived extracts). The positive control, 
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nevirapine, is depicted in red. The black, dashed lines indicate the inhibitory effects of 
nevirapine (82.6%) and all the extracts tested with inhibition greater than nevirapine were 
considered to be noteworthy. Thirteen of the 30 extracts (43%) exhibited such activity, with 
six being mannitol-derived (A) and seven medium 5294-derived (B). Of the nine that exhibited 
RT-inhibitory activities of >95%, four were mannitol-derived and 5 were medium 5294-
derived. 
 
4.4 Discussion and conclusion 
While sponge-associated bacteria have been investigated for a myriad of pharmaceutical 
applications, such as their anti-virulence and antibacterial properties (Perdicaris et al., 2013; 
Bramhachari et al., 2016; Grandclément et al., 2016; Saurav et al., 2016), very little work has 
investigated these microorganisms for their antiviral properties. This is surprising, as many 
viruses pose a substantial threat to public healthcare (Janardhan et al., 2015), especially in 
developing countries such as South Africa where over 7 million people are living with HIV 
(UNAIDS, 2017). What research has been done has yielded promising results, with sponge-
associated compounds such as 2-undecyl-4-quinolone and menzamine A being effective 
against DNA viruses, including HIV-1 (Santos-Gandelman et al., 2014; Bramhachari et al., 
2016; Indraningrat et al., 2016).   
 Although studies focussing on sponge-associated bacteria are rare, metabolites 
derived from sponge Stylissa carteri were beneficial in HIV treatment, with hymenialdisine 
and debromohymenialdisine inhibiting HIV infection by 40% at 3.1 µM and 30% at 13 µM, 
respectively (O’Rourke et al., 2016). Similarly, aeroplysinin-1, derived from sponge Aplysina, 
was able to inhibit HIV RT activity, among other viral processes, by 67% at 10 M (García-Vilas 
et al., 2016). In terms of plant based studies, extracts from medicinal plant Rhus verniciflua 
were shown to have anti-HIV RT activity, with l,2-dihydroxyphenyl-3-[80(Z),100(E),120(E)-
pentadecatrienyl]-140-ol exhibiting the strongest activity with a IC50 value of approximately 
12.6 µM (Kadokura et al., 2015). These results were difficult to compare to the sponge-
associated extracts under investigation as all three studies utilized purified compounds, 
whereas in this study crude extracts were employed at a single concentration and IC50 values 
not determined. However, these studies lend precedence to the increased use of natural 
products in HIV treatment.  
 In a study that did employ crude extracts (100 µg/ml) from 13 marine organisms (two 
of which were sponges), none of the extracts were able to inhibit HIV-RT activity (Ellithey et 
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al., 2014), where the authors considered an activity of 50% RT-inhibition to be notable and a 
90% inhibition to be potent. All 13 of the positive extracts tested in this investigation can, 
therefore, be said to be potent inhibitors of HIV-RT activity. However, as a maximal treatment 
concentration/IC50 value of 50 µg/ml has also been described in literature as being potent 
(Gómez-Cansino et al., 2015), the active extracts within this study should be fractionated and 
purified, with purified active compounds being re-tested in order to determine their IC50 
values.  
 In terms of the antiviral potential of the two groups of organisms used, both 
actinomycetes and Bacillus have been used to some extent to produce antiviral agents, 
although only a few have been elucidated (Janardhan et al., 2015). Actinomycete-derived 
antiviral compound penta-lactone, extracted following fermentation of Streptomyces M-
2719, proved to be active against several DNA viruses (Janardhan et al., 2015). Additionally, 
although not marine-derived, Brazilian Streptomyces sp. exhibited antiviral activity against 
numerous viruses including HSV type 1 while metabolites from Streptomyces lavendulae 
inhibited influenza A and B in vitro (Janardhan et al., 2015). Furthermore, active against HSV 
was benzastatin C derived from marine Streptomyces nitrosporus, with EC50 values of 1.92 and 
0.53 g/ml against HSV-1 and HSV-2, respectively (Janardhan et al., 2015). Although less work 
has been done on Bacillus, a Bacillus sp. associated with sponge Petromica citrina yielded 
promising antiviral activity against hepatitis C (Kurian and Elumalai, 2017) as well as bovine 
viral diarrhea virus (Indraningrat et al., 2016). Marine Geobacillus thermodenitrificans 
prevented replication of HSV-2 in human peripheral blood mononuclear cells (Cheung et al., 
2014). Although these studies were not HIV-based, they do serve to highlight the antiviral 
potential of bacterial isolates belonging to these groups, especially those from marine 
sources.  
  As very little research has been done using sponge-associated bacteria to inhibit 
reverse transcriptase activity of HIV-1, and due to the promising results of the above extracts 
in regard to HIV RT inhibition, it may be concluded that sponge-associated bacterial extracts 
should indeed be investigated further for the anti-HIV properties. This research should not be 
limited to anti-RT activity, but should be extended to other targets such protease or integrase 
enzymes. Cytotoxicity assays will also need to be performed in the future should this research 
be undertaken, and the active compounds need to be purified and identified in order to 
determine accurate MIC values.  The marine world, and sponge-associated bacteria in 
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particular, remain a relatively untapped resource in terms of their pharmacological potential, 
and yet the possibilities of sponge-associated bacterial-derived compounds for disease 
treatment may yet prove to be the answer the scientific world has been seeking. Research 
into this area should, therefore, undoubtedly be increased.  
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CHAPTER FIVE 
GENERAL DISCUSSION AND CONCLUSIONS 
 
The misuse of antimicrobial agents has led to the rapid emergence of multiple drug-resistant 
bacteria, such as Pseudomonas aeruginosa (Devaraj et al., 2017). Based on the current state 
of antimicrobial resistance, it is possible that the next generation will inherit a medical system 
that, in respect to the treatment of infectious diseases, is more similar to that of the 1930s 
than that of today. Antibiotics may be no more and the search for new bacterial treatments 
is well underway (Steckbeck et al., 2014). Quorum sensing inhibitory (QSI) molecules may 
then potentially serve as the next generation's penicillin; the solution to the current 
antimicrobial crisis which allows the medical field to once again advance (Steckbeck et al., 
2014). Marine sponges have been shown to harbour bacterial species more diverse than that 
of seawater, corals or sediments (Sun et al., 2015), and these sponge-associated 
microorganisms are considered the topmost producers of natural products within their 
environment (Kurian and Elumalai, 2017). It seems viable, therefore, that sponge-associated 
bacteria may produce novel metabolites possessing unique pharmacological qualities and as 
such should be explored, especially in the treatment of resistant pathogens such as P. 
aeruginosa or viruses such as HIV.   
 With 3% of the Bacillus genome being dedicated to secondary metabolite production 
(Bastos et al., 2013), sponge-associated Bacillus spp., especially those belonging to the B. 
cereus subgroup (Patiño-Navarrete and Sanchis, 2017), have been shown to be amongst the 
top producers of active secondary metabolites such as QS inhibitory compounds (Musthafa 
et al., 2011; Tang and Zhang, 2014; Banerjee and Ray, 2016; Bramhachari et al., 2016; Saurav 
et al., 2016; Kurian and Elumalai, 2017). Sponge-associated Actinomycete isolates have shown 
similar promise, with members such as Rhodococcus spp. and Streptomyces spp. producing a 
wide range of enzymatic and small molecule-based QSI compounds (Banerjee and Ray, 2016; 
Bramhachari et al., 2016; Devaraj et al., 2017; Kurian and Elumalai, 2017). Ninety-eight 
sponge-associated bacterial isolates isolated off the coast of KwaZulu-Natal were thus 
screened for QSI activity. Violacein-producing Chromobacterium violaceum was used for 
primary QSI screening assays, followed by the screening of extracts obtained from 15 
selected, promising sponge-associated bacterial isolates (five Bacillus spp. and 10 
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Actinomycete spp.) against P. aeruginosa ATCC 27853. Extracts were obtained using two 
production media, viz. mannitol medium and medium 5294.  
 Initial QSI sandwich assay screening revealed that 88% of sponge-associated isolates 
tested were capable of short chain AHL inhibition. This was an improvement on the results 
obtained by Saurav et al. (2016), Singh et al. (2017) and Gutiérrez-Barranquero et al. (2018) 
who observed that 28%, 4% and 4% of their isolates, respectively, were capable of QSI using 
the same organism. Seventeen of the sponge-associated isolates were further capable of long 
chain QSI, 16 of which had displayed short chain QSI activity. Fifteen of these isolates were 
then selected for further QSI screening and were identified as being Bacillus and 
Actinomycete spp. using 16S rRNA gene amplification, followed by sequencing and BLAST 
analysis. Thirty extracts were subsequently obtained and screened against P. aeruginosa 
virulence factor production as well as against HIV reverse transcriptase (RT) activity, in order 
to determine if the extracts possessed anti-virulence and antiviral activity worthy of further 
investigation.  
 In terms of the QSI efficacy of the two production media tested, varying trends could 
be seen for the two organism groups. Medium 5294 Bacillus spp. extracts yielded higher 
and/or more significant inhibition of rhamnolipid, pyoverdine, protease, initial and mature 
biofilm production, as well as higher inhibition of swimming and swarming motilities when 
compared to mannitol-derived extracts.  The opposite proved to be true for the Actinomycete 
spp. extracts, with mannitol-derived extracts yielding higher and/or more significant 
inhibition of pyocyanin, pyoverdine, elastase, rhamnolipid, and mature biofilm production as 
well as swimming motility. This suggests that production media may need to be selected 
specifically for the isolates being screened for QSI activity, and that medium 5294 should be 
used for Bacillus spp. isolates while mannitol may be preferable for Actinomycete spp. 
isolates. As mannitol extracts yielded higher pyocyanin and elastase inhibitions regardless of 
the organism being tested, the virulence factor being tested may also play a role in deciding 
which production media to use. Further testing needs to be done on the specificity of the 
production media in terms of producing QSI compounds against specific P. aeruginosa QS 
systems of virulence factors, such as targeting PQS-based virulence factor production which 
would make therapies directed at Pseudomonas more specific.  
 Ideally, QSI compounds capable of inhibiting both long and short chain acyl 
homoserine lactone (AHL) molecules are desired, as P. aeruginosa utilizes both C4-AHL (rhl 
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system) and C12-AHL (las system) QS (Guendouze et al., 2017). In terms of the Bacillus spp. 
isolates, B. weihenstephanensis SP5-AB7 yielded the most significant and broad spectrum QSI 
results. Extracts SP5-AB7 (Mann) and SP5-AB7 (5294) resulted in 93.88% and 79.96% 
rhamnolipid inhibition, while SP5-AB7 (Mann) was additionally amongst the top inhibitors of 
mature biofilm formation. Extract SP5-AB7 (Mann) was also the best inhibitor of elastase 
(71.32%) and pyocyanin (39.36%) production and was amongst the top inhibitors of 
pyoverdine (33.4%) and initial biofilm (66.51%) production. Finally, SP5-AB7 (5294) resulted 
in a 55.88% inhibition in swimming motility. Extracts of B. weihenstephanensis SP5-AB7, 
therefore, were able to inhibit virulence factors mediated by all three of the P. aeruginosa QS 
systems, and should be investigated further as a potential broad spectrum QSI organism.  
 Extracts from Streptomyces spp. SP4-AB2 and SP3-AB22 showed similar broad 
spectrum QSI activity. Extract SP4-AB2 (Mann) was the best Actinomycete-derived inhibitor 
of pyocyanin (55.73%), elastase (61.77%) and protease (71.95%) production, while SP4-AB2 
(5294) was additionally amongst the top inhibitors of protease production (69.76%). Extracts 
from SP3-AB22 also performed well against a number of virulence factors, including the 
inhibition of mature biofilm formation (50.64%) by SP3-AB22 (Mann). Extracts SP3-AB22 
(Mann) and SP3-AB22 (5294) were both amongst the top inhibitors of elastase production 
(44.12% and 53.6%, respectively), while SP3-AB22 (Mann) was additionally a top inhibitor of 
pyocyanin production (41.05%) and swarming motility (53.16%) and SP3-AB22 (5294) a top 
inhibitor of swimming motility (55.76%). Both Streptomyces SP4-AB2 and Streptomyces SP3-
AB22 should, therefore, be further investigated in order to elucidate the genes and 
compounds responsible for the observed QSI activity.  
 All 30 extracts were further screened for the ability to inhibit HIV-RT activity, using an 
HIV-1 RT non-radioactive assay kit (Roche Diagnostics GmbH, Germany). While these extracts 
were originally derived in order to test their potential as anti-QS compounds, research has 
shown that often promising bioactivities of natural compounds get overlooked due to narrow-
spectrum research (Agrawal et al., 2016; O’Rourke et al., 2016). Nevirapine was used as a 
positive control, achieving an HIV-RT inhibition of 82.6%. Therefore, only sponge-associated 
extracts capable of HIV-RT inhibitions greater than this were considered noteworthy, as they 
would therefore be an improvement on an existing treatment option.  Thirteen of the 30 
sponge-associated bacterial extracts tested (43.33%) resulted in HIV-RT inhibition >90%, five 
of which were Bacillus spp. extracts and eight Actinomycete spp. extracts. A maximum HIV-
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RT inhibition of 96.93% was achieved using extract SP-AB2 (Mann). This extract had shown 
primarily PQS-inhibitory results (i.e. pyocyanin and pyoverdine inhibition) against P. 
aeruginosa. The second greatest inhibitor of HIV-RT activity, Streptomyces spp. extract SP1-
V4 (5294), was additionally the strongest inhibitor of pyoverdine production, suggesting there 
may be a link between compounds capable of PQS and HIV-RT inhibition. This will need to be 
studied further. Interestingly, all four extracts capable of long chain QSI inhibition during the 
C. violaceum agar well diffusion assay were also capable of anti-RT activity. These extracts 
were Bacillus spp. extracts SP-AB2 (Mann) and SP2-W6 (Mann), and Streptomyces spp. 
extracts SP2-AB3 (5294) and SP4-AB2 (Mann). In the case of SP4-AB2 (Mann) and SP2-AB3 
(5294), the corresponding medium 5294 and mannitol extracts yielded anti-RT activities of 
<15%, suggesting that there may also be a link between long chain QSI and RT-inhibitory 
potential.   
 The role of QS in mediating virulence phenotypes in pathogenic bacteria has long since 
been established (Gutiérrez-Barranquero, 2018). However, there is currently only a limited 
amount of research currently available on marine sponge bacteria capable of QSI (Saurav et 
al., 2016). To the best of our knowledge, no work has previously been done examining the 
QSI potential or anti-HIV potential of sponge-associated bacteria isolated off the coast of 
KwaZulu-Natal, South Africa, making this study the first of its kind. Furthermore, although 
sponge-associated bacteria have shown putative anti-viral activity (Tong et al., 2012), very 
few of the characterized, marine, HIV-targeting products discussed above were identified 
from sponge-associated bacteria, making this a novel area of research. 
Due to the promising results obtained in both aspects, sponge-associated bacteria 
isolated from this region should receive increased attention as a source of potential QSI 
agents, with both the anti-virulence and anti-HIV potential of the extracts needing to be 
elucidated in future. Focus in future research should additionally be on bacterial genera which 
have shown promise in this study as well as in previous research, such as Actinomycetes or 
Bacillus spp. (Bastos et al., 2013), especially those belonging to the B. cereus sub-group 
(Patiño-Navarrete and Sanchis, 2017) or Streptomyces genus (Miao et al., 2017). Additionally, 
it is advisable to pursue research investigating the combinatorial effects of QSI substances, 
antimicrobial therapy, and immunotherapies to determine if an improved outcome is 
achieved (García-Contreras, 2016). Techniques such as genomic analysis, metabolomics and 
other biomedical screening approaches should be applied to further explore the variety and 
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nature of these compounds (Santos-Gandelman et al., 2014). Lastly, although QSI compounds 
have been tested in vivo, clinical studies remain rare (Castillo-Juarez et al., 2017), making this 
a potential future goal in terms of testing these promising sponge-associated bacterial 
extracts further, potentially within an established mouse model (Castillo-Juarez et al., 2017). 
In order to achieve this, however, individual active compounds and agents will need to be 
elucidated from the crude sponge-associated bacterial extracts used in the present study. The 
enzymatic and/or small molecule nature of the active QSI agents within promising extracts 
will primarily need to be assessed, potentially via heat treatment (Gutiérrez-Barranquero et 
al., 2018), followed by isolation and purification of the active enzymes or compounds, thereby 
allowing the establishment of important clinical values such as the MIC and IC50 values.   
In conclusion, given the importance of QS in mediating P. aeruginosa virulence, QSI 
has been proposed as a suitable alternative to antimicrobial therapies (Musthafa et al., 2011; 
Miao et al., 2017; Gutiérrez-Barranquero et al., 2017). Furthermore, due to the variety of QSI 
compounds discovered thus far, and the promising activity of the sponge-associated Bacillus 
and Actinomycete spp. extracts examined in this study, it can be clearly seen that the marine 
environment, and sponge-associated bacteria in particular, may be an exciting potential 
source of novel treatment options to combat nosocomial and clinical pathogens such as P. 
aeruginosa and/or HIV. Sponge-associated extracts tested in this study have shown immense 
promise as quorum-sensing and reverse transcriptase inhibitors, and as such should be 
studied further to identify the active agents as well as to determine their future clinical 
potential. 
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